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Abstract 
 
The human heart has poor endogenous regeneration. If myocytes are lost due 
to injury, the myocardium is unable to restore its myocyte content and instead 
undergoes compensatory hypertrophy and remodeling. Cardiac tissue 
engineering aims to recreate and provide functional myocardium that replaces 
the injured myocardium. In this study, human engineered heart muscle (EHM) 
from cardiomyogenically differentiated human embryonic stem cells was 
generated. EHMs consisted of elongated, anisotropically organized 
cardiomyocyte bundles and responded “physiologically” to increasing calcium 
concentrations. To generate large myocardium capable of encompassing the 
ventricles, a novel process to systematically upscale the dimensions of 
engineered myocardium to a humanized Biological Ventricular Assisted Device 
(hBioVAD) was introduced. The hBioVADs formed a “pouch-like” myocardium at 
rabbit heart dimensions and were beating spontaneously. Further enhancement 
by biomimetic pulsatile loading generated “more mature” myocardium. 
Additional paracrine functionality was integrated by generating insulin-like 
growth factor-1 (IGF-1) secreting fibroblasts for tissue engineering applications. 
IGF-1 release induced higher levels of Akt phosphorylation and hypertrophy in 
cardiomyocytes resulting in increased force generation of EHM. Finally, 
feasibility of “paraBioVAD” (IGF-1 cell line and cardiomyocytes) implantation 
was demonstrated in a healthy rat model. Histological observations 
demonstrated engraftment on the heart and the presence of vascular structures. 
In conclusion, a humanized “paraBioVAD” technology for mechanic and 
paracrine heart support was developed. Future studies will assess its 
therapeutic utility in heart failure. 
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1.  Introduction 
 
1.1   Heart function and failure 
 
The human heart is a four-chambered pump capable of providing an optimal 
continuous blood flow to the rest of the body. It is mainly comprised of 
cardiomyocytes, fibroblasts, endothelial and smooth muscle cells of which 
cardiomyocytes are responsible for the contractility of the heart while 
fibroblasts synthesize and secrete extracellular matrix (ECM) to form the 
scaffold of the heart. In addition, growth factors are also secreted by 
fibroblasts, which promote growth, proliferation and maturation of 
cardiomyocytes in a paracrine manner. Cardiomyocytes are one of the least 
endogenously regenerative cell types in the human body (Mallory et al. 1939, 
Pasumarthi and Field 2002, Laflamme and Murry 2005, Rubart and Field 
2006, Laflamme et al. 2007) with only 1% of cardiomyocytes in the human 
heart regenerating till the age of 25 and a subsequent gradual reduction to 
0.5% till age of 75 (Bergmann et al. 2009). Hence, a loss of cardiomyocytes, 
for example as a consequence of myocardial ischemia, cannot be 
compensated effectively. Instead replacement fibrosis can be observed. This 
process also goes along with cardiomyocyte hypertrophy, which may partially 
compensate for the loss in cardiomyocytes, but will not suffice to restore 
proper function in most cases. Under these conditions, heart failure can 
develop. 
 
Heart failure is the leading cause of mortality globally with higher incidence in 
developed nations. It is however projected by the WHO to affect more 
populations in the future and be the main cause of death worldwide in less 
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then a decade (http://www.who.int/cardiovascular_diseases/en/). Unless 
promptly diagnosed and appropriate management strategies are implemented, 
heart failure progresses to severe forms where blood volume demands 
outstrip the ability of the heart to pump effectively. The only causal therapy for 
these patients is heart transplantation. Due to a shortage of organs many 
patients die before receiving a transplant. Hence, novel therapeutic modalities 
are needed urgently to bridge the time-to-transplant or re-muscularize the 
heart. 
 
Alternative therapeutic approaches, either in clinical practice or still under 
development, have been proposed to reverse pathological remodeling and 
halt disease progression in heart failure (Figure 1): 
  
 
 
Figure 1. Summary of therapeutic strategies in heart failure. 
Figure adapted from Dr. Edwin P. Ewing, CDC, USA. 
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1.2  Drug therapy 
Several classes of drugs have been shown to increase survival of heart failure 
patients. Beta-adrenergic receptor blockers, angiotensin-converting enzyme 
inhibitors / angiotensin II receptor 2 antagonists and aldosterone receptor 
antagonists have been demonstrated in clinical trials as individual or 
combinatorial drug therapy to lower total mortality and hospitalization by 30 - 
40% and also shown to improve left ventricular function in patients with class 
II through class IV heart failure (SOLVD-Investigators 1992, MERIT-HF-
Investigators 1999, Pitt et al. 1999). These drugs have in common that they 
reduce neurohormonal activity and here in particular the stimulatory effects of 
endogenous catecholamines and the renin-angiotensin-aldosterone-system. 
Despite their success in clinical practice they do not stimulate cardiomyocyte 
proliferation and regeneration, and thus typically delay, but do not prevent the 
onset of late stage heart failure. 
 
1.3  Device therapy 
Throughout the progression of heart failure, the biophysical changes occurring 
in the cardiomyocytes lead to ventricle remodeling such as dilation of the 
myocardium, resulting in reduced left ventricular ejection fraction (LVEF); a 
critical index measured by amount of blood volume ejected from the left 
ventricle to the aorta and thus a widely used indicator of myocardium function. 
In end stage heart failure decrease of LVEF results in limited blood supply to 
the peripheral organs. To assist the failing heart cope with its pumping 
function, left ventricular assist devices (LVADs) can be implanted. LVADs are 
portable battery driven mechanical pumps which re-route blood supply from 
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the left ventricle and pumps it into the aorta at an adjustable flow-rate. Recent 
developments in LVAD technologies have resulted in 2nd and 3rd generation 
non-pulsatile continuous-flow VADs yielding higher survival rates, better 
quality of life and longer device durability (Slaughter et al. 2009). However, 
while LVADs are able to reduce the overload of the heart and in some cases 
even appear to reverse heart failure progression, they do not represent a 
long-term solution, because of high unwanted side-effect rates; typically minor 
and major strokes in 70% of the patients in one year (Moazami et al. 1997, 
Lazar et al. 2004, Thoennissen et al. 2006).  
 
An alternative “device” strategy was introduced with the Acorn Cor Cap 
Cardiac Support Device (ACSD; Acorn Cardiovascular Inc.; St Paul, MN, 
USA). ACSDs resemble knitted polyethylene terephthalate (PET) “bags” 
designed to be placed over the dilated heart as mesh wrap to restrict further 
dilation (Walsh 2005). In canine studies, restraint of left ventricle dilation was 
observed after ACSD placement (Sabbah 2005). Similar observations were 
made in a clinical study (Oz et al. 2003). However constriction of the heart 
was also observed in some patients, further compromising heart function. 
Finally, the ACSD was disapproved by the FDA primarily due to safety 
concerns (www.fda.gov/ohrms/dockets/ac/06/briefing/2006-
4269b1_09_sponsor.pdf).  
 
Taken together, neither LVADs nor ACSDs are capable of assisting in heart 
re-muscularization.  
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As an ultimate device therapy the concept of building a complete artificial 
heart was introduced (Morrissey 2012). Following a successful preclinical 
attempt in a canine model by Kolff and colleagues in 1958 (Norman 1975, 
Cooley 2003), the first clinical artificial heart was successfully implanted in a 
man suffering acute coronary arterial occlusion and complete heart block 
(Cooley et al. 1969). Since then, continuous research led to several 
improvements for example by introducing novel materials and advanced 
design principles (Copeland et al. 2001, Gray and Selzman 2006). While 
these heart replacement devices extend life in patients with end-stage heart 
failure, they can only serve as a temporary solution while the patients await 
total heart transplantation, also because of procedure related side effects i.e. 
thrombosis, embolism, infections and device failure.   
 
1.4  Cell-based therapy 
Given the obvious limitations of drug and device therapy, novel cell-based 
approaches to achieve biological replacement of damaged myocardium have 
been introduced (Dimmeler et al. 2005, Murry et al. 2005). Skeletal myoblasts 
were tested first in animal models of myocardial infarction and demonstrated 
some therapeutic effects, despite their inability to trans differentiate into 
cardiomyocytes (Koh et al. 1993, Taylor et al. 1998, Atkins et al. 1999, 
Chedrawy et al. 2002, Reinecke et al. 2002). A first clinical trial was 
conducted and involved the implantation of autologous myoblasts directly into 
the infarcted scar tissue (Menasche et al. 2008). However, while the majority 
of patients demonstrated enhanced systolic function, 4 patients developed 
arrhythmias within 2 weeks of cell injections (Menasché 2009). Interestingly, 
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there was no evidence for proper myoblasts integration into the host 
myocardium.  
 
Other groups experimented with intravenous application of bone marrow 
derived mesenchymal stem cells (BM-MSCs) into a large infarcted region of 
the hearts from rats, mice and pigs (Tomita et al. 1999, Shake et al. 2002, 
Nagaya et al. 2005). Nagaya and co-workers injected MSCs directly into 
dilated hearts of a rat DCM model and demonstrated that surviving 
transplanted MSCs expressed connexin-43 at junctions between MSCs as 
well as with native cardiomyocytes suggesting that autologous MSCs are 
capable of survival and integration when heterotopically transplanted. The 
MSCs also secrete high levels of angiogenic and antiapoptotic factors such as 
insulin like growth factor 1 (IGF1), vascular endothelial growth factor (VEGF) 
and hepatocyte growth factor (HGF).  Subsequently, clinical trials have been 
conducted demonstrating that autologous bone marrow cell transplantation 
can improve cardiac function likely by the inhibition of myocardial fibrosis as 
well as secretory growth factors that support myogenesis and angiogenesis 
(Murry, et al. 2005, Guarita-Souza et al. 2008, Strauer and Steinhoff 2011). 
Here it is important to note that additional animal studies have demonstrated 
that bone marrow cells and MSCs possess the risks of ectopic calcifications 
and ossifications in the heart (Breitbach et al. 2007). Nevertheless, human 
clinical trials are ongoing to ultimately assess safety, tolerability, and efficacy 
of bone marrow cell and MSC-based therapies (Schachinger et al. 2006, 
Assmus et al. 2010, Hare 2011). All of these trials target primarily patients 
with acute or sub-acute heart syndromes. In this scenario protective rather 
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than reparative approaches may suffice to offer a substantial therapeutic 
benefit to patients. 
 
In scenarios of chronic heart failure with substantial scarring there is clearly a 
need for re-muscularization. This may be best achieved by implantation of 
cardiomyocytes. In support of this, several groups have documented survival 
and integration of cardiomyocyte grafts in the heart (Soonpaa et al. 1994). 
These fundamental observations have been made in different animal models, 
but cannot be easily translated to the human, unless a reliable source for 
human cardiomyocytes can be identified.  
 
In light of this, the introduction of robust protocols to derive and maintain 
human embryonic stem cells (hESCs) in a self-renewing state with pluripotent 
differentiation potential was a major breakthrough (Thomson et al. 1998). 
More recently, alternative human pluripotent stem cells, including induced 
pluripotent stem cells (Takahashi et al. 2007) and parthenogenetic stem cells 
(Turovets et al. 2011), became available and may offer new perspectives to 
overcome the obvious ethical restraints associated with a potential use of 
hESC (Laflamme and Murry 2005, Zimmermann 2011). 
 
Today hESCs remain the gold standard for pluripotency and any pluripotent 
cell-based technology will have to be compared to it. hESCs can give rise to 
derivatives of the 3 germ lines – ectoderm, mesoderm and endoderm. 
Ectodermal differentiation is apparently the default differentiation pathway in 
most hESC lines (Vallier et al. 2004). Spontaneous mesoderm and in 
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particular cardiomyocyte differentiation are minimal in ESCs, but may be 
enhanced by stage specific differentiation protocols, adapted to simulate the 
paracrine milieu that governs embryonic heart development (Kattman et al. 
2011, Hudson et al. 2012). Coupled with new technologies to scale up the 
quantity of differentiated cardiomyocytes (Zweigerdt et al. 2011), these 
approaches would theoretically provide enough cardiomyocytes to replace 
and replenish those that were lost during myocardial infarction in a human 
heart (approx. 1x109 cardiomyocytes) (Reinecke et al. 2008). Alternatively, 
cardiomyocytes may be isolated and enriched by manual dissection of 
spontaneously beating areas within differentiating embryoid bodies (EBs) 
(Kehat et al. 2001, Xu et al. 2002), Percoll gradient centrifugation (Laflamme, 
et al. 2007), genetic selection in transgenic hESC-lines (Xu et al. 2008), or 
immune-assisted cell sorting via unique cell surface markers (Dubois et al. 
2011, Elliott et al. 2011). Direct implantations of hESC-derived 
cardiomyocytes into pigs with experimental atrial-ventricular conduction block 
and guinea pig models demonstrated that these cardiomyocytes were able to 
function as pacemaker cells (Kehat et al. 2004, Xue et al. 2005) and further 
experiments in rodent models and mice demonstrated that these 
cardiomyocytes are capable of survival, engraftment and maturation long term 
(Laflamme et al. 2005, Dai et al. 2007, van Laake et al. 2007). However, this 
direct approach has its limitations and conflicting reports. Most studies report 
that direct injection of the cardiomyocytes into a pulsing heart leads to 
massive cell loss by immediate ejection. The remaining cells that are lodged 
in the myocardium typically undergo cell death (Müller-Ehmsen 2002, Muller-
Ehmsen et al. 2002, Reinecke and Murry 2002, Dow et al. 2005). Well 
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controlled animal studies demonstrate that only <10% of the injected cells are 
retained (Zhang et al. 2001, Dow, et al. 2005, Qiao et al. 2009). In addition, 
when hESC derived cardiomyocytes were transplanted into rodents hearts, 
most of the transplanted cells secrete their unique extracellular matrix 
components which prevents the cells from integrating and connecting to the 
host myocardium; such fibrotic areas could also potentiate the risk for 
arrhythmia induction (Passier et al. 2008). However, a very recent study 
demonstrated that hESC derived cardiomyocytes can electrically couple and 
also prevent arrhythmias in infarcted guinea pig hearts (Shiba et al. 2012).  
 
Another recently discovered pool of cells - cardiac progenitor cells (CPCs) - 
has raised the possibility of endogenous heart regeneration (Hierlihy et al. 
2002, Beltrami et al. 2003). These progenitors can be isolated by flow 
cytometry either by making use of a Hoechst dye extrusion assay (Jackson et 
al. 2001) or by selection via surface markers such as c-kit (Beltrami et al. 
2003) and Sca-1 (Oh et al. 2003). Preliminary studies with transplanted 
animal CPCs and also sheets of clonally expanded Sca-1+ cells into infarcted 
animals suggested that CPCs are able to home to the injured myocardium 
(Oh, et al. 2003) and improve cardiac functions post infarct through VCAM-
1/VLA-4 signaling (Matsuura et al. 2009). These endogenous cells were also 
able to respond to growth factor stimulation via mobilization to the injured 
areas (Bocchi et al. 2011, Ellison et al. 2011). In humans, CPCs were also 
identified (Messina et al. 2004) and could be genetically modified to proliferate, 
survive, engraft with enhanced improvement to the injured myocardium 
structure and function (Mohsin et al. 2011). In clinical trials, patients with 
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ischemic cardiomyopathy were transplanted with human cardiac stem cells 
and preliminary results demonstrated that intracoronary infusion of autologous 
cardiac stem cells improved left ventricular systolic function and also reduced 
the infarcted size in patients with heart failure (Bolli et al. 2011). Similar 
results were obtained in another study from the Marban laboratory using the 
autologous CPC approach (Makkar et al. 2012). Both studies were not 
powered to draw any conclusions towards efficacy. This will have to be tested 
in follow-up trials. In addition, the mechanism of action of the cell grafts is not 
well understood. 
 
1.5  Paracrine Support – IGF-1 
A key observation from the many experimental and clinical cell-based studies 
is that irrespective of the cell entity employed, therapeutic effects could be 
observed. This raised the question whether a set of commonly secreted 
factors underlies the cell-based therapeutic effect rather than functional 
integration of contractile units into the heart, which was not observed in most 
of the tested cell types. Among the many paracrine factors released from cell 
grafts IGF-1 appears to exhibit strong “therapeutic” activities, i.e. enhanced 
cell survival, cardiomyocyte hypertrophy, and enhanced angiogenesis (Welch 
et al. 2002, Shyu et al. 2005, Dobrucki et al. 2010). 
 
IGF-1 application has been introduced clinically in the treatment of patients 
with Rett Syndrome (ClinicalTrials.gov Identifier: NCT01253317), amyotrophic 
lateral sclerosis (ClinicalTrials.gov Identifier: NCT00035815) and Duchenne 
muscular dystrophy (ClinicalTrials.gov Identifier: NCT00004646). In heart 
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failure, IGF-1 was tested to induce physiological hypertrophy in dilated 
ventricular myocardium (Osterziel et al. 1998, Vasan et al. 2003); these 
investigators could, however, not identify a clear therapeutic benefit of 
systemically applied IGF-1. Presently, safety and efficacy of IGF-1 
(Mecasermin; single dose, intracoronary injection) is tested in patients with 
ST-elevation Acute Myocardial Infarction (STEMI; ClinicalTrials.gov Identifier: 
NCT01438086). 
 
Biologically active IGF-1 is a 70 amino acid protein that is encoded on 6 
exons. It is mainly produced in the liver in response to growth hormone 
stimulation and circulates throughout the body bound to its binding protein 
(IGFBP3). There are 4 IGF-1 splice variants, which can be further grouped in 
2 classes (Figure 2). The mature peptide is encoded in exons 3 and 4. The 
definite roles of the IGF-1 splice variants are not fully understood, but most 
biological activities are affiliated to class 1 IGF-1 protein variants (Bloor et. al., 
2001). 
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Figure 2: Schematic overview of IGF-1 splice variants. Numbers 
represents exons. The biologically active IGF-1 peptide is encoded on exons 
3 and 4. 
 
 
IGF-1 binds to a specific receptor (IGF-1R) and activates a variety of signaling 
cascades (Mourkioti and Rosenthal 2005), which include phosphatidylinositol-
3-kinase (PI3K)/Akt, mitogen-activated-protein-kinase (MAPK), and 
calmodulin dependent kinase (CaMK) signaling (Figure 3). Of particular 
therapeutic interest in heart failure may be its activation of pro-survival 
pathways and induction of physiological cardiomyocyte hypertrophy. 
Unwanted effects include the possibility to induce oncogenic cell growth.  
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Figure 3. Schematic overview of IGF-1R signaling pathways. 
Adapted from Moukioti and Rosenthal (2005).  
 
 
1.6  Heart muscle tissue engineering  
Tissue engineering has been developed to biophysically support the failing 
heart, but also to provide in vitro test-beds for drug development and studies 
of organogenesis (Eschenhagen and Zimmermann 2005). In heart muscle 
repair the main goals are to (1) add contractile elements to the failing heart for 
functional support and (2) provide restraint similar to the ACSD approach, but 
fully humanized. The most direct approach involves the use of scaffolds, 
either synthetic (Carrier et al. 1999) or biological (Li et al. 1996, Eschenhagen 
et al. 1997, Zimmermann et al. 2000, Zimmermann et al. 2002, Bursac et al. 
2007, Tian and Morrisey 2012), and seeding of cardiomyocytes in or on these 
scaffold. The first macroscopic contractile three-dimensional heart-like tissue 
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was engineered from embryonic chick cardiomyocytes as in vitro model for 
target validation (Eschenhagen, et al. 1997). This was followed by the advent 
of mammalian engineered heart tissues (EHTs) for drug screening and 
therapeutic applications (Zimmermann, et al. 2000, Zimmermann, et al. 2002, 
Zimmermann et al. 2004, Naito et al. 2006, Zimmermann et al. 2006) In 
contrast to other original tissue-engineered heart muscle models (Bursac et al. 
1999, Carrier, et al. 1999, Li et al. 1999, Kelm and Fussenegger 2004, Leung 
and Sefton 2010), EHTs displayed coordinated beating with directed force 
development and heart muscle-like physiology (e.g., Frank-Starling 
mechanism) and pharmacological responses (e.g., beta-adrenergic and 
muscarinic modulation of contractile properties). Subsequently, alternative 
tissue engineering modalities with comparable functionality have been 
introduced (Radisic et al., 2004; Shimizu et al., 2002). Importantly, EHT 
cultures support anisotropic tissue organization and maturation of immature 
cardiomyocytes (Zimmermann, et al. 2002, Tiburcy et al. 2011). Based on this, 
it appeared straightforward to postulate that the EHT culture format would 
also support the assembly of immature hESC-derived cardiomyocytes into 
functional myocardium.  
 
Despite the recent increased focus on developing advanced models of 
engineered tissues, several key clinical challenges remain to be addressed: 
engineered cardiac constructs should be of a clinically relevant size and 
thickness and consist of immunologically tolerable cell populations in 
collagen-based matrix similar to the host heart (Vunjak-Novakovic and 
Scadden 2011). These constructs must also be able to connect to the host 
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blood supply, propagate electrical pulses which must be synchronized with 
the host myocardium, and subsequently generate sufficient contractile force to 
aid in blood circulation. First proof-of-concept for these in vivo functionalities 
stems from EHT engraftment in rats with myocardial infarction (Zimmermann, 
et al. 2006). 
 
To address the size issue, attempts were made by up scaling the physical 
area and thickness of cardiac tissue constructs. Most of these involve the 
fusion or stacking of tissue constructs such as EHTs (Naito et al., 2006) or 
with cell sheets (Shimizu et al. 2006). To further extend the applications of the 
EHT technology, a different approach to provision of cardiac restraint with 
contractile elements was attempted. This involved the development of a 
continuous pouch-like EHT (Yildirim et al. 2007), which allowed the 
embracement of the heart ventricles with an anticipated function as biological 
ventricular assist device (BioVAD). The BioVADs were generated using 
neonatal rat cardiomyocytes mixed with collagen type 1 and placed over a 
spherical glass mold to allow tissue condensation within 7 days.  BioVADs 
were observed to maintain spontaneous contractions throughout the casting 
and condensation stages, and force measurements demonstrated heart-like 
contractile properties. In addition, these BioVADs stably grafted onto the 
epicardial surface of rat hearts. Vascularization occurred rapidly in vivo. The 
study suggested that BioVADs could be engineered to provide a large tissue 
construct capable of therapeutically restraining the failing heart and adding 
contractile elements to aid in myocardial force generation. 
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1.7  Objectives 
The overarching aim of this dissertation was to advance the BioVAD concept 
to a human model with enhanced (paracrine) functionality. Following main 
objectives were defined and are summarized in Figure 4: 
 
1) Implementation of robust protocols to direct cardiogenicity in human 
ESC cultures 
2) Development of human engineered heart muscle (EHM) with properties 
of native myocardium 
3) Construction of human BioVADs based on the knowledge gained from 
the human EHM and rat BioVAD models 
4) Integration of paracrine IGF-1 activity into the human BioVAD 
approach. 
5) Testing the feasibility of human BioVAD implantation in vivo.  
 
Figure 4: Experimental outline of the dissertation.
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2.  Materials and methods 
 
All experiments were performed according to institutional regulations and 
good laboratory practice rules. Animal experiments were approved by LAVES 
(AZ 10.13, AZ 33.9-42502-04-12/0830). All substances were acquired at 
highest grade from SIGMA ALDRICH if not indicated otherwise. 
 
 
2.1  Human embryonic stem cell culture 
Import and experimentation with human embryonic stem cells were approved 
by the Robert-Koch-Institute (www.rki.de; approval #12 from 13.09.2005 to 
W.H. Zimmermann according to §11 Stammzellgesetz). 
 
 
2.1.1 Human feeder cells preparation 
Human foreskin fibroblasts (HFFs) cells were purchased from the American 
Type Culture Collection (SCRC-1041; ATCC) and propagated in HFF-medium 
(Appendix) to passage 20 for cryopreservation at -152oC in cryo-medium 
(Appendix) for controlled freezing rate of cells. Passage 21 and onwards HFF 
cells were subsequently used to support hESC culture. Briefly, 2x106 HFF 
cells were harvested by trypsinization and exposed to 30 Gray γ-irradiation 
(STS Biobeam 8000, Germany) to mitogenically arrest the cells. 
Subsequently, inactivated HFF cells were plated down on a cell culture dish. 
The culture dish was then incubated in a 37oC cell culture incubator for 24 
hours. Thereafter, the cells were rinsed with PBS to remove the serum and 
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fresh hESC medium (Appendix) was overlaid. Subsequently, hESC colonies 
can be plated on top of the irradiated HFF cells. 
 
 
2.1.2  Embryonic stem cell culture 
hESC lines, HES2 and HES3 (ES Cell International, Singapore), were 
obtained and adapted to culture on γ-inactivated HFFs. hESC-medium was 
exchanged daily until colonies covered 80% of the culture dish. hESC cultures 
were tested to be free of mycoplasma using the MycoAlert™ Mycoplasma 
detection kit (Lonza). 
 
 
2.1.2.1 “Cut and Paste” passaging 
Undifferentiated hESCs were cultured as intact colonies and split at 1:9 ratio 
when confluent. The colonies were then enzymatically digested with 
collagenase IV working solution (Appendix) and either manually scored using 
a glass needles or by rolling with the StemPro® EZPassage™ Tool 
(Invitrogen) to obtain homogeneously sized cell rafts (Figure 5). These cell 
rafts were then either seeded onto another plate of irradiated HFFs for 
continual passage or subjected to embryoid bodies (EB) based cardiac 
differentiation protocols. 
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Figure 5:  hESC colonies scored with the EZ Passage tool. Image displays 
a representative HES3 culture. Scale bar 1 mm. Image from Soong et al., 
2012. 
 
 
 
2.1.2.2 Monolayer passaging 
Undifferentiated hESC were first single cell adapted to a monolayer culture as 
outlined (Hudson, et al. 2012). Briefly, confluent hESC cultures were gently 
enzymatically dissociated with TrypLE (Invitrogen) and triturated with a 10 ml 
serological pipette (Sarstedt) to obtain a homogenous suspension of single 
hESC with little contaminating fibroblast cells. The dissociated hESC were 
then plated onto 2.6x106 γ-irradiated HFFs and allowed to expand for further 7 
days in a 37oC humidified 5% CO2 incubator. After at least 10 rounds of cell 
passaging, hESC were considered “single cell adapted” and suitable for 
monolayer cardiomyogenesis differentiation protocols. 
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2.1.3 Embryonic stem cell differentiation 
 
 
2.1.3.1  Embryoid body differentiation 
HES 3 cell rafts were first adapted to serum free conditions in SF adaptation 
medium (Appendix) and incubated in a 100 mm Ultra-low® Petri dish 
(Corning) where EBs are spontaneously forming. These were then subjected 
to cardiomyocyte differentiation (Graichen et al. 2008) as follows. First a 40 
µm cell strainer was inverted into an open 50 ml centrifuge tube and placed 
carefully in a tube rack. Next, the Ultra Low® petri dishes containing the EBs 
were removed from the incubator. Then, the entire culture was passed 
through the inverted cell strainer rinsed with bSFS medium (Appendix). After 
the flow through was completed, the cell strainer was turned so that it sat 
properly inside the opening of a new sterile 50 ml centrifuge tube. 10 ml of 
bSFS containing 5 µmol/L of SB203580 (p38 MAPK inhibitor) was added in 
the dark and used to flush the EBs back into a centrifuge tube. Then they 
were transferred back into the source Ultra Low® Petri dish and incubated 
further (Figure 6). This was marked as Day 2 of differentiation. Medium 
change was performed every day until culture day 3 where it was then 
changed every 2 days. Spontaneously beating EBs can be observed from 
culture day 8 onwards. 
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Figure 6. Embryoid body differentiation. SB203580 (5 µmol/L) was added 
on day 2 (D2). Beating was observed to start on culture day 8 with increasing 
beating areas until culture day 14. D-1 denotes day of ESC seeding. 
 
 
2.1.3.2 Monolayer differentiation 
hESC colonies were first single cell adapted to form monolayers and then 
subjected to a modified cardiomyocyte differentiation protocol as outlined 
(Hudson, et al. 2012). Briefly, single cell adapted hESCs (0.5 x 104 cells per 
cm2 in a 24 well culture dish format) were exposed to a mesodermal induction 
protocol of 16 days (Figure 7).  
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Figure 7. Monolayer differentiation. Activin and BMP were added for 3 days 
before Wnt signaling was inhibited with IWP4 (Wnt inhibitor) on culture day 3. 
First beating was observed on culture day 10.   
 
 
From days 0 - 2, hESCs were cultured in serum free basal monolayer 
differentiation medium (Appendix) supplemented with 9 ng/ml Activin A, 5 
ng/ml BMP4 (both R&D Systems), 5 ng/ml bFGF (Millipore). From Day 3 - 10, 
Activin A, BMP4 and bFGF were withdrawn. Culture medium was exchanged 
and supplemented with 5 µmol/L IWP4 (Stemgent) every 3rd day until day 13. 
From day 13 - 16, cardiomyocyte specification was enhanced withdrawal of 
IWP4 from basal monolayer differentiation medium. Typically, first beating 
areas in the cultures were observed between days 10 - 13. 
 
 
2.1.4 Flow cytometry 
For analyzing pluripotency and cardiac differentiation efficiency cells were 
dissociated with trypsin and pelleted at 300 x g for 4 minutes. The supernatant 
was aspirated. The dissociated cells were fixed with 4% paraformaldehyde 
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(Histofix, Roth) for 24 hours. Next, 2 wash steps with PBS were performed 
and samples were then permeabilized with Triton X-100 in a blocking buffer 
(Appendix) for 10 minutes at room temperature followed by the staining by 
primary antibodies against Tra1-60, Oct4, SSEA4 for 1 hour at 4 oC. Following 
3 additional wash steps with blocking buffer, secondary antibodies (goat anti-
mouse IgG conjugated with Alexa Fluor® 488, Invitrogen 1:1000) and nuclear 
label dye, DAPI (1 µg/ml, 1:1000) were then incubated with the cells for 30 
minutes at 4 oC in the dark.  
 
For ESC derived cardiomyocytes analysis, 70% ethanol fixed single cells 
were incubated in blocking buffer (Appendix) for 10 minutes followed by 
incubation with primary antibodies against alpha sarcomeric actinin (Sigma-
Aldrich A7811, 1:4000) for 1 hour at 4 oC. Following 3 additional wash steps 
with blocking buffer, secondary antibodies (goat anti-mouse, IgG conjugated 
with Alexa Fluor® 488, Invitrogen 1:1000) and nuclear label dye, DAPI, were 
then added and the cardiomyocytes were incubated for 30 minutes at 4oC in 
the dark.  
 
In parallel, cell populations incubated with IgG isotype control primary 
antibodies with appropriate secondary antibodies served as negative controls. 
Recordings were performed on a LSRII cytometer (BD) and analyzed using 
FACSDiva Software 6.0 (BD) or Cyflogic Software. The following gating 
strategy was applied. The population of interest was first displayed in FSC 
and SSC (Figure 8 A). A DNA stain was used to gate out dead cells (sub-G1 
fraction, Figure 8 B). The width of the DNA signal was then used exclude cell 
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doublets (Figure 8 C). These gated cells were then displayed based on actinin 
fluorescence (Figure 8 D) to distinguish between cardiomyocytes (CM; 
actinin+) and non-myocytes (NM; actinin-). 
 
 
 
 
 
Figure 8. Flow cytometry gating strategy. (A) Cells were displayed as 
scatter plot based on SSC + FSC. (B) Viable cells in G1 + G2 were selected 
based on DAPI signal intensity. (C) Doublets were excluded based on DAPI 
signal width. (D) Cardiomyocytes (CM) and non-myocytes (NM) were 
distinguished based on actinin positivity. Similar gating strategies were applied 
for detection of stem cell markers. 
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2.2 Generation and characterization of human Engineered Heart 
Muscle (EHM) 
 
2.2.1 Preparation of casting molds 
To generate the casting molds for EHMs, 4 Teflon spacers of 11 mm diameter 
and 5 mm height were evenly spaced in a glass petri dish (Figure 9 A). 9 ml of 
Sylgard Silicone 184 (Dow Corning) and 1 ml of curing agent were pipetted 
and mixed thoroughly in a 50 ml centrifuge tube and spun at 300 x g for 3 
minutes to remove air bubbles. The silicone mixture was then poured into the 
glass dish around the Teflon spacers, allowed to harden for 24 hours at room 
temperature. Next, the Teflon spacers were carefully removed with forceps 
and a droplet of premixed silicone was applied to each of the centers of the 
four recesses to attach a short silicone core upright (Figure 9 A, ii) The 
assembled casting mold was allowed to cure at 55 °C overnight. 
 
To ensure the removal of toxic residuals from casting molds, they were placed 
in a glass beaker filled with distilled water, boiled and drained at least 4 times. 
Thereafter, silicone tubings (Figure 9 A, iii) were slipped over the silicone 
cores and the fully assembled casting mold was wrapped in aluminum and 
autoclaved until ready for use. These casting molds can be reused indefinitely. 
 
Materials and Methods 
	   26 
 
 
 
Figure 9: Casting mold and silicone holder for EHM culture. A: Glass 
culture dish filled with transparent silicone and 4 circular recesses with central 
spacers: (i) Teflon disc of 11 mm diameter and 5 mm height with central hole 
used as spacer during the silicone hardening process; (ii) recess with thin 
silicone core; (iii) silicone tubing used as inner spacer during the EHM 
formation process placed over a central silicon core. B: Flexible silicone poles 
for mechanical loading of EHM. Scale bars: 10 mm. Image from Soong et al., 
2012. 
 
 
2.2.2 Preparation of holding devices 
Flexible silicone poles (length: 11 mm, thickness: 1.5 mm, inner/outer 
distance: 3/6 mm) with circular base (diameter: 20 mm, thickness: 1.6 mm) 
were made from Sylgard Silicone 184 (Dow Corning) as resilient holder 
(Figure 9 B) Before use they were boiled in distilled water, drained and 
autoclaved.  
 
A B 
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2.2.3 Preparations of cells 
Human EHM generation involves the casting of single cells, ESC-derived 
cardiomyocytes with or without non-myocytes such as fibroblasts, into a 
collagen-based hydrogel to form a 3 dimensional organoid.  
 
 
2.2.3.1 Embryonic stem cells 
To obtain single hESC derived cardiomyocytes from EBs or monolayer cells 
for human EHM generation, cells were first incubated with 0.2 % collagenase 
type 1 (C0130, Sigma Aldrich) for 45 minutes at 37oC and then incubated with 
0.25 % trypsin (Invitrogen) for 5 minutes at room temperature. Trituration with 
micropipettes was performed to further dissociate cell clumps for 5 minutes at 
room temperature. Full neutralization with complete human EHM medium 
(Appendix) was next carried out and cells were centrifuged at 300 x g, 4 
minutes. Supernatant was aspirated and the cell pellet was resuspended in 
complete medium until a homogenous single cell suspension was obtained. 
Cells were counted with a Neubauer counting chamber. 
 
 
2.2.3.2 Human foreskin fibroblasts (HFF) 
To obtain single HFF cell suspensions, wild type or transgenically modified 
HFF cells were incubated with TrypLE Express (Invitrogen) for 3 minutes at 
37 oC and then triturated with a 10 ml serological pipette to further dissociate 
cell clumps. Next, complete HFF medium (Appendix) was added to neutralize 
the enzymatic activity. Cells were then centrifuged at 300 x g, 4 minutes and 
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supernatant was aspirated. The required number of cells was counted in a 
Neubauer cell counting chamber.    
 
 
2.2.4 Construction and culture of EHM 
Single cells were mixed thoroughly with collagen type I, 2X DMEM (Appendix), 
NaOH and Matrigel in a prechilled 15 ml centrifuge tube accordingly (Table 1). 
NaOH was added drop wise until Phenol red color indicator changes from 
yellow (acidic) to pink. Then, 450 µl of the master mix was quickly distributed 
into individual casting mold recesses (Figure 9 A) and placed in a 37 °C 
humidified incubator with 5% CO2 for 1 hour. Following that, 6 ml of 
prewarmed complete EHM medium was overlaid until all EHMs were 
completely covered with medium and then incubated for a further 24 hours 
and medium was exchanged thereafter every other day. After the EHMs had 
progressively condensed, typically after 3 days, they were transferred onto 
resilient silicone holders (Figure 9 B). 
Number of EHM 4 20 
Rat Collagen (3.2 mg/ml) 440 µl 2,200 µl 
2X DMEM 535 µl 2,675 µl 
NaOH 0.1N  95 µl 475 µl 
Matrigel® 200 µl 1,000 µl 
Cell Suspension (1.5x106 per EHM) 829 4,145 
TOTAL VOLUME 2,100 µl 10,500 µl 
 
Table 1: EHM reconstitution mixture.  
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Prior to the transfer of condensed EHMs, the necessary number of silicone 
holders was first placed into a tissue culture plate filled with EHM medium. 
Thereafter, the top of the removable silicone tubing of a casting mold dish 
was pinched gently with a pair of curved forceps and slowly removed from 
the casting dish. Next, the silicon tube was placed over one of the paired 
silicone poles of a silicone holder and the EHM was released by gentle 
shaking or nudging with a pipette tip. With the help of another sterile pipette 
tip, the other silicone pole was gently bent to suspend the EHM between the 
2 poles. The contracting EHM will bend the silicone holders inducing dynamic 
load for the EHM to work against. Medium was exchanged every 2 days over 
the next 7 days of EHM maturation. EHMs were ready for end-point analyses 
on culture day 10. 
 
 
2.2.5 Isometric force measurements 
Force measurements of EHMs were performed in thermostatted organ baths 
(FMI GMbH) as previously described (Zimmermann, et al. 2000). Briefly, after 
day 7 of EHM culture on silicone stretchers, EHMs were carefully removed 
and placed over the hooks of a force transducer in an organ bath filled with 
Tyrode’s solution (Appendix). EHMs were field stimulated via two platinum 
electrodes at 2 Hz (5 ms monophasic pulses, 200 mA) and preloaded to the 
length of maximal force production (Lmax). Then the responses to increasing 
calcium concentrations (0.2 to 4 mmol/L) data were acquired using BMON 
software and analyzed by AMON software (both Jäckel; Hanau, Germany). 
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2.2.6 Immunofluorescence imaging 
Whole mount immunofluorescence antibody staining was performed to 
visualize cardiac muscle formation within the EHM. EHMs were fixed in 4% 
formaldehyde solution (Histofix, Roth) overnight. EHMs were then incubated 
in a permeabilizing blocking buffer for 24 hours. Next, EHMs were incubated 
with primary antibodies against alpha sarcomeric actinin (Sigma-Aldrich 
A7811, 1:4,000) for 3 days at 4oC on a rotary microfuge holder. Thereafter, 3 
thorough wash steps with blocking buffer (Appendix) were performed followed 
by the incubation with secondary antibodies (goat anti-mouse 2 mg/ml, IgG 
conjugated with Alexa Fluor® 488, Invitrogen 1:1,000), phalloidin (conjugated 
with Alexa Fluor® 546, Mobitec 1:60) and nuclear label dye, DAPI (1 µg/ml, 
1:1000) for 24 hours at 4oC in the dark. The EHMs were thoroughly washed 
with PBS and finally mounted on microscope slides for image capture and 
analysis. Images were taken with a Zeiss LSM710 confocal microscope. 
 
 
2.2.7 Dissociation of EHM for flow cytometry 
To obtain cells from EHMs for flow cytometry, each EHM was cut into half and 
incubated in 1 ml of collagenase for 30 minutes at room temperature. 
Thereafter, the remaining large pieces were gently teased apart with two 27G 
needles to obtain smaller pieces in the cell culture well. Next, further 
enzymatic dissociation of the pieces was performed according to the 
procedures highlighted in section 2.2.3.1. After single cells were obtained 
from the dissociation of EHMs, the cells were fixed in 70% EtOH and kept in 4 
oC until flow cytometry. 
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2.3 Generation and characterization of BioVADs 
 
2.3.1  Construction of BioVADs 
Modifications of the original rat BioVAD protocols (Yildirim et al., 2007) were 
required to create a scalable casting mold for the generation of large 
humanized BioVADs. In addition, to confer a biomimetic culture format with 
regular pulsatile action, an inflatable inner structure required to be designed. 
 
A series of casting cubes from Makrolon® (Bayer MaterialScience) were 
spherically machine-hollowed out and aligned to generate 18 mm, 20 mm and 
30 mm casting molds. 10% molten agarose was poured into the 18 mm 
casting mold and cooled to form a solidified spherical agarose ball and 
speared with a central wooden spine. Next, the ball and stick was removed, 
centrally placed in a 20 mm casting mold and liquid silicone (Silicone 2000 
and curing agent 9:1 ratio) was poured around the 18 mm agarose ball and 
allowed to cure uniformly for 24 hours at room temperature. Thereafter, the 
solidified silicone coated ball and stick were removed and placed in boiling 
water until the inner agarose dissolved, yielding an inflatable sphere with 20 
mm outer diameter and a wall thickness of 1 mm. This 20 mm inflatable 
sphere was then placed in a 30 mm casting mold and connected to a 10 G 
silicone urinary catheter (BARD, USA). 
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2.3.2  Preparation of casting molds for biomimetic support 
First, the silicone sphere was connected to a mechanical animal ventilator 
(FMI, GmbH) and inflated to check for surface tears so as to ensure proper 
pulsatile function. Next, the casting blocks with attached silicone spheres 
were boiled, drained and autoclaved to sterilize the whole apparatus prior to 
use. After cooling down to room temperature, the BioVAD casting mold could 
then be used for the seeding of cells to generate humanized BioVAD. 
 
 
2.3.3 Preparation of cells 
Initially, cardiomyocytes harvested from neonatal rat hearts were used to 
determine the feasibility of BioVAD formation. Thereafter, we attempted to 
generate human BioVADs with hESC derived cardiomyocytes.  
 
 
2.3.3.1 Rat model 
Rat myocytes were prepared by using a trypsin/DNase dissociation protocol 
(Zimmermann et al., 2002). 8 ml reconstitution mixture containing 2.6 x 107 
cells and rat-tail collagen (4.2 mg) was poured into the mold and allowed to 
condense for 72 hours. After day 10, the rat BioVAD was harvested and 
analyzed. 
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2.3.3.2 Human model 
Single cells obtained from the dissociation of hESC-derived cardiomyocytes 
were used to generate the human BioVAD (hBioVAD)s as outlined in Table 2 
and allowed to condense for 24 hours. From culture days 3 to 8, uniform 
pulsatile stretch (10% strain, 90 beats per minute) was initiated using a 
mechanical ventilator to inflate and deflate the central sphere. Non-pulsatile 
conditions served as control (0% strain). 
 
Human BioVAD 1 
Bovine collagen (6.1 mg/ml) 1,030 µl 
2x DMEM 1,030 µl 
NaOH 0.1 N 200 µl 
cells suspension 6,140 µl 
cell number (x106) 26 
total 8,400 µl 
 
Table 2: Components required to generate human BioVADs 
 
 
2.3.4 Immunofluorescence imaging 
Tissue samples from BioVADs were harvested and fixed in 4% formaldehyde 
(Histofix, Roth) overnight and then permeabilized with blocking buffer. 
Immunofluorescence labeling and imaging were performed as highlighted in 
section 2.2.6.  
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2.3.5 RNA preparation 
Total RNA was prepared using standard Trizol® (Invitrogen) extraction 
protocols. BioVAD and EHM tissue samples were first rinsed with PBS prior to 
snap freezing in liquid nitrogen. 500 µl of Trizol® and 7 mm stainless steel 
beads (Qiagen) were added to each sample tube and homogenized with a 
Tissue Lyser II (Qiagen) at 25 Hz for 5 minutes. Next, 100 µl of chloroform 
was added into the samples and the tubes were agitated vigorously for 1 
minute and allowed to settle for 10 minutes at room temperature. The tubes 
were then spun at 12,000 x g for 20 minutes at 4oC centrifuge (Eppendorf 
5417). The aqueous phase from the samples were transferred to individual 
RNAse free microfuge tubes and vigorously mixed with equal parts of 
isopropanol for 1 minute and allowed to settle for 5 minutes at room 
temperature. Next, the tubes were spun at 12,000 x g for 20 minutes to pellet 
the RNA and then rinsed with 70% EtOH. Following another centrifuge step of 
12,000 x g for 5 minutes, the RNA tubes were allowed to air dry prior to 
suspension in RNAse free water. The amount of RNA was quantified and 
quality ensured (260 / 280nm OD. ratio ≥ 1.8) with the Nanodrop 
spectrophotometer (Thermo Scientific) and subsequently stored at -80 oC. 
 
 
2.3.6 Reverse transcription 
Extracted RNA samples were first treated with DNAse I (Roche) to remove 
contaminating DNA. A reaction mix consisting of 1 µg RNA, 1 µl DNAse I 
buffer (Roche), 0.2 µl DNAse I enzyme was incubated at 37 oC for 20 minutes 
followed by an addition of 0.2 µl EDTA and incubation at 75 oC for 10 minutes 
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to inactivate DNAse I activity. For reverse transcription and quantitative RT-
PCR the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
was used according to manufacturer's instructions. 50 ng cDNA was mixed 
with a mastermix of RT-PCR reactions consisting of 300 nM 5’ primer and 3’ 
primer each, 100 nM Taqman probe and 2 X Taq polymerase were 
assembled in a 384 well plate (Applied Biosystems).  
 
 
2.3.7 Quantitative RT-PCR 
Amplification was performed on an ABI PRISM 7900HT Fast Real-Time PCR 
system (Applied Biosystems) with the following parameters: 50oC for 2 
minutes, denaturation at 95oC for 10 minutes and a cyclical amplification at 
95oC for 15 seconds and 60oC for 1 minute for a total of 40 cycles. No 
template and no reverse transcriptase reactions served as controls to ensure 
product specificity. Results from the run were determined by using ΔΔCT 
method (Livak and Schmittgen 2001). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) served as housekeeping gene standard. Primer 
sequences are listed in the Appendix, page 127.  
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2.4 Development of a cell based IGF-1 secretion technology 
 
2.4.1  Plasmids 
The plasmids pCMV-XL4 (SC119792; Origene), pLVx-Tight-Puro and pTetOn 
(both Lenti-X™ TetOn® Advanced inducible expression system, 632162;  
Clontech) were purchased and used in the development of cell based IGF-1 
secretion. pCMV-XL4 consists of the full length human IGF-1 transcript; pLVx-
Tight-Puro is an expression response vector which consists of a modified 
CMV promoter (PTight) with regulatory elements of the tetracycline operator 
sequences and includes a puromycin resistance gene; pTet-On-Advanced is 
the transactivator plasmid which contains an improved version of the reverse 
tetracycline controlled transactivator protein (rtTA), and also includes a 
neomycin resistance gene. 
 
 
2.4.2  Cells 
In this study, TSA cells (Giovarelli et al. 1995) were exploited to test the 
expression of human IGF-1 from pCMV-XL4 by transfection and as host cells 
for the packaging of genetically engineered lentivirus plasmids and lastly, to 
serve as production cells for transgenic lentivirus. HFF cells were used as 
target cells for transgenic lentivirus transduction to generate a stable inducible 
IGF-1 secreting cell line. Both TSA and HFF cells were cultured till 80% 
confluence prior to transfection or transduction respectively. 
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2.4.2.1 TSA cells 
TSA cells were cultured in TSA medium (Appendix) on 100 mm cell culture 
plates (Nunc).  
 
 
2.4.2.2 Human foreskin fibroblasts 
HFF cells were cultured in HFF medium (Appendix) as highlighted in 2.1.1 on 
100 mm cell culture plates (Nunc).  
 
 
2.4.3 Lipofection of pCMV-XL4 into TSA cells 
TSA cells were transiently transfected with 3 µg of pCMV-XL4 plasmids using 
lipofection with Polyfect (Qiagen) according to manufacturer’s protocol. The 
cell culture medium was exchanged after 16 hours and cells were incubated 
for another 48 hours.  
 
 
2.4.4  Analysis of IGF-1 expression and secretion 
Supernatants from transfected cells and untransfected cells were harvested 
and stored in -20oC until further use. To obtain cell lysates from these cultures, 
cells were rinsed thoroughly with PBS to avoid supernatant contamination. 
Next, 400 µl CytoBuster protein extraction buffer (Novagen) was layered over 
the cells and allowed to incubate on ice for 30 minutes. Thereafter, with the 
help of a cell scraper, the lysates were collected individually in 1.5 ml 
microfuge tubes and centrifuged at 12,000 x g for 30 minutes to pellet the cell 
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debris. The supernatant above this cell debris was then collected into sterile 
microfuge tubes and designated as cell lysates and stored at -20oC until 
further required. 
 
 
2.4.4.1 Western blot detection of IGF-1 
Cell lysates and supernatants were first quantified with standard Bradford 
protein assay to standardize loading protein concentrations and processed 
using standard western blot protocols. Briefly, proteins were resolved on a 
10% SDS-polyacrylamide gel followed by 400 mA electrophoretic transfer to a 
0.2 - 0.4 µm nitrocellulose membrane (Protran, Whatman) at 400 mA for 1 
hour. All membrane blots were blocked with blocking buffer (5% goat serum in 
PBS) for 1 hour followed by incubation with primary antibodies against hIGF-1 
(abcam, 1:5,000) and GAPDH (Santa Cruz, 1:1,000) overnight at 4oC. 
Thereafter, the membrane was washed with 1% TBST buffer (Appendix) 
thoroughly and incubated with secondary antibodies (goat anti-mouse IgG, 
1:20,000) for 1 hour at room temperature. To visualize the protein bands, the 
membrane was incubated with horseradish peroxidase substrate 
(SuperSignal West Femto kit; Pearce, Thermo Scientific) and developed with 
a membrane detection system (VersaDoc; BioRad) and analyzed with 
Quantity One software (BioRad). 
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2.4.4.2 ELISA detection of IGF-1 
IGF-1 concentration in cell culture supernatants was measured with a 
sandwich enzyme linked immunosorbent assay (ELISA) following the 
manufacturer’s protocol (Quantikine® human IGF-1; R&D systems). Results 
were recorded at 450 nm and analyzed with a microplate reader (FlexStation 
3; Molecular Devices).  
 
 
2.4.5 IGF-1 PCR cloning 
The IGF-1 variant 4 sequence was PCR amplified from pCMV-XL4 with high 
fidelity hot start DNA polymerase  (Platinum® Taq; Invitrogen) and the 
following hIGF-1 primers with flanking restriction enzyme cutting sites: 5’– 
GCGGCCGCATGGGAAAAATCAGCAGTCTTCC, 3’– 
TCTAGACTACATCCTGTAGTTCTTGTTTCC (5’-NotI and 3’-XbaI sites 
underlined respectively). The PCR mastermix had the following composition: 
1 X PCR buffer, 1.5 mM MgCL2, 0.2 mM dNTP mix, 0.2 µM 5’ forward primer , 
0.2 µM 3’ reverse primer, 0.25 µg plasmid DNA and 0.2 µl of DNA Taq 
polymerase (1 unit) was subjected to 35 cycles in a thermal cycler (GeneAmp 
9600, Applied Biosystems) using the following temperature profiles: 
denaturation at 94oC for 1 min; annealing at 60oC for 1 min; and extension at 
72oC for 1 min. The PCR product for IGF-1 was separated on 1% agarose 
gels, visualized by ethidium bromide (EtBr) staining, excised and purified 
according to the manufacturer’s protocol (QIAquick gel extraction kit; 
QIAGEN). The purified IGF-1 product was stored at -20oC until required. 
Sequencing was performed to ensure the correct sequence of IGF-1 variant 4. 
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2.4.6  Construction of IGF-1 encoding lentivirus 
First, the plasmid pLVx-Tight-Puro was digested with restriction enzymes NotI 
and XbaI (both FastDigest®, Fermentas) in a double digestion reaction to 
generate a linearized plasmid (linpLVx-Tight-Puro). The restriction reaction 
mix included: 1.0 µl NotI, 1.0 µl XbaI, 2 µl FastDigest® Buffer, 1 µg/µl plasmid 
pLVx-Tight-Puro. This was incubated at 37oC for 4 hours and subsequently 
heat inactivated at 85oC for 5 minutes. The restriction digest product was 
separated on a 1% agarose gel, visualized by EtBr staining, excised and 
purified as described in 2.4.5. The purified linearized linpLVx-Tight-Puro 
vector was stored at -20oC until required.  
 
Next, a mastermix reaction containing 250 ng purified human IGF-1 amplified 
product, 100 ng linpLVx-Tight-Puro, 4 µl rapid ligation buffer (5X), 1 µl T4 
DNA ligase (5 units/µl) was assembled and incubated at room temperature for 
10 minutes to generate the recombinant pLVx-Tight-hIGF1-Puro plasmid.  
 
Then, chemically competent DNA methylase negative (dam-) E. coli strain 
(One Shot®INV110; Invitrogen) was chemically transformed with 2 µl pLVx-
Tight-hIGF1-Puro plasmid according to the manufacturer’s protocol. Positive 
colonies containing the ligated plasmid were selected for by ampicillin 
resistance and further confirmed by colony PCR with hIGF-1 primers listed 
above. Briefly, one colony of transformed E. coli was picked and inoculated 
into a tube containing the same PCR master mix outlined in 2.4.5. and PCR 
amplified. Amplification of a positively transformed E. coli colony containing 
the plasmid was then performed by sterile loop inoculation of a single colony 
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into a 2 L glass conical flask containing 250 ml of LB medium (Appendix) 
supplemented with 100 µg/ml ampicillin in a 37 oC shaking incubator (Innova 
4300) with constant 200 rpm agitation for 24 hours. Next, the amplified pLVx-
Tight-hIGF1-Puro plasmid was extracted and purified according to the 
manufacturer’s protocol for maximum pure plasmid recovery (NucleoBond® 
Xtra Maxi; Macherey-Nagel). The purified ligated plasmid was stored in -20oC 
until required. 
 
 
2.4.7  Lentivirus production 
To generate IGF-1 encoding lentivirus, TSA cells were transfected with 3 µg 
of pLVx-Tight-hIGF1-Puro, 2 µg of pCMV2.1 and 3 µg pMD2G plasmids 
(Trono Lab, EPFL, Switzerland) using lipofection with Polyfect (Qiagen). The 
cell culture medium was changed after 16 hours and medium containing 
recombinant IGF-1 lentiviral particles were harvested 48 hours later. The 
LentiX™ Go Stix™ (Clontech) was used according to the manufacturer’s 
protocol to determine the titer of >5 x 106 IFU/ml of the lentiviral particles. 
 
To generate the virus containing the Tet-On transactivator, TSA cells were 
also used as host cells and transfected with the same technique as described 
above. Again, cell culture medium was changed after 16 hours and medium 
containing recombinant Tet-On lentiviral particles were harvested 48 hours 
later. Both hIGF-1 and Tet-On lentivirus were then stored in -80oC freezer 
until required. 
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2.4.8  Lentiviral transduction of human foreskin fibroblasts 
Prior to transduction of HFF with the lentivirus, fresh cell culture medium with 
0.5% FBS was exchanged and supplemented with 10 µg/ml hexadimethrine 
bromide (polybrene, Millipore) at 37 oC for 10 minutes. Polybrene is a cationic 
polymer, which neutralizes cell membrane charges and increases the 
efficiency of transduction of viruses when added to cell culture medium. 
Thereafter, conditioned cell medium from TSA cells containing recombinant 
IGF-1 lentivirus was layered over HFF cells cultured in a 100 mm cell culture 
plate in a drop wise manner and then incubated in a 5% CO2, 37 oC cell 
culture incubator for 72 hours. Thereafter, fresh HFF medium with 15% FBS 
was exchanged and supplemented with 10 ng/ml basic Fibroblast Growth 
Factor (bFGF; Miltenyi) and 1 µg/ml Puromycin (Invitrogen). After 7 days, 
surviving cells were selected as HFFhIGF1+ cells. 
 
To generate a stable inducible secretion of human IGF-1 from HFF cells, the 
HFFhIGF1+ cells were next transduced with pTet-On-Advanced lentivirus as 
outlined above followed by extended culture in medium containing 1 µg/ml 
puromycin and 800 µg/ml neomycin (Invitrogen) for 7 days. Cells that survived 
double antibiotic selection were deemed successfully transduced with both 
hIGF-1 and Tet-On viruses to generate the inducible human IGF-1 cell line: 
HFFhIGF1+TetOn+. These cells were amplified till a desired quantity and frozen 
down as stock cell cultures in -80 oC until required.  
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2.4.9  Cell size measurement 
Cells were dispersed as outlined above in 2.2.3.2 and subjected to size 
measurements using a CASY counter (Roche). 
 
 
 
2.5 In vivo testing of human BioVAD (hBioVAD) with paracrine 
activity 
 
2.5.1  Assembly of hBioVAD with paracrine activity 
To confer the paracrine modality to the hBioVAD, 18.2 x 106 hESC derived 
cardiomyocytes and 7.8 x 106 HFFhIGF1+TetOn+ cells were mixed together to 
generate a BioVAD as highlighted in 2.3.2.2 and allowed to condense 
overnight. Thereafter, the hBioVAD was allowed to condense further for 
another 9 days prior to implantation. 
 
 
2.5.2  Implantation of hBioVAD in Wistar rat 
The hBioVAD was implanted into a 450 g male Wistar rat (Charles River). The 
implantation was performed under isoflurane (4%) anesthesia. The heart was 
exposed after median sternotomy and careful refraction of pericardium. Next, 
the hBioVAD was slipped over the hearts, enveloping the apex, left and right 
ventricles and secured with 2 sutures (6-0 prolene, Ethicon). Following 
closure of sutures, cyclosporine A (5 mg/kg) and methylprednisolone (2 
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mg/kg) were administered daily subcutaneously to suppress the immune 
response. 
 
 
2.6 Video capture 
Raw footages of spontaneously beating HES 2 cardiomyocytes and 
contracting BioVADs were captured with SONY HDR-HC9 1080p HD video 
camera and processed with Final Cut Pro software (Apple). 
 
 
2.7  Statistics 
GraphPad Prism software (GraphPad Software Inc; San Diego) was used to 
convert data sets into graphs (displayed as mean ± SEM) and subjected to 
Student’s t-test, one-way, or two-way ANOVA test where appropriate. P < 
0.05 was considered to be significant. 
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3. Results 
 
3.1  Human embryonic stem cell culture 
The ability to maintain high quality hESC cultures was a precondition for the 
successful execution of the following experiments. Basic hESC cultures are 
generally maintained under serum (Thomson, et al. 1998). We prefer to 
induce cardiogenesis in serum-free conditions for optimal control of this highly 
sensitive process by making use of recently published protocols (Graichen, et 
al. 2008, Hudson, et al. 2012). Embryoid body (3D) differentiation was 
considered the standard for many years. Recently monolayer (2D) 
differentiation was introduced to further enhance and better control in vitro 
cardiogenesis in hESC (Kattman et al. 2011, Burridge et al. 2012). 
 
 
3.1.1.  Human embryonic stem cell quality 
To assess whether hESCs would retain pluripotency characteristics after 2D 
monolayer adaptation, flow cytometry was performed and expression of 
pluripotency surrogate markers Oct4, Tra1-60 and SSEA4 (Andrews 1984, 
Badcock et al. 1999, Schopperle et al. 2003, Richards et al. 2004, Boyer et al. 
2005) analyzed. This experiment demonstrated that typically >99% cells 
expressed Oct4, Tra1-60 and SSEA4 in 2D cultured hESC (Figure 10). 
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Figure 10: Detection of pluripotency surrogate markers in monolayer 
hESC cultures. Cells were analyses by flow cytometry after labeling of the 
indicated proteins; IgG isotype served as control. Representative experiment 
with HES2 cells. 
 
 
3.1.2  Cardiomyocyte differentiation 
To test the hypothesis that 2D adapted hESC cultures would respond better to 
directed differentiation protocols, a direct comparison of 3D vs. 2D culture was 
performed. In the “classical” 3D embryoid differentiation protocol, 
Results 
	   47 
spontaneously beating EBs could typically be observed from culture day 8 
onwards. In contrast, cardiomyocyte 2D differentiation developed beating cell 
clusters later, i.e. typically from culture day 10 onwards. For direct comparison 
of cardiogenic induction efficacy cells were harvested on culture days 12 and 
16 from 3D and 2D cultures, respectively. These individual time-points were 
selected based on the observation that then steady-state beating activity was 
reached in the different culture protocols. Quantification of cardiomyocytes 
after specific labeling of the sarcomeric protein actinin by flow cytometry 
revealed 10-20% cardiomyocytes in 3D vs. 40-60% cardiomyocytes in 2D 
differentiation culture (Figure 11). 
 
Figure 11: Enhanced cardiogenesis in 2D vs. 3D cultures. 3D and 2D 
denotes embryoid body culture and monolayer culture, respectively (n = 5 
per/group). The ordinate displays the percentage of cells labeled positively 
for actinin, assessed by flow cytometry. Experiments were performed with 
HES2 hESCs. *p < 0.05 3D vs. 2D (two-sided, unpaired Student’s t-test).  
 
 
 
* 
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3.2  Generation of human Engineered Heart Muscle 
 
3.2.1 EHM exhibit heart like morphology and functionality 
EHM were generated from hESC after cardiogenic induction. Interestingly, 
EHM development, morphological and functional properties were similar in 
EHTs generated from 3D or 2D differentiation protocols. Beating was 
observed typically 48 hours after EHM generation. After 10 days EHMs were 
subjected to isometric force measurements or morphological studies. 
Immunolabelling of sarcomeric proteins (actinin and actin) revealed formation 
of anisotropically organized muscle bundles inside EHMs (Figure 12 A). 
EHMs responded to increasing extracellular calcium concentrations with a 
positive inotropic effect. Maximal contractile force was recorded at 2.8 ± 0.4 
mM calcium (apparent EC50: 0.7372 ± 0.1770 mM; n = 4). These human 
EHMs were then used as models to determine the impact of secreted human 
IGF-1 proteins on the functionality of the EHMs in the later part of this 
dissertation. 
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Figure 12. Morphological and functional parameters of human EHMs. (A) 
Anisotropically organized muscle bundle with characteristic sarcomeric cross-
striation documented by confocal laser-scaning microscopy (red: α-actinin; 
green: f-actin; blue: DAPI stained nuclei). Scale bar: 20 µm. (B) Force of 
contraction measured under isometric conditions at 37 °C, electrical field 
stimulation at 2 Hz, and increasing extracellular calcium (n=4). 
 
 
3.3  Generation of human BioVAD 
 
3.3.1  Construction of novel casting molds  
The challenge was to develop a scalable BioVAD technology, suitable to 
envelope the ventricles of a rabbit heart. This required the construction of 
novel spherical casting molds of 18 mm, 20 mm and 30 mm diameter. To 
achieve this, cube blocks of Makrolon® (Bayer) (Figure 13 A) were cut and 
hollowed using metal spherical bore drills respective to the diameters. 
Inflatable silicone spheres of 20 mm were also generated (section 2.3.1) 
(Figure 13 B) to enable “biomimetic” culture, i.e. culture under cyclic loading. 
A B 
Ca2+ (mmol/L) 
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Figure 13. Casting molds construction for BioVAD technology. 
Components required to generate a BioVAD includes (A) scalable casting 
molds. (B) Inner inflatable silicone sphere.  
 
 
3.3.2 Cells tested to generate BioVAD 
The utility of the casting molds was first determined by making use of non-
contractile fibroblasts and neonatal rat heart cells. Here the anticipated results 
were (1) formation of a tissue sphere at rabbit heart size and (2) contractile 
properties of native myocardium.  
 
 
3.3.2.1 BioVADs from fibroblasts 
To determine if the casting molds were feasible for cell seeding, we first mixed 
16.8x106 naïve HFF cells with collagen 1 and pipetted the cell/collagen 
mixture into the interspace between the inflatable silicone sphere and inner 
A 
B 
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wall of the casting mold. These cells were able to survive and formed a dense, 
albeit thin pouch like tissue within 72 hours (Figure 14). 
 
 
 
Figure 14. Pouch like tissue structure made from HFF. Scale bar: 10 mm 
 
 
3.3.2.2 BioVADs from neonatal rat heart cells 
Next, we attempted to generate a similar BioVAD using whole heart cell 
preparations containing rat cardiomyocytes. 26x106 cells were seeded with 
collagen and after 24 hours, a dense tissue was observed (Figure 15) in 
agreement with a previous study (Yildirim et al., 2007). When released from 
the silicone sphere, the neonatal rat BioVAD was able to spontaneously 
contract in a synchronized manner. 
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Figure 15: BioVAD from neonatal rat cardiomyocytes. After casting of the 
BioVAD reconstitution mix, formation of a tissue sphere could be observed 
within 24 hours. Beating was identified after additional 3 days. Images are 
from confocal laser scanning microscopy (red: f-actin; green: actinin; blue: 
DAPI stained nuclei). Scale bar: 50 µm. 
 
 
3.3.2.3  BioVAD from human embryonic stem cell derived 
cardiomyocytes 
Given the feasibility of the new molds to support BioVAD generation, we 
aimed at providing proof–of-concept for a humanized BioVAD approach. 
Enzymatically dissociated hESC-derived cardiomyocytes were obtained, 
mixed with bovine collagen (section 2.3.2.2) and poured into the BioVAD 
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casting molds. The humanized BioVAD (hBioVAD) condensed within 24 hours 
to the size of a rabbit heart of approx. 35 mm in diameter (Figure 16).  
 
 
 
Figure 16: BioVAD from hESC derived cardiomyocytes. (left) hBioVAD 
after 10 days in culture; (right) adult rabbit heart. 
 
Taken together, the data demonstrates that the mold design will enable larger 
scale tissues to be formed. 
 
3.3.3 Biomimetic pulsatile load on BioVAD 
We next asked if the BioVAD could be improved further by introducing 
pulsatile load. To achieve this, the central silicone sphere was connected to a 
rodent ventilator via a silicone tube catheter and pulsed via a series of 
inflation and deflation cycles. We then tested this hypothesis using HFF and 
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adjusted the maxial strain to 110% of baseline at 90 inflation/deflation cycles 
per minute.  
 
 
3.3.3.1 Pulsatile load confers morphological rearrangements in 
fibroblasts 
To characterize the effects of the pulsatile loading immunofluorescence 
stainings for abundant cytoskeletal proteins (smooth muscle actin, vimentin 
and f-actin) were performed and identified superior elongation and alignment 
of HFFs in pulsed vs. unpulsed BioVADs (Figure 17). 
 
 
Figure 17. Mechanical load directs morphology in HFF-BioVADs. 
Unpulsed HFF-BioVAD (A) vs. pulsed BioVADs (B) stained for smooth muscle 
actin (red), vimentin (grey), actin (green) and nuclei staining with DAPI (blue). 
Images were recorded with a Zeiss LSM710 system. Scale bar: 100 µm. 
 
 
A B 
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3.3.3.2 Pulsatile load confers morphological rearrangements in 
cardiomyocytes 
When the pulsatile conditioning was applied to hESC-derived cardiomyocyte 
BioVADs cardiomyocyte elongation and enhanced sarcomere organization 
was observed (Figure 18 A, B). In contrast, unpulsed BioVADs showed mainly 
isotropic aggregation of cardiomyocytes (Figure 18 C). 
 
 
 
Figure 18: Mechanical pulsing improves morphology of hESC-BioVADs. 
Pulsed (A, B) vs. unpulsed hBioVADs (C) stained for actinin (green), actin 
(red) and nuclei staining with DAPI (blue). Scale bar: 50 µm. 
 
 
A B 
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3.3.3.3 Pulsatile load leads to tissue maturation 
Based on the morphological enhancements in pulsed BioVAD constructs, we 
further investigated surrogates of maturation by qPCR.  Pulsatile loading of 
BioVADs enhanced the expression of cardiac actin, skeletal actin, alpha- and 
beta-myosin heavy chain, ryanodine receptor 2 (RYR2) and calsequestrin 2 
(CSQ2; Figure 19). In contrast, sarcoplasmic reticulum calcium-ATPase 
(SERCA2a) and phospholamban (PLB) transcript levels were unchanged 
compared to unpulsed BioVADs (Figure 19).  
 
 
 
Figure 19. Pulsatile loading improves BioVAD maturation. Abundance of 
indicated transcripts was assessed by qPCR. The dotted line indicates the 
mean transcript abundance in unpulsed hBioVADs. The ordinate denotes the 
relative difference from this mean. * p<0.05 vs unpulsed; two-way ANOVA. 
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3.3.3.4 Pulsatile load enhances cell cycle activity 
Cell cycle activity was analyzed in isolated cells from BioVADs after DAPI 
labeling by flow cytometry. Pulsing increased the number of cells in G2/S 
phase in pulsed vs. unpulsed BioVADs (Figure 20), suggesting an increased 
cell cycle activity and/or DNA synthesis. 
 
           
 
 Figure 20. Pulsatile loading enhances cell cycle activity in BioVAD. Cell 
cycle phase was determined in isolated cells from BioVADs by flow cytometry 
after DNA labeling with DAPI. *p<0.05 vs. unpulsed (two-sided, unpaired 
Student’s t-test; n=5 for all groups). 
 
 
3.4 Pharmacological control of IGF-1 release from cells 
To further advance the functionality of the hBioVAD, supplementation of the 
system with inducible IGF-1 producing cells was proposed. The main goal of 
IGF-1 release in an EHM is to provide localized paracrine growth and survival 
support that can be controlled pharmacologically. One such system that allows 
* 
* 
B 
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the controlled release of IGF-1 is the Lenti-X™ TetOn® Advanced Expression 
system (Clontech). For this system to function, IGF-1 or any other gene of 
interest would need to be cloned into the Multiple Cloning Site (MCS), 
downstream of a modified CMV promoter which controls the expression of 
IGF-1. The promoter in turn is bound by Tet-controlled transactivators, which 
activates transcription in the presence of doxycycline. 
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3.4.1 PCR cloning of human IGF-1 gene 
The gene transcript for human IGF-1 variant 4 cDNA encoded on pCMV6-XL4 
plasmid (SC119792, Origene) spans 7,260 bp . The mature IGF-1 peptide is 
encoded on exons 3 and exons 4 (Figure 21 A). PCR amplification yielded an 
anticipated 462 bp fragment (Figure 21 B), which codes for the 153 amino 
acids of the secreted IGF-1 protein. 
  
 
 
 
 
Figure 21: PCR cloning of IGF-1.  (A) Schematic of exon arrangements in 
IGF-1 variant 4; PCR primer positions indicated by F1 and F2. (B) Lanes: (1) 
IGF-1 PCR amplified with F1 and F2. (M) DNA ladder (100 bp; Fermentas).  
	   	   	   	  1 3 4 6 IGF 1 v4 
M 1 
IGF1 500 bp 
400 bp 
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Next, restriction enzyme digestion of pLVx-Tight-Puro plasmid at the MCS 
with NotI and XbaI generated a 7791 bp linearized plasmid for the insertion of 
the amplified IGF-1. Subsequent ligation to generate recombinant pLVx-Tight-
hIGF1-Puro plasmid yielded 8253 bp (Figure 22, lanes 2) 
 
 
 
 
Figure 22: Construction of pLVx-IGF-1-Tight-Puro. Lanes: (1) Restriction 
enzyme digestion of hIGF-1 subcloned into TOPO TA plasmid with NotI and 
XbaI yields hIGF-1 (462 bp). (2) Linearized pLVx-hIGF1-Tight Puro with NotI 
only (8253 bp). (M) DNA ladder (1 kb plus, Fermentas). 
 
 
3.4.2   Transient expression of human IGF-1 in TSA cells 
To determine if IGF-1 could be transcribed, translated and secreted in human 
cells, TSA cells were first transiently transfected with pCMV-XL4, encoding for 
full length human IGF-1. Cell lysates and supernatants were harvested and 
analyzed by Western blot after 24 hours. Supernatants of pCMV-XL4 
M 1 2 
8,253 bp 
hIGF-1 
5,000 bp 
500 bp 
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transfected but not EGFP transfected TSA cells contained human IGF-1 
protein with similar apparent molecular weight as the recombinant human 
IGF-1 positive control (Figure 23). 
 
 
 
 
Figure 23. Secretion of IGF-1 from pCMV-XL4 transfected TSA cells 
Lanes: (1) Cell lysate from TSA cells transfected with EGFP plasmid. (2) 
Supernatant from TSA cells transfected with EGFP. (3-5) Cell lysates from 
TSA cells transfected with increasing concentrations of pCMV-XL4; (6-8) 
Supernatant from TSA cells transfected with increasing concentrations of 
pCMV-XL4 plasmid. Samples were run on a 10% SDS PAGE at 120 Volts. (9) 
IGF-1 protein control (17 kDa) (Peprotech). 
 
Thereafter, TSA cells were transfected with pLVx-Tight-hIGF1-Puro and pTet-
On-Advanced plasmids together, only pLVx-Tight-hIGF1-Puro plasmid, only 
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pCMV-XL4 plasmid as a positive control or with EGFP as a negative control 
plasmid. After 48 hours stimulation with 10 ng/ml doxycycline, cell lysates and 
supernatants were harvested. Western blot analyses of transfected cell 
supernatants demonstrated that human IGF-1 protein was secreted from 
TSApLVx-Tight-hIGF1-Puro and pTetOn+ and TSApLVx-Tight-hIGF1-Puro only cells into the cell 
culture medium. In TSAEGFP culture, no IGF-1 could be detected in the 
respective supernatant. In addition, the amount of secreted human IGF-1 
protein is further increased when 10 ng/ml doxycycline was added to the cell 
culture (Figure 24). 
 
 
 
Figure 24: Expression of IGF-1 from pLVx-IGF transfected TSA cells. 
Lanes: (1-2) TSA cells transfected with pLVxIGF1 and pTetOnAct 
supplemented with 10 ng/ml doxycycline. (3-4) TSA cells transfected with 
pLVxIGF1 and pTetOnAct in the absence of doxycycline. (5-6) TSA cells 
transfected with pLVx-IGF1 only. (7-8) TSA cells transfected with EGFP 
plasmid as negative control. (9-10) TSA cells transfected with pCMV-XL4 
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plasmid as positive control. (S) Represents supernatants. (L) Represents cell 
lysates. 
 
Taken together, this data demonstrates that that the secretion of human IGF-1 
can be induced in this system. Interestingly, no detectable amounts of human 
IGF-1 protein could be detected in cell lysates, suggesting that TSA cells are 
highly efficient host cells that are capable of processing and secreting the 
human IGF-1 protein.  
 
 
 
 
3.4.3  Quantification of IGF-1 release. 
In addition, ELISA analysis of supernatants from these TSA cell lines also 
revealed that human IGF-1 protein secretion was 11 times higher when 
induced by doxycycline (Figure 25).  
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 0 ng Dox 10 ng Dox 
-ve Ctrl (medium) 0.164  - 
Origene hIGF-1 11.697 - 
pLVx hIGF-1 0.884 - 
pLVx hIGF-1 + pTetOn 0.599 11.806 
 
Figure 25: Quantification of secreted IGF-1 from transfected TSA cells. 
The IGF-1 standard curve demonstrates linearity of the ELISA between 0 and 
6 ng/ml. IGF-1 release under baseline and doxycycline as displayed in table 
format. 
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3.4.4 Lentivirus transduction of IGF-1 
Given that IGF-1 could be secreted in TSA cells, lentiviruses were produced 
using pLVx-Tight-hIGF1-Puro and pTet-On in TSA cells as highlighted in 2.4.7. 
 
 
3.4.4.1  Antibiotic kill curves 
The recombinant plasmids contain antibiotic resistance genes. To determine 
the effective concentrations of antibiotics to select for positively transduced 
cells, we performed a toxicity killing assay on non transgenic HFF cells with 
the following concentrations of antibiotics; puromycin: 0, 0.01, 0.03, 0.1, 0.3 
and 1 µg/ml, neomycin: 0, 10, 30, 100, 300 and 1000 µg/ml. Surviving cells 
were counted for each concentration. 
 
This revealed that 1 mg/ml neomycin (Figure 26 A) and 1 µg/ml puromycin 
(Figure 26 B) were the effective concentrations required to inhibit naïve 
(HFFwt) cell growth. These concentrations were then selected for transgenic 
HFF cell growth. 
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Figure 26: Antibiotic kill curves. (A) Effective killing concentration of 
neomycin at 1000 µg/ml (B) Effective killing concentration of puromycin at 1 
µg/ml. n = 1. 
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3.4.4.2 Generation of IGF-1 transgenic cell line 
After confirming the inducible expression of hIGF-1 from transfected TSA cells 
and the effective antibiotic concentration to kill non transgenic HFF, we 
generated hIGF-1 lentivirus and/or pTetOn transactivator virus by transiently 
transfecting TSA cells with the recombinant pLVx-Tight-hIGF1-Puro plasmid 
or pTet-On-Advanced plasmid together with packaging pCMV and pMDG 
plasmids. Supernatant samples obtained were tested by the LentiX GoStix® 
rapid lentiviral p24 indicative test. More than 5 X 105 IFU/ml (infectious units / 
ml) of pLVx-Tight-hIGF1-Puro and pTet-On-Advanced viruses were obtained.  
 
Viruses from pLVx-Tight-hIGF1-Puro and pTet-On-Advanced were used to 
transduce HFF cells as outlined in 2.4.8. Effective integration was tested by 
stringent antibiotic selection. Double transduced transgenic HFF 
(HFFIGF1+TetOn) cells proliferated in the antibiotic supplemented cell culture 
medium while control HFFwt cells were killed. 
 
 
 
 
3.4.5  Expression of IGF-1 from lentiviral transduced fibroblasts 
After successful generation of the HFFIGF1+TetOn line, the expression of IGF-1 
was tested by quantitative ELISA assay and immunostaining.  
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3.4.5.1 Detection of IGF-1 in transgenic fibroblasts 
We first examined whether IGF-1 would be enriched in HFFIGF1+TetOn 
compared to HFFwt by immunofluorescence labeling of respective cultures. As 
anticipated, IGF-1 could be detected particularly in HFFIGF1+TetOn in the 
endoplasmic reticulum (Figure 27). 
 
 
 
Figure 27. Increased expression of IGF-1 in HFFIGF1+TetOn. HFFwt (A) and 
HFFIGF1+TetOn (B) labeled for IGF-1 (green). (C) Magnification identifies IGF-1 
primarily in the endoplasmic reticulum, Golgi of HFFIGF1+TetOn.  
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3.4.5.2   Quantification of IGF-1 release 
To demonstrate the reliability and functionality following transduction of HFF 
cells with this Tet-On lentiviral transduction system, we quantified the levels of 
human IGF-1 protein in the 72 hour conditioned supernatants and cell lysates 
harvested from HFFwt and transduced HFFhIGF1+TetOn with and without 
doxycycline exposure. Different concentrations of doxycycline were tested (10 
- 1000 ng/ml). We observed that in the supernatants of non-stimulated 
HFFhIGF1+TetOn cells, human IGF-1 protein levels were secreted at 
approximately 2.8 ng/ml of medium while HFFwt cells secreted only 0.4 ng/ml 
IGF-1 protein. In cell lysates from HFFwt and HFFhIGF1 cells, minimal human 
IGF-1 protein was detected (0.16 ng/ml and 0.23 ng/ml respectively). 
Exposure to doxycycline stimulation led to a 10 fold increase of human IGF-1 
protein in the supernatants and cell lysates of HFFhIGF1+TetOn cells, while 
minimal IGF-1 protein was detected from HFFwt cells (Figure 28). Increasing 
the doxycycline concentrations did not significantly increase IGF-1 protein 
production. 
 
Taken together, this result suggested that, the HFFs were successfully 
transduced with the inducible Tet-On lentivirus and both production and 
secretion of human IGF-1 proteins can be induced by pharmacological 
concentrations of doxycycline, demonstrating a proof of concept that growth 
factor production and expression can be controllable with pharmacological 
drug stimulation. On the other hand, leaky expression was observed in 
unstimulated HFFIGF1, however, at 10-fold lower levels compared to 
doxycycline induced cells. 
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Doxycycline 
 (ng/ml) 0 10 30 100 
HFFwt 
Supernatant 0.394346 0.3970632 0.3889115 0.3780425 
Cell Lysate 0.1633805 0.1633805 0.168815 0.1606633 
HFFIGF+TetOn 
Supernatant 2.774649 20.28998 19.57807 20.06717 
Cell Lysate 0.2313115 20.34704 20.37693 20.03728 
 
 
Figure 28. Human IGF-1 protein secretion from inducible HFFs. 10 ng/ml 
doxycycline was sufficient to induce 10 fold higher level of IGF-1 expression in 
HFFIGF1+TetOn cells and also secretion into the supernatants. Naïve HFFwt cells 
were investigated as negative controls. 
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3.4.6   Biological activity of human IGF-1 
 
3.4.6.1 Hypertrophy in IGF-1 transgenic fibroblasts 
Next we asked if the secreted hIGF from generated transgenic cell line 
confers biological activity in vitro. We observed that transduced HFFhIGF1+TetOn 
cells appeared larger in size compared to HFFwt cells during routine cell 
culture passaging (Figure 29). 
 
  
 
	     
Figure 29. Hypertrophy in IGF-1 transduced HFFs. Brightfield image of 
HFFIGF1+TetOn (A) and HFFwt (B). (C) Cell volumes in HFFwt and HFFIGF1+TetOn 
in the presence and absence of 10 ng/ml doxycycline. 
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3.4.6.2  Paracrine action of IGF-1 activates Akt in cardiomyocytes 
As our overall goal of this study was to induce a beneficial effect in the human 
heart we next examined the downstream mediators of paracrine action of 
secreted IGF-1 on hypertrophy signaling pathway in hESC-derived 
cardiomyocytes. 72 hour serum-free conditioned medium from unstimulated 
and doxycycline stimulated HFFwt and HFFhIGF1+TetOn cells were harvested and 
layered over day 16 hESC-derived cardiomyocytes for 30 minutes. The 
cardiomyocytes were then harvested and lysed. Western blot of the hESC 
cardiomyocytes lysates revealed that phosphorylated Akt (pAkt) proteins were 
higher in unstimulated and stimulated HFFhIGF1+TetOn cells compared to HFFwt 
cells (Figure 30 A). 
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Figure 30. IGF-1 conditioned medium induces Akt phosphorylation in 
cardiomyocytes. Western blot analyses of pAkt, Akt and GAPDH in hESC-
derived cardiomyocytes exposed to supernatant from HFFwt and HFFIGF1+TetOn 
(± doxycycline stimulation). (B) Summary of Western blot  (n = 3 per group). * 
p< 0.05 vs HFFwt (± doxycycline; two-sided, unpaired Student’s t-test) 
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3.4.6.3   IGF-1 enhances force generation of human EHMs 
We supplemented EHMs with 20% of either HFFwt or HFFIGF-1TetOn cells. 
Subsequently, EHMs were transferred onto flexible silicone poles on culture 
day 3. On culture day 7, 10 ng/ml doxycycline was added to the EHMs 
medium to induce hIGF-1 secretion from HFF cells. Control EHMs were left 
without doxycycline. EHMs were subjected to force measurements 72 hours 
later. Analyses of the forces revealed that, despite no doxycycline stimulation, 
EHMs generated with HFFIGF1+TetOn cells developed stronger contraction 
forces compared to EHMs generated with HFFwt cells. However, doxycycline 
supplemented EHM with HFFhIGF1+TetOn cells developed highest forces 
compared to all other EHM groups (Figure 31) across varying calcium 
concentrations, with maximum force at 3.2 mmol/L Ca2+.  
 
Figure 31.  Force generation of EHMs is enhanced by doxycycline 
activiation of HFFIGF1+TetOn. The ordinate display  twitch tension in mN. The 
abscissa denotes extracellular calcium concentrations. * p < 0.05 vs HFFwt 
EHM; two way ANOVA. 
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3.4.6.4  IGF-1 induces cell hypertrophy in human EHMs 
We then enzymatically digested these human EHMs, isolated single cells and 
analyzed the cell sizes from each group using flow cytometry and observed 
that cells were larger in the presence of human IGF-1 (Figure 32). Enhanced 
size of non-myocytes may be due to the addition of “large” HFFIGF1+TetOn. In 
contrast, cardiomyocyte hypertrophy seems to be stimulated by the HFFs 
paracrine activity. 
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Figure 32. IGF-1 induces cardiomyocytes hypertrophy in EHMs. 
Cardiomyocyte (A) and (B) non-myocyte size measured by flow cytometry. 
*p<0.05 vs HFFwt.  
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3.4.6.5   IGF-1 improves morphology of human EHMs 
We performed whole mount immunofluorescence staining on both groups of 
EHMs and observed that cardiomyocytes were generally elongated and 
anisotropically aligned and form cardiac bundles (Figure 33 A). However, 
EHMs generated from cardiomyocytes mixed with HFFIGF1+TetOn appear to 
contain thicker muscle bundles and enlarged cardiomyocytes (Figure 33 B). 
  
 
Figure 33: Wholemount stainings of EHMs. (A) EHMs cultured with HFFwt. 
(B) EHMs cultured with HFFIGF1+TetOn cells. EHMs stained for actinin (red), 
actin (green) and nuclei staining with DAPI (blue). Scale bar: 50 µm. 
 
 
3.5   “paraBioVAD” generation 
To finally prepare the BioVAD with paracrine IGF-1 release, 20% HFFIGF1+TetOn 
were added to the BioVAD reconstitution mixture. This yielded “paraBioVAD” 
with similar appearance as the “simple” BioVAD (Figure 34). 
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Figure 34. Human “paraBioVAD”. Diameter of 20 mm. 
 
 
3.5.1 Implantation of “paraBioVAD” 
A single “paraBioVAD” was implanted in an immunosuppressed Wistar rat 
and harvested after 3 weeks (Figure 35). The explant was observed to have 
contracted towards the apex but remain attached and still encompassed the 
ventricles. 
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Figure 35. Explant of human “paraBioVAD”. Explanted “paraBioVAD” 
remains attached to rat heart 3 weeks post implantation. 
 
 
3.5.2  Histological observations of explanted “paraBioVAD” 
We then performed routine Haematoxylin & Eosin (H&E) and Sirius Red 
stainings to study the morphology of the explanted “paraBioVAD” relative to 
the rat heart and observed that the “paraBioVAD” generally remained intact 
over the rat heart.  
 
A clear border zone between the heart and the “paraBioVAD” was observed 
(Figure 36). Generally, a gap of 50-100 µm distinguishes the heart from the 
“paraBioVAD”. However, in several areas, there were clear “contact zones” 
between the “paraBioVAD” and recipient myocardium (Figure 36 A, B, C). 
“paraBioVAD” 
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“Myocardial-like” elongated cells were also observed (Figure 36 C). 
Interestingly, several areas showed developing vascular structures (Figure 36 
D, E, F), suggesting early vascularization. 
 
 
 
 
 
Figure 36. Histological sections of “paraBioVAD” on rat heart. (A) 
Grafting areas of  “paraBioVAD” to the rat heart (arrows). Scale bar 100 µm 
(B) Magnified area of engraftment with rat myocardium. Scale bar 50 µm. (C) 
Elongated muscle like strands engrafted to rat heart. Scale bar 50 µm. (D-F) 
Vascularization of “paraBioVAD”. (D) arrows indicate developing vasculature 
structures. Scale bar 100 µm. (E) Magnified image of vessels (arrows). Scale 
bar 100 µm. (F) Developing vascular structures in the “paraBioVAD” showing 
vessels containing blood. Scale 50 µm. 
 
D E F 
A B C 
Results 
	   81 
In Sirius red stained sections, we observed clear demarcation of collagen 
(stained red) stemming from the “paraBioVAD” matrix. Collagen was also 
observed at several points where the “paraBioVAD” engrafted onto the rat 
heart (Figure 37). Vascular structures were also observed in several areas of 
the “paraBioVAD” (Figure 36). 
 
 
 
Figure 37. Morphology of “paraBioVAD” stained with Sirius red. (A-C) 
Red staining indicates collagen. (A) Scale bar 100 µm (B) Scale bar 100 µm. 
(C) Vascular structures containing blood (arrows). Scale bar 100 µm. 
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4. Discussion 
 
Heart failure develops typically after myocardial infarction or chronic 
hypertension. However, not all patients with these conditions develop end-
stage heart failure and the mechanisms underlying its disease progression 
and conversion into severe heart failure are not well understood. Given the 
limitations in drug and device therapy today, cell therapy has been proposed 
as an alternative with the potential to replenish the disease heart with 
cardiomyocytes. Yet, until recently, direct cell replacement approaches have 
not yielded favorable results consistently (Schachinger, et al. 2006, Lunde 
and Aakhus 2008, Perin et al. 2012). In particular in chronic heart failure, 
where seeding of cardiomyocytes would likely elicit an optimal therapeutic 
effect, little advance has been made.  This is partly due to a lack of suitable 
cells (cardiomyocytes) and low cell retention rates following transplantations. 
The discovery of ESCs and subsequent establishment of stem cell lines have 
rekindled the possibility of obtaining unlimited amounts of cardiomyocytes 
(Thomson, et al. 1998). However, ethical and safety concerns have prevented 
the wide use and application of ESC as a therapy. Only the recent 
establishment of induced pluripotent stem cells (iPSC) circumvented this 
issue and allowed the use of virtually any adult cell to be transformed to an 
“ESC-like” state (Takahashi and Yamanaka 2006). This also led to a surge in 
up scaling technologies to rapidly increase the quantities and availability of 
naïve stem cells (Nie et al. 2009, Singh et al. 2010, Chen et al. 2011, 
Zweigerdt, et al. 2011). Despite these advances, differentiation of stem cells 
to obtain pure cardiomyocytes remains challenging, let alone obtaining large 
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quantities and quality. This is also due in part to the lack of understanding of 
the underlying mechanisms for proper cardiomyocyte differentiation.  
 
In recent years, the paradigm to replace the defective myocardium has shifted 
from direct cell replacement strategies to tissue-based approaches (Li, et al. 
1999, Shimizu et al. 2002, Zimmermann and Eschenhagen 2003, 
Zimmermann, et al. 2006). Applications of these engineered cardiac tissues in 
animal models have been encouraging, albeit insufficient to fully repair 
diseased heart muscle. The next phase of bioengineering advancements was 
to scale the tissue engineering concepts (Naito et al. 2006, Yildirim et al. 
2007). Based on this previous work, it was hypothesized that a large 
continuous human “pouch-like” tissue construct (BioVAD) can be generated 
with additional protective paracrine activity.  
 
The following results were achieved: 
- Robust cardiomyocyte derivation from hESCs. 
- Generation of human EHM from hESC-derived cardiomyocytes 
- Creation of a biomimetic culture platform to scale and mature BioVADs. 
- Development of a drug-inducible IGF-1 release cell line. 
- Proof-of-concept for tissue engineered paracrine support BioVAD 
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4.1 hESC differentiation to generate cardiomyocytes for tissue 
engineering 
In this study, two different protocols to generate cardiomyocytes from hESC 
cell lines were used. The first protocol involved the generation of 
spontaneously beating 3D embryoid bodies, which resulted in 10 – 20 % 
cardiomyocytes being generated. This differentiation protocol required hESC 
cell “rafts”; small pieces of uniformly cut HES colonies to be generated as 
starting material (Soong et al. 2012). This technique, while easily mastered is 
laborious and variable with respect to total cardiomyocyte yield. On day 2 of 
differentiation, cardiomyogenesis was initiated with the addition of a small 
molecule, SB203580, which is a specific inhibitor of the p38 - Mitogen 
Activated Protein Kinase (MAPK) pathway. This has been demonstrated to 
greatly enhance cardiomyogenesis in hESCs within a narrow range of 1 - 10 
µM concentrations (Graichen, et al. 2008) and marked dephosphorylation of 
p38 at 5 µM (Kempf et al. 2011). However, the inhibition of p38 MAPK has 
also been reported to inhibit ERK and JNK kinases and PKB (Henklova et. al., 
2008, Muniyappa et. al., 2008) and also inducing differentiation in human 
myeloid leukemia cells (Ishii et. al., 2001), suggesting that the inhibitory action 
also has widespread downstream effects on other important cell signaling 
pathways and hence is not an ideal small molecule to direct differentiation of 
HES cells into cardiomyocytes.   
 
Although the 3D EB formation approach may have been developed to mimic 
the environment during embryo development in the blastocyst stage and also 
as a method to initiate spontaneous differentiation into the 3 germ lineages, 
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directed cardiomyogenesis to yield large amounts of cardiomyocytes with 
such a model remains challenging. Embryoid bodies possess a layer of 
epithelial like cells which secretes extracellular matrix containing collagen and 
forms a thin barrier which limits uniform diffusion across the layer and also 
creates gradients of nutrients and metabolites reaching the cells within the 
(Sachlos and Auguste 2008, Carpenedo et al. 2009, Kinney et al. 2011, Van 
Winkle et al. 2012). This suggests that the cells within the EB which receives 
optimal concentrations of growth factors will undergo differentiation while 
others do not, leading to heterogeneous decreased efficiency in an EB and 
suboptimal numbers of cardiomyocytes. However, recent reports suggest that 
the 3D EB culture method may yield more physiologically similar and matured 
cardiac phenotype cells with decreased fetal genes expression and respond 
more rapidly to T3 hormonal stimulation than parallel 2D cultures (Akins et al. 
2010).  
 
The second differentiation protocol involves the generation of cardiomyocytes 
from 2D monolayer hESCs and is based on the differentiation protocol from 
Hudson et. al. 2012. First, heterogeneity of undifferentiated hESCs were 
reduced by single cell adaptation of hESCs and then cultured in a monolayer 
of 0.5x105 cells per cm2 in a tissue culture well of a 24 well plate. This cell 
number is critical to prevent overgrowth of cells during mesodermal cell type 
proliferation and is optimal for primitive streak cell specification with Activin A 
and BMP 4 supplementation and also allows even diffusion of the growth 
factors and oxygen concentrations into the culture, thus exposing a monolayer 
of cells to undergo uniform temporal differentiation in the well. The result is a 
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high yield of 40–60 % differentiated cardiomyocytes. In addition, 
supplementation of IWP4 inhibits Wnt/ß-catenin signaling; a signaling 
pathway implicated in hESC cardiogenesis (Klaus et al. 2007, Tzahor 2007, 
Paige et al. 2010, Hudson and Zimmermann 2011). Inhibition of the Wnt 
signaling pathway at day 3 was critical as BMP4 was withdrawn from the 
differentiation medium. This was done to prevent the continual activation and 
accumulation of Wnt, which then drives the expression of 
hematopoietic/vascular markers in the cells, and reduce cardiomyogenesis.  
 
Taking the results from both protocols, one can conclude that generation of 
cardiomyocytes from human ESCs involves the inhibition of key signaling 
pathways such as the p38-MAPK and Wnt regardless of human ESC lines. 
This can be accomplished by the antagonistic action of small molecules at 
critical concentrations. However, specific inhibition of the Wnt/ß-catenin 
signaling pathway offers the most effective way to achieve high yields of 
cardiomyocytes in an in vitro system compared to that of p38-MAPK pathway. 
Hence, a 2D direct differentiation protocol may be more suited in situations 
where large quantities of cardiomyocytes are required such as generating 
large cardiac constructs for application in humans. 
 
4.2 Generation of human EHM from ESC derived cardiomyocytes 
To engineer cardiac constructs capable of synchronous contraction and force 
generation, a finely balanced environment similar in composition to the native 
heart had to be recapitulated. Previous rodent EHT models generated with 
hydrogels containing collagen type 1 and Matrigel have been demonstrated to 
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be highly reproducible (Zimmermann, et al. 2000, Tiburcy, et al. 2011). The 
constructs also demonstrated enhanced maturity when subjected to strain 
(Fink et al. 2000, Zimmermann, et al. 2000, Zimmermann, et al. 2006). In this 
study, similar concepts were exploited to demonstrate the feasibility of human 
EHM construction with hESC-derived cardiomyocytes. The term Engineered 
Heart Muscle (EHM) was introduced instead of Engineered Heart Tissue 
(EHT) because it better describes the identity of the engineered construct and 
clearly distinguishes it from heart valve and vessel engineering. EHMs 
contracted spontaneously, generated appreciable forces, and responded to 
inotropic interventions (i.e. increase in extracellular calcium concentration) as 
expected for heart muscle, albeit with a higher calcium sensitivity. 
Morphologically, EHMs contained elongated and anisotropically aligned 
cardiomyocytes with highly ordered sarcomere arrangements. This is in clear 
contrast to monolayer cardiomyocyte cultures, where cell morphology does 
typically not resemble the in vivo situation (Kehat, et al. 2001, Mummery et al. 
2003). Hence, the human EHM platform may also for in vitro studies be 
considered more suitable than monolayer cultures. 
 
4.3 Generation of a large humanized BioVAD 
To overcome the limitations of restraint medical devices and the size of 
hEHMs, we rationalized that large functional human cardiac constructs can be 
generated by combining the large quantities of cardiomyocytes obtained from 
the 2D differentiation protocol of hESC together with an improvement of 
casting stages of the construct. It was of particular importance to fabricate 
“perfectly” spherical casting molds and spacers to ensure homogenous tissue 
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formation. This not only allowed the advancement of the previously developed 
BioVAD concept (Yildirim et al. 2007) from the rat to the human model, but 
also scaling of the BioVADs towards human heart applications.  
 
A further improvement was this implementation of biomimetic pulsatile 
mechanical stretch by making use of an inflatable inner “spacer”. Our results 
demonstrated that with conditioning by pulsatile stretch, we could obtained a 
rabbit heart sized human BioVAD that contained more cells undergoing DNA 
synthesis than unpulsed constructs, consistent with reports that mechanical 
stretching regulates DNA synthesis (Iwasaki et al. 2000, Adam et al. 2004), 
and activates stress activated protein kinases (Komuro et al. 1996). Whether 
this was in cardiomyocytes or non-myocytes remains to be clarified.  
 
Transcript analysis demonstrated higher abundance of sarcomeric protein and 
some, but not all, analyzed calcium handling protein encoding mRNAs in 
pulsed vs. unpulsed BioVADs. This is in agreement with previous studies 
demonstrating high maturity in tissue engineered heart muscle developed 
under mechanical load (Tiburcy, et al. 2011). Whether additional biophysical 
stimuli such as electrical stimulation would further facilitate tissue maturation 
remains to be studied. 
 
4.4 Drug-inducible IGF-1 release for paracrine heart support  
We reasoned that pharmacologically controlled paracrine secretion of IGF-1 
could confer an additional therapeutic benefit to the BioVAD technology. To 
achieve this, a fibroblast cell line with stable IGF-1 secretion was under the 
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control of the Tet-On activator domain was generated. However, already 
under unstimulated conditions IGF-1 release was enhanced, but could be 
further enhanced by doxycycline supplementation. In these cells IGF-1 
secretion reached maximum concentration already under 10 ng doxycycline. 
This was unexpected and either argues for an all-or-nothing activation, the 
need to test even lower doxycycline concentrations or insufficient linearity of 
the IGF-1 ELISA. Finally, alternative drug-inducible systems may need to be 
exploited to enable full control of IGF-1 release. 
 
Half-maximal activation (EC50) of the IGF-1 receptor is at 2 ng/ml IGF-1. IGF-
1 transduced cells supplemented the culture medium with 20.3 ng/ml IGF-1 in 
30 minutes. We also observed hypertrophy in IGF-1 expressing fibroblasts, 
which could be either an indirect effect of the transgenic approach or due to 
autocrine stimulation.  
 
IGF-1 has been studied extensively in skeletal muscle biology and its effects 
on aging (Renganathan et al. 1998, Musaro et al. 2001, Rommel et al. 2001, 
Rabinovsky et al. 2003, Musarò et al. 2004, Musarò et al. 2004, Song 2005, 
Perrini et al. 2010, Taekema et al. 2011). Circulating IGF-1 produced from the 
liver typically activates PI3K/Akt/mTOR and MAPK pathways (Mourkioti et. al., 
2005). Its effects on cardiomyocytes are mainly enhanced survival (Katjstura 
et. al., 2001) and hypertrophy (Kinugawa et al. 1999, Iwanaga et al. 2000, 
Kajstura et al. 2001, Yamashita et al. 2001, Welch, et al. 2002, McDevitt et al. 
2005, Millis et al. 2012); both are likely in response to AKT-activation. 
Different IGF-1 isoforms have been implicated in cardiomyocyte biology 
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(Vinciguerra et. al., 2009). In this study, IGF-1 variant 4 (Figure 3) was 
overexpressed to activate prosurvival and physiological hypertrophy in EHMs. 
Conditioned medium from human IGF-1 secreting fibroblasts increased Akt 
phosphorylation in hESC-derived cardiomyocytes in a paracrine manner. 
These cardiomyocytes were also significantly bigger than those not exposed 
to IGF-1 suggesting hypertrophic gene activation program. 
 
In three dimensional human cardiac tissue constructs, our results 
demonstrated that IGF-1-enriched EHMs developed enhanced contractile 
forces compared to non IGF-1-enriched EHTs. Here doxycycline addition to 
enhance IGF-1 release did indeed further improve contractile force. Whether 
this is due to better enrichment of the paracrine micro milieu in the EHM as 
compared to medium supernatant remains to be clarified.  
  
Given that IGF-1 plays a key role in many signaling pathways including 
proliferation, differentiation and hypertrophy (Figure 4), it would not be 
surprising that IGF-1 levels may be responsible for the regulation of 
contraction forces. Indeed, several studies have demonstrated that IGF-1 
binds to receptor tyrosine kinase and activates Akt via PI3K, and enhances L-
type Ca2+ current channels (Kamp and Chiamvimonvat 2006). Moreover, Akt 
overexpression studies in the myocardium also suggest an increased calcium 
channel activity in ventricular myocytes (Macrez et al. 2001, Quignard et al. 
2001, Kim et al. 2003). 
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4.5 Feasibility of “para BioVAD” generation and implantation 
Finally, we integrated the IGF-1 releasing fibroblasts into the human BioVAD 
system. The “paraBioVADs” were generated with 20 % HFFIGF1+TetOn cells. So 
far, only one attempt of implantation of a humanized “paraBioVAD” has been 
carried out. Importantly, the recipient rat survived the operation with no 
evidence of pericardial constriction or other complications. Teratoma 
formations were not detected despite the administration of cyclosporine. 
Longer observational studies are necessary to rule out this risk typically 
associated with pluripotent stem cell-derivatives. On the other hand, the 
relatively low numbers of undifferentiated hESCs after 2D differentiation 
(Hudson, et al. 2012) may not pose a risk for teratoma formation. 
 
Following explantation of the rat heart, histological stainings revealed areas of 
“paraBioVAD” that resemble “myocardial” structures. There was clear survival 
of cells within the graft which are elongated and aligned at the border zone, 
confirming that such engineered cardiac constructs can survive after 
transplantations in agreement with other studies (Zimmermann, et al. 2006, 
Yildirim, et al. 2007, Shiba, et al. 2012).  
 
We were encouraged by the observation of vascularization in several areas 
within the “paraBioVAD”. Indeed, vascularization is a critical point in attempts 
to generate humanized cardiac tissue constructs. In the human heart, 
vascular networks consisting of smaller arteries and capillaries are present to 
deliver oxygen and also transport growth factors to the contracting 
cardiomyocytes. This complicated network stems from the endothelial 
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mesenchymal lineage precursor cells (Martens et al. 2006) that is regulated 
by the extracellular cell matrix secreted by stromal cells (Kreutziger et al. 
2011). Any tissue engraftments then will need to develop connections to the 
host vascular system to obtain oxygen and important growth factors to allow 
the survival and further maturation of such tissues. Several cardiac constructs 
such as stacked cell sheets (Shimizu, et al. 2006), overlapping looped EHTs 
to form fused multiloops (Zimmermann, et al. 2006) and the neonatal rat 
BioVAD (Yildirim, et al. 2007) have also demonstrated some form of 
angiogenesis following engraftment of the construct. One major caveat is the 
potential hypoxia arising from the thickness of the BioVAD. Data from the cell 
sheet stacks demonstrated that the maximum thickness for tissues to survive 
with angiogenesis was 4 cell sheet layers amounting to ~45 µm (Shimizu, et 
al. 2002). This limitation could be circumvented by allowing the first blocks of 
cell sheet stacks to develop vasculature followed by polysurgery to further 
stack other cell sheet layers till a thick tissue is formed (Shimizu, et al. 2006). 
However, the “paraBioVAD” was generated to form a thick myocardial tissue 
of at least 1 mm and was also designed to prevent multiple surgical 
interventions during therapy. In light of this, we believe that the human 
“paraBioVAD” with enhanced survival will be able to obtain nutrients and 
oxygen via its developing vascularization network. However, further studies 
will have to characterize oxygen and nutrient supply in BioVAD grafts.   
 
The outlook of generating large viable and clinically applicable engineered 
cardiac constructs seems promising. Owing to the advancement and 
understanding of key signaling pathways and role of growth factors in hESC 
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development, improvements made in hESC cardiac differentiation protocols 
have significantly increased and enriched the amount of human 
cardiomyocytes that can be derived in vitro (Kattman et al. 2006, Hudson and 
Zimmermann 2011, Kattman et al. 2011, Hudson, et al. 2012). Coupled with 
mass scaling approaches with bioreactors (Zweigerdt, et al. 2011), the 
amount (~ 1 billion) of cardiomyocytes required to repair a myocardial 
infarcted region may soon be attained.  
 
Despite this advancement, further developments pertaining to the application 
of these cardiomyocytes have to be understood and addressed. Small models 
of engineered heart tissues using hESC-derived cardiomyocytes and non-
myocytes have only been recently established. Results gleaned from previous 
studies using similar animal EHT models have demonstrated that tissues 
engineered with only cardiomyocytes will not be sufficient to generate 
sufficient force and are structurally inferior to those generated with an equal 
composition of non myocytes and cardiomyocytes (Naito, et al. 2006, Yildirim, 
et al. 2007), suggesting a more complex mix of cell types would be required to 
engineer tissues that are deemed faithful to a healthy myocardium. In addition, 
these cells mix within the tissue must also demonstrate maturity of the tissue 
by responding to various stimuli (positive inotropic response to extracellular 
calcium and isoprenaline) through the generation of strong contractile forces 
and non-myocytes within such tissues must also secrete beneficial paracrine 
factors to the cardiomyocytes. Currently, we have addressed these issues in 
our human EHM model and are investigating the application to larger human 
engineered cardiac constructs such as the BioVAD. 
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For any contracting bioengineered cardiac construct to deliver an effective 
and improved function to the heart, the tissue must be able to integrate and 
electrically couple with the native heart. In addition, such constructs must also 
propagate the electrical impulses throughout the entire construct. We were 
encouraged to see areas of engraftments of the BioVAD to the rat heart in our 
study as well as possible microvasculature within the implant. This could 
potentially be derived from the surrounding pericard, however, further 
investigations would have to be performed to confirm the origins of such 
vascular structures. Concerns with electrical conduction issues pertaining to 
synchronization of tissue beating rate to host heart leading to arrhythmic 
events can be rectified by transient integrating pacemakers during early 
transplantation of the BioVAD.  
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5.  Outlook  
 
A new technology  to “build” scalable BioVADs from hESCs under “biomimetic” 
pulsatile stretching was developed. In addition, the concept of 
pharmacological inducible paracrine support in tissue engineered myocardium 
was established. First proof-of-concept for a BioVAD technology with 
paracrine activity was provided. This will further be exploited to investigate the 
hypothesis that BioVADs with paracrine activity can support a failing heart via 
(1) mechanical restraint, (2) contractile support, and (3) and paracrine activity. 
Currently, a doxorubicin induced dilated cardiomyopathy rat model is being 
established for first tests in a disease model. Further optimization of the 
BioVAD approach will likely be necessary to offer the necessary bio-artificial 
muscle mass to elicit a direct therapeutic effect and to identify optimal timing 
and “dosing” of its paracrine activity. Moreover, IGF-1 may turn out to not be 
the best choice to support a failing heart, requiring tests of other factors and 
combinations thereof. Given the use of potentially tumorigenic cells on the 
one hand and electrically excitable and conducting cells on the other hand it 
will be essential to define the risks associated with the proposed biological 
support approach. This will have to involve long-term large animal studies and 
“clinical” surveillance. Whether alternatives to the hESC approach will become 
available will depend on the implementation of robust methods to control 
cardiogenicity in vitro and on further advances in stem cell immunology and 
banking to facilitate allogeneic or autologous stem cell applications. 
 
 
 
Bibliography 
96 
6. Bibliography 
 
[1] Adam RM, Eaton SH, Estrada C, Nimgaonkar A, Shih SC, Smith LE, 
Kohane IS, Bagli D and Freeman MR. 2004. Mechanical stretch is a 
highly selective regulator of gene expression in human bladder smooth 
muscle cells. Physiol Genomics. 20 (1):36-44 
 
[2] Akins RE, Jr., Rockwood D, Robinson KG, Sandusky D, Rabolt J and 
Pizarro C. 2010. Three-dimensional culture alters primary cardiac cell 
phenotype. Tissue Eng Part A. 16 (2):629-41 
 
[3] Andrews PW. 1984. Retinoic acid induces neuronal differentiation of a 
cloned human embryonal carcinoma cell line in vitro. Dev Biol. 103 
(2):285-93 
 
[4] Assmus B, Rolf A, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, 
Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Tonn 
T, Dimmeler S, Dill T, Zeiher AM and Schachinger V. 2010. Clinical 
outcome 2 years after intracoronary administration of bone marrow-
derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 
3 (1):89-96 
 
[5] Atkins BZ, Lewis CW, Kraus WE, Hutcheson KA, Glower DD and 
Taylor DA. 1999. Intracardiac transplantation of skeletal myoblasts 
yields two populations of striated cells in situ. Ann Thorac Surg. 67 
(1):124-9 
 
[6] Badcock G, Pigott C, Goepel J and Andrews PW. 1999. The Human 
Embryonal Carcinoma Marker Antigen TRA-1-60 Is a Sialylated 
Keratan Sulfate Proteoglycan. Cancer Research. 59 (18):4715-4719 
 
[7] Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, 
Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-
Ginard B and Anversa P. 2003. Adult cardiac stem cells are multipotent 
and support myocardial regeneration. Cell. 114 (6):763-76 
 
[8] Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, 
Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S and 
Frisen J. 2009. Evidence for cardiomyocyte renewal in humans. 
Science. 324 (5923):98-102 
 
[9] Bocchi L, Savi M, Graiani G, Rossi S, Agnetti A, Stillitano F, Lagrasta C, 
Baruffi S, Berni R, Frati C, Vassalle M, Squarcia U, Cerbai E, Macchi E, 
Stilli D, Quaini F and Musso E. 2011. Growth factor-induced 
mobilization of cardiac progenitor cells reduces the risk of arrhythmias, 
in a rat model of chronic myocardial infarction. PLoS One. 6 (3):e17750 
 
[10] Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, 
Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, 
Bibliography 
	   97 
Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, 
Slaughter MS, Kajstura J and Anversa P. 2011. Cardiac stem cells in 
patients with ischaemic cardiomyopathy (SCIPIO): initial results of a 
randomised phase 1 trial. The Lancet. 378 (9806):1847-1857 
 
[11] Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, 
Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton 
DA, Jaenisch R and Young RA. 2005. Core transcriptional regulatory 
circuitry in human embryonic stem cells. Cell. 122 (6):947-56 
 
[12] Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries 
JWU, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen 
SEW and Fleischmann BK. 2007. Potential risks of bone marrow cell 
transplantation into infarcted hearts. Blood. 110 (4):1362-1369 
 
[13] Burridge PW, Keller G, Gold JD and Wu JC. 2012. Production of de 
novo cardiomyocytes: human pluripotent stem cell differentiation and 
direct reprogramming. Cell Stem Cell. 10 (1):16-28 
 
[14] Bursac N, Loo Y, Leong K and Tung L. 2007. Novel anisotropic 
engineered cardiac tissues: studies of electrical propagation. Biochem 
Biophys Res Commun. 361 (4):847-53 
 
[15] Bursac N, Papadaki M, Cohen RJ, Schoen FJ, Eisenberg SR, Carrier 
R, Vunjak-Novakovic G and Freed LE. 1999. Cardiac muscle tissue 
engineering: toward an in vitro model for electrophysiological studies. 
Am J Physiol. 277 (2 Pt 2):H433-44 
 
[16] Carpenedo RL, Bratt-Leal AM, Marklein RA, Seaman SA, Bowen NJ, 
McDonald JF and McDevitt TC. 2009. Homogeneous and organized 
differentiation within embryoid bodies induced by microsphere-
mediated delivery of small molecules. Biomaterials. 30 (13):2507-2515 
 
[17] Carrier RL, Papadaki M, Rupnick M, Schoen FJ, Bursac N, Langer R, 
Freed LE and Vunjak-Novakovic G. 1999. Cardiac tissue engineering: 
cell seeding, cultivation parameters, and tissue construct 
characterization. Biotechnol Bioeng. 64 (5):580-9 
 
[18] Chedrawy EG, Wang J-S, Nguyen DM, Shum-Tim D and Chiu RCJ. 
2002. Incorporation and integration of implanted myogenic and stem 
cells into native myocardial fibers: Anatomic basis for functional 
improvements. The Journal of Thoracic and Cardiovascular Surgery. 
124 (3):584-590 
 
[19] Chen AK, Chen X, Choo AB, Reuveny S and Oh SK. 2011. Critical 
microcarrier properties affecting the expansion of undifferentiated 
human embryonic stem cells. Stem Cell Res. 7 (2):97-111 
 
[20] Cooley DA. 2003. The total artificial heart. Nat Med. 9 (1):108-11 
 
Bibliography 
	   98 
[21] Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD and 
Milam JD. 1969. Orthotopic cardiac prosthesis for two-staged cardiac 
replacement. Am J Cardiol. 24 (5):723-30 
 
[22] Copeland JG, 3rd, Smith RG, Arabia FA, Nolan PE, Mehta VK, 
McCarthy MS and Chisholm KA. 2001. Comparison of the CardioWest 
total artificial heart, the novacor left ventricular assist system and the 
thoratec ventricular assist system in bridge to transplantation. Ann 
Thorac Surg. 71 (3 Suppl):S92-7; discussion S114-5 
 
[23] Dai W, Field LJ, Rubart M, Reuter S, Hale SL, Zweigerdt R, Graichen 
RE, Kay GL, Jyrala AJ, Colman A, Davidson BP, Pera M and Kloner 
RA. 2007. Survival and maturation of human embryonic stem cell-
derived cardiomyocytes in rat hearts. J Mol Cell Cardiol. 43 (4):504-16 
 
[24] Dimmeler S, Zeiher AM and Schneider MD. 2005. Unchain my heart: 
the scientific foundations of cardiac repair. J Clin Invest. 115 (3):572-83 
 
[25] Dobrucki LW, Tsutsumi Y, Kalinowski L, Dean J, Gavin M, Sen S, 
Mendizabal M, Sinusas AJ and Aikawa R. 2010. Analysis of 
angiogenesis induced by local IGF-1 expression after myocardial 
infarction using microSPECT-CT imaging. J Mol Cell Cardiol. 48 
(6):1071-9 
 
[26] Dow J, Simkhovich BZ, Kedes L and Kloner RA. 2005. Washout of 
transplanted cells from the heart: a potential new hurdle for cell 
transplantation therapy. Cardiovasc Res. 67 (2):301-7 
 
[27] Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG, 
Gramolini A and Keller G. 2011. SIRPA is a specific cell-surface 
marker for isolating cardiomyocytes derived from human pluripotent 
stem cells. Nat Biotechnol. 29 (11):1011-8 
 
[28] Elliott DA, Braam SR, Koutsis K, Ng ES, Jenny R, Lagerqvist EL, Biben 
C, Hatzistavrou T, Hirst CE, Yu QC, Skelton RJ, Ward-van Oostwaard 
D, Lim SM, Khammy O, Li X, Hawes SM, Davis RP, Goulburn AL, 
Passier R, Prall OW, Haynes JM, Pouton CW, Kaye DM, Mummery CL, 
Elefanty AG and Stanley EG. 2011. NKX2-5eGFP/w hESCs for 
isolation of human cardiac progenitors and cardiomyocytes. Nat 
Methods. 8 (12):1037-40 
 
[29] Ellison GM, Torella D, Dellegrottaglie S, Perez-Martinez C, Perez de 
Prado A, Vicinanza C, Purushothaman S, Galuppo V, Iaconetti C, 
Waring CD, Smith A, Torella M, Cuellas Ramon C, Gonzalo-Orden JM, 
Agosti V, Indolfi C, Galinanes M, Fernandez-Vazquez F and Nadal-
Ginard B. 2011. Endogenous cardiac stem cell activation by insulin-like 
growth factor-1/hepatocyte growth factor intracoronary injection fosters 
survival and regeneration of the infarcted pig heart. J Am Coll Cardiol. 
58 (9):977-86 
 
Bibliography 
	   99 
[30] Eschenhagen T, Fink C, Remmers U, Scholz H, Wattchow J, Weil J, 
Zimmermann W, Dohmen HH, Schafer H, Bishopric N, Wakatsuki T 
and Elson EL. 1997. Three-dimensional reconstitution of embryonic 
cardiomyocytes in a collagen matrix: a new heart muscle model system. 
FASEB J. 11 (8):683-94 
 
[31] Eschenhagen T and Zimmermann WH. 2005. Engineering myocardial 
tissue. Circ Res. 97 (12):1220-31 
 
[32] Fink C, Ergun S, Kralisch D, Remmers U, Weil J and Eschenhagen T. 
2000. Chronic stretch of engineered heart tissue induces hypertrophy 
and functional improvement. FASEB J. 14 (5):669-79 
 
[33] Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, 
Consalvo M, Cavallo F, di Pierro F and De Giovanni C. 1995. Local 
release of IL-10 by transfected mouse mammary adenocarcinoma cells 
does not suppress but enhances antitumor reaction and elicits a strong 
cytotoxic lymphocyte and antibody-dependent immune memory. The 
Journal of Immunology. 155 (6):3112-23 
 
[34] Graichen R, Xu X, Braam SR, Balakrishnan T, Norfiza S, Sieh S, Soo 
SY, Tham SC, Mummery C, Colman A, Zweigerdt R and Davidson BP. 
2008. Enhanced cardiomyogenesis of human embryonic stem cells by 
a small molecular inhibitor of p38 MAPK. Differentiation. 76 (4):357-70 
 
[35] Gray NA, Jr. and Selzman CH. 2006. Current status of the total artificial 
heart. Am Heart J. 152 (1):4-10 
 
[36] Guarita-Souza LC, Teixeira de Carvalho KA, Francisco JC, Simeoni R 
and Faria-Neto JR. 2008. Cellular transplantation for the treatment of 
non-ischaemic dilated cardiomyopathies. European Heart Journal 
Supplements. 10 (Suppl K):K7-K10 
 
[37] Hare JM. 2011. Bone marrow therapy for myocardial infarction. JAMA. 
306 (19):2156-7 
 
[38] Hierlihy AM, Seale P, Lobe CG, Rudnicki MA and Megeney LA. 2002. 
The post-natal heart contains a myocardial stem cell population. FEBS 
Lett. 530 (1-3):239-43 
 
[39] Hudson J, Titmarsh D, Hidalgo A, Wolvetang E and Cooper-White J. 
2012. Primitive cardiac cells from human embryonic stem cells. Stem 
Cells Dev. 21 (9):1513-23 
 
[40] Hudson JE and Zimmermann WH. 2011. Tuning Wnt-signaling to 
enhance cardiomyogenesis in human embryonic and induced 
pluripotent stem cells. J Mol Cell Cardiol. 51 (3):277-9 
 
[41] Iwanaga Y, Kihara Y, Yoneda T, Aoyama T and Sasayama S. 2000. 
Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-
Bibliography 
	   100 
1 and angiotensin-converting enzyme inhibitor: relationship between 
change in myosin isoform and progression of left ventricular 
dysfunction. JAC. 36 (2):635-642 
 
[42] Iwasaki H, Eguchi S, Ueno H, Marumo F and Hirata Y. 2000. 
Mechanical stretch stimulates growth of vascular smooth muscle cells 
via epidermal growth factor receptor. American journal of physiology. 
Heart and circulatory physiology. 278 (2):H521-9 
 
[43] Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, 
Entman ML, Michael LH, Hirschi KK and Goodell MA. 2001. 
Regeneration of ischemic cardiac muscle and vascular endothelium by 
adult stem cells. J Clin Invest. 107 (11):1395-402 
 
[44] Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, 
Limana F, Nadal-Ginard B, Leri A and Anversa P. 2001. IGF-1 
overexpression inhibits the development of diabetic cardiomyopathy 
and angiotensin II-mediated oxidative stress. Diabetes. 50 (6):1414-24 
 
[45] Kamp TJ and Chiamvimonvat N. 2006. Mission impossible: IGF-1 and 
PTEN specifically "Akt"ing on cardiac L-type Ca2+ channels. Circ Res. 
98 (11):1349-51 
 
[46] Kattman SJ, Huber TL and Keller GM. 2006. Multipotent flk-1+ 
cardiovascular progenitor cells give rise to the cardiomyocyte, 
endothelial, and vascular smooth muscle lineages. Dev Cell. 11 
(5):723-32 
 
[47] Kattman SJ, Koonce CH, Swanson BJ and Anson BD. 2011. Stem 
cells and their derivatives: a renaissance in cardiovascular translational 
research. J Cardiovasc Transl Res. 4 (1):66-72 
 
[48] Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, 
Ellis J and Keller G. 2011. Stage-specific optimization of activin/nodal 
and BMP signaling promotes cardiac differentiation of mouse and 
human pluripotent stem cell lines. Cell Stem Cell. 8 (2):228-40 
 
[49] Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, 
Ellis J and Keller G. 2011. Stage-Specific Optimization of Activin/Nodal 
and BMP Signaling Promotes Cardiac Differentiation of Mouse and 
Human Pluripotent Stem Cell Lines. Stem Cell. 8 (2):228-240 
 
[50] Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, 
Livne E, Binah O, Itskovitz-Eldor J and Gepstein L. 2001. Human 
embryonic stem cells can differentiate into myocytes with structural and 
functional properties of cardiomyocytes. J Clin Invest. 108 (3):407-14 
 
[51] Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, 
Satin J, Itskovitz-Eldor J and Gepstein L. 2004. Electromechanical 
Bibliography 
	   101 
integration of cardiomyocytes derived from human embryonic stem 
cells. Nat Biotechnol. 22 (10):1282-9 
 
[52] Kelm JM and Fussenegger M. 2004. Microscale tissue engineering 
using gravity-enforced cell assembly. Trends in biotechnology. 22 
(4):195-202 
 
[53] Kempf H, Lecina M, Ting S, Zweigerdt R and Oh S. 2011. Distinct 
regulation of mitogen-activated protein kinase activities is coupled with 
enhanced cardiac differentiation of human embryonic stem cells. Stem 
Cell Res. 7 (3):198-209 
 
[54] Kim YK, Kim SJ, Yatani A, Huang Y, Castelli G, Vatner DE, Liu J, 
Zhang Q, Diaz G, Zieba R, Thaisz J, Drusco A, Croce C, Sadoshima J, 
Condorelli G and Vatner SF. 2003. Mechanism of enhanced cardiac 
function in mice with hypertrophy induced by overexpressed Akt. J Biol 
Chem. 278 (48):47622-8 
 
[55] Kinney MA, Sargent CY and McDevitt TC. 2011. The Multiparametric 
Effects of Hydrodynamic Environments on Stem Cell Culture. Tissue 
Engineering Part B: Reviews. 17 (4):249-262 
 
[56] Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K and 
Takeshita A. 1999. Positive inotropic effect of insulin-like growth factor-
1 on normal and failing cardiac myocytes. Cardiovascular Research. 43 
(1):157-164 
 
[57] Klaus A, Saga Y, Taketo MM, Tzahor E and Birchmeier W. 2007. 
Distinct roles of Wnt/beta-catenin and Bmp signaling during early 
cardiogenesis. Proc Natl Acad Sci U S A. 104 (47):18531-6 
 
[58] Koh GY, Klug MG, Soonpaa MH and Field LJ. 1993. Differentiation and 
long-term survival of C2C12 myoblast grafts in heart. Journal of Clinical 
Investigation. 92 (3):1548-1554 
 
[59] Komuro I, Kudo S, Yamazaki T, Zou Y, Shiojima I and Yazaki Y. 1996. 
Mechanical stretch activates the stress-activated protein kinases in 
cardiac myocytes. Faseb Journal. 10 (5):631-636 
 
[60] Kreutziger KL, Muskheli V, Johnson P, Braun K, Wight TN and Murry 
CE. 2011. Developing vasculature and stroma in engineered human 
myocardium. Tissue Eng Part A. 17 (9-10):1219-28 
 
[61] Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras 
SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins 
L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J and Murry CE. 
2007. Cardiomyocytes derived from human embryonic stem cells in 
pro-survival factors enhance function of infarcted rat hearts. Nat 
Biotechnol. 25 (9):1015-24 
 
Bibliography 
	   102 
[62] Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, 
Muskheli V and Murry CE. 2005. Formation of Human Myocardium in 
the Rat Heart from Human Embryonic Stem Cells. The American 
Journal of Pathology. 167 (3):663-671 
 
[63] Laflamme MA and Murry CE. 2005. Regenerating the heart. Nat 
Biotechnol. 23 (7):845-56 
 
[64] Lazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, 
Damme L, Dembitsky W, Hosenpud JD, Gupta L, Tierney A, Kraus T 
and Naka Y. 2004. Neurological events during long-term mechanical 
circulatory support for heart failure: the Randomized Evaluation of 
Mechanical Assistance for the Treatment of Congestive Heart Failure 
(REMATCH) experience. Circulation. 109 (20):2423-7 
 
[65] Leung BM and Sefton MV. 2010. A modular approach to cardiac tissue 
engineering. Tissue Eng Part A. 16 (10):3207-18 
 
[66] Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A and Yau TM. 1999. 
Survival and function of bioengineered cardiac grafts. Circulation. 100 
(19 Suppl):II63-9 
 
[67] Li RK, Mickle DA, Weisel RD, Zhang J and Mohabeer MK. 1996. In 
vivo survival and function of transplanted rat cardiomyocytes. Circ Res. 
78 (2):283-8 
 
[68] Livak KJ and Schmittgen TD. 2001. Analysis of relative gene 
expression data using real-time quantitative PCR and the 2(-Delta 
Delta C(T)) Method. Methods. 25 (4):402-8 
 
[69] Lunde K and Aakhus S. 2008. Intracoronary injection of mononuclear 
bone marrow cells after acute myocardial infarction: lessons from the 
ASTAMI trial. European Heart Journal Supplements. 10 (Suppl K):K35-
K38 
 
[70] Macrez N, Mironneau C, Carricaburu V, Quignard JF, Babich A, 
Czupalla C, Nurnberg B and Mironneau J. 2001. Phosphoinositide 3-
Kinase Isoforms Selectively Couple Receptors to Vascular L-Type 
Ca2+ Channels. Circulation Research. 89 (8):692-699 
 
[71] Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, 
Czer LSC, Marbán L, Mendizabal A, Johnston PV, Russell SD, 
Schuleri KH, Lardo AC, Gerstenblith G and Marbán E. 2012. 
Intracoronary cardiosphere-derived cells for heart regeneration after 
myocardial infarction (CADUCEUS): a prospective, randomised phase 
1 trial. The Lancet. 379 (9819):895-904 
 
[72] Mallory GK, White PD and Salcedo-Salgar J. 1939. The speed of 
healing of myocardial infarction-A study of the pathologic anatomy in 
seventy two cases. The American Heart Journal. 18 (6):647-671 
Bibliography 
	   103 
 
[73] Martens TP, See F, Schuster MD, Sondermeijer HP, Hefti MM, 
Zannettino A, Gronthos S, Seki T and Itescu S. 2006. Mesenchymal 
lineage precursor cells induce vascular network formation in ischemic 
myocardium. Nat Clin Pract Cardiovasc Med. 3 Suppl 1 S18-22 
 
[74] Matsuura K, Honda A, Nagai T, Fukushima N, Iwanaga K, Tokunaga M, 
Shimizu T, Okano T, Kasanuki H, Hagiwara N and Komuro I. 2009. 
Transplantation of cardiac progenitor cells ameliorates cardiac 
dysfunction after myocardial infarction in mice. J Clin Invest. 119 
(8):2204-17 
 
[75] McDevitt TC, Laflamme MA and Murry CE. 2005. Proliferation of 
cardiomyocytes derived from human embryonic stem cells is mediated 
via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol. 39 
(6):865-73 
 
[76] Menasché P. 2009. Cell-based Therapy for Heart Disease: A Clinically 
Oriented Perspective. Molecular Therapy. 17 (5):758-766 
 
[77] Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, 
Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, 
Chatellier G, Solomon S, Desnos M and Hagege AA. 2008. The 
Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) 
trial: first randomized placebo-controlled study of myoblast 
transplantation. Circulation. 117 (9):1189-200 
 
[78] MERIT-HF-Investigators. 1999. Effect of metoprolol CR/XL in chronic 
heart failure: Metoprolol CR/XL Randomised Intervention Trial in-
Congestive Heart Failure (MERIT-HF). The Lancet. 353 (9169):2001-
2007 
 
[79] Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, 
Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, 
Cossu G and Giacomello A. 2004. Isolation and expansion of adult 
cardiac stem cells from human and murine heart. Circ Res. 95 (9):911-
21 
 
[80] Millis RM, Alvin ZV, Zhao A and Haddad GE. 2012. Effects of IGF-1 on 
IK and IK1 Channels via PI3K/Akt Signaling in Neonatal Cardiac 
Myocytes. International Journal of Cell Biology. 2012 1-6 
 
[81] Moazami N, Roberts K, Argenziano M, Catanese K, Mohr JP, Rose EA 
and Oz MC. 1997. Asymptomatic microembolism in patients with long-
term ventricular assist support. ASAIO J. 43 (3):177-80 
 
[82] Mohsin S, Siddiqi S, Collins B and Sussman MA. 2011. Empowering 
Adult Stem Cells for Myocardial Regeneration. Circulation Research. 
109 (12):1415-1428 
 
Bibliography 
	   104 
[83] Morrissey M. 2012. Willem J Kolff (1911-2009): physician, inventor and 
pioneer: father of artificial organs. J Med Biogr. 20 (3):136-8 
 
[84] Mourkioti F and Rosenthal N. 2005. IGF-1, inflammation and stem 
cells: interactions during muscle regeneration. Trends Immunol. 26 
(10):535-42 
 
[85] Müller-Ehmsen J. 2002. Survival and Development of Neonatal Rat 
Cardiomyocytes Transplanted into Adult Myocardium. Journal of 
Molecular and Cellular Cardiology. 34 (2):107-116 
 
[86] Muller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Long TI, 
Laird PW and Kloner RA. 2002. Rebuilding a damaged heart: long-term 
survival of transplanted neonatal rat cardiomyocytes after myocardial 
infarction and effect on cardiac function. Circulation. 105 (14):1720-6 
 
[87] Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van 
den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la 
Riviere AB, Passier R and Tertoolen L. 2003. Differentiation of human 
embryonic stem cells to cardiomyocytes: role of coculture with visceral 
endoderm-like cells. Circulation. 107 (21):2733-40 
 
[88] Murry CE, Field LJ and Menasche P. 2005. Cell-based cardiac repair: 
reflections at the 10-year point. Circulation. 112 (20):3174-83 
 
[89] Musarò A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, 
Ottolenghi S, Cossu G, Bernardi G, Battistini L, Molinaro M and 
Rosenthal N. 2004. Stem cell-mediated muscle regeneration is 
enhanced by local isoform of insulin-like growth factor 1. Proceedings 
of the National Academy of Sciences of the United States of America. 
101 (5):1206-1210 
 
[90] Musarò A, Giacinti C, Dobrowolny G, Pelosi L and Rosenthal N. 2004. 
The Role of Igf-1 on Muscle Wasting: a Therapeutic Approach. 1-4 
 
[91] Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro 
M, Barton ER, Sweeney HL and Rosenthal N. 2001. Localized Igf-1 
transgene expression sustains hypertrophy and regeneration in 
senescent skeletal muscle. Nat Genet. 27 (2):195-200 
 
[92] Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, Fujii 
T, Uematsu M, Ohgushi H, Yamagishi M, Tokudome T, Mori H, 
Miyatake K and Kitamura S. 2005. Transplantation of mesenchymal 
stem cells improves cardiac function in a rat model of dilated 
cardiomyopathy. Circulation. 112 (8):1128-35 
 
[93] Naito H, Melnychenko I, Didie M, Schneiderbanger K, Schubert P, 
Rosenkranz S, Eschenhagen T and Zimmermann WH. 2006. 
Optimizing engineered heart tissue for therapeutic applications as 
surrogate heart muscle. Circulation. 114 (1 Suppl):I72-8 
Bibliography 
	   105 
 
[94] Nie Y, Bergendahl V, Hei DJ, Jones JM and Palecek SP. 2009. 
Scalable culture and cryopreservation of human embryonic stem cells 
on microcarriers. Biotechnol Prog. 25 (1):20-31 
 
[95] Norman JC. 1975. THE ARTIFICIAL HEART: PERSPECTIVES, 
PROSPECTS AND PROBLEMS OF A HIGH APPLIED TECHNOLOGY 
An Editorial Comment. Cardiovasc Dis. 2 (3):259-264 
 
[96] Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, 
Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML and 
Schneider MD. 2003. Cardiac progenitor cells from adult myocardium: 
homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U 
S A. 100 (21):12313-8 
 
[97] Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock 
R, Anker SD, Poole-Wilson PA, Ranke MB and Dietz R. 1998. 
Randomised, double-blind, placebo-controlled trial of human 
recombinant growth hormone in patients with chronic heart failure due 
to dilated cardiomyopathy. The Lancet. 351 (9111):1233-1237 
 
[98] Oz MC, Konertz WF, Kleber FX, Mohr FW, Gummert JF, Ostermeyer J, 
Lass M, Raman J, Acker MA and Smedira N. 2003. Global surgical 
experience with the Acorn cardiac support device. J Thorac Cardiovasc 
Surg. 126 (4):983-91 
 
[99] Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H and Murry CE. 
2010. Endogenous Wnt/β-Catenin Signaling Is Required for Cardiac 
Differentiation in Human Embryonic Stem Cells. PLoS ONE. 5 
(6):e11134 
 
[100] Passier R, van Laake LW and Mummery CL. 2008. Stem-cell-based 
therapy and lessons from the heart. Nature. 453 (7193):322-9 
 
[101] Pasumarthi KB and Field LJ. 2002. Cardiomyocyte cell cycle regulation. 
Circ Res. 90 (10):1044-54 
 
[102] Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva 
GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, 
Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, 
Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, 
Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, 
Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, 
Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, 
Moye LA and Simari RD. 2012. Effect of transendocardial delivery of 
autologous bone marrow mononuclear cells on functional capacity, left 
ventricular function, and perfusion in chronic heart failure: the FOCUS-
CCTRN trial. JAMA. 307 (16):1717-26 
 
Bibliography 
	   106 
[103] Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A and 
Giorgino F. 2010. The GH/IGF1 axis and signaling pathways in the 
muscle and bone: mechanisms underlying age-related skeletal muscle 
wasting and osteoporosis. J Endocrinol. 205 (3):201-10 
 
[104] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, 
Palensky J and Wittes J. 1999. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. 
Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 
341 (10):709-17 
 
[105] Qiao H, Surti S, Choi SR, Raju K, Zhang H, Ponde DE, Kung HF, Karp 
J and Zhou R. 2009. Death and proliferation time course of stem cells 
transplanted in the myocardium. Mol Imaging Biol. 11 (6):408-14 
 
[106] Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, 
Nurnberg B, Mironneau C and Macrez N. 2001. Phosphoinositide 3-
kinase gamma mediates angiotensin II-induced stimulation of L-type 
calcium channels in vascular myocytes. J Biol Chem. 276 (35):32545-
51 
 
[107] Rabinovsky ED, Gelir E, Gelir S, Lui H, Kattash M, DeMayo FJ, 
Shenaq SM and Schwartz RJ. 2003. Targeted expression of IGF-1 
transgene to skeletal muscle accelerates muscle and motor neuron 
regeneration. FASEB J. 17 (1):53-5 
 
[108] Reinecke H, Minami E, Zhu WZ and Laflamme MA. 2008. Cardiogenic 
differentiation and transdifferentiation of progenitor cells. Circ Res. 103 
(10):1058-71 
 
[109] Reinecke H and Murry CE. 2002. Taking the death toll after 
cardiomyocyte grafting: a reminder of the importance of quantitative 
biology. J Mol Cell Cardiol. 34 (3):251-3 
 
[110] Reinecke H, Poppa V and Murry CE. 2002. Skeletal muscle stem cells 
do not transdifferentiate into cardiomyocytes after cardiac grafting. J 
Mol Cell Cardiol. 34 (2):241-9 
 
[111] Renganathan M, Messi ML and Delbono O. 1998. Overexpression of 
IGF-1 exclusively in skeletal muscle prevents age-related decline in the 
number of dihydropyridine receptors. J Biol Chem. 273 (44):28845-51 
 
[112] Richards M, Tan SP, Tan JH, Chan WK and Bongso A. 2004. The 
transcriptome profile of human embryonic stem cells as defined by 
SAGE. STEM CELLS. 22 (1):51-64 
 
[113] Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, 
Yancopoulos GD and Glass DJ. 2001. Mediation of IGF-1-induced 
skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and 
PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 3 (11):1009-13 
Bibliography 
	   107 
 
[114] Rubart M and Field LJ. 2006. Cardiac regeneration: repopulating the 
heart. Annu Rev Physiol. 68 29-49 
 
[115] Sabbah HN. 2005. Global left ventricular remodeling with the Acorn 
Cardiac Support Device: hemodynamic and angiographic findings in 
dogs with heart failure. Heart Fail Rev. 10 (2):109-15 
 
[116] Sachlos E and Auguste DT. 2008. Embryoid body morphology 
influences diffusive transport of inductive biochemicals: a strategy for 
stem cell differentiation. Biomaterials. 29 (34):4471-80 
 
[117] Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, 
Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, 
Assmus B, Tonn T, Dimmeler S and Zeiher AM. 2006. Intracoronary 
bone marrow-derived progenitor cells in acute myocardial infarction. N 
Engl J Med. 355 (12):1210-21 
 
[118] Schopperle WM, Kershaw DB and DeWolf WC. 2003. Human 
embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. 
Biochemical and Biophysical Research Communications. 300 (2):285-
290 
 
[119] Shake JG, MD, Gruber PJ, MD, PhD, Baumgartner WA, MD, Senechal 
G, MS, Meyers J, BS, Redmond JM, MD, Pittenger MF, PhD, Martin BJ 
and PhD. 2002. Mesenchymal Stem Cell Implantation in a Swine 
Myocardial Infarct Model: Engraftment and Functional Effects. 1-8 
 
[120] Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, Kim J, Palpant 
NJ, Gantz J, Moyes KW, Reinecke H, Van Biber B, Dardas T, Mignone 
JL, Izawa A, Hanna R, Viswanathan M, Gold JD, Kotlikoff MI, 
Sarvazyan N, Kay MW, Murry CE and Laflamme MA. 2012. Human 
ES-cell-derived cardiomyocytes electrically couple and suppress 
arrhythmias in injured hearts. Nature. 489 (7415):322-5 
 
[121] Shimizu T, Sekine H, Yang J, Isoi Y, Yamato M, Kikuchi A, Kobayashi 
E and Okano T. 2006. Polysurgery of cell sheet grafts overcomes 
diffusion limits to produce thick, vascularized myocardial tissues. 
FASEB J. 20 (6):708-10 
 
[122] Shimizu T, Yamato M, Isoi Y, Akutsu T, Setomaru T, Abe K, Kikuchi A, 
Umezu M and Okano T. 2002. Fabrication of pulsatile cardiac tissue 
grafts using a novel 3-dimensional cell sheet manipulation technique 
and temperature-responsive cell culture surfaces. Circulation Research. 
90 (3):e40 
 
[123] Shyu KG, Ko WH, Yang WS, Wang BW and Kuan P. 2005. Insulin-like 
growth factor-1 mediates stretch-induced upregulation of myostatin 
expression in neonatal rat cardiomyocytes. Cardiovasc Res. 68 
(3):405-14 
Bibliography 
	   108 
 
[124] Singh H, Mok P, Balakrishnan T, Rahmat SN and Zweigerdt R. 2010. 
Up-scaling single cell-inoculated suspension culture of human 
embryonic stem cells. Stem Cell Res. 4 (3):165-79 
 
[125] Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman 
D, Sun B, Tatooles AJ, Delgado RM, 3rd, Long JW, Wozniak TC, 
Ghumman W, Farrar DJ and Frazier OH. 2009. Advanced heart failure 
treated with continuous-flow left ventricular assist device. N Engl J Med. 
361 (23):2241-51 
 
[126] SOLVD-Investigators. 1992. Effect of enalapril on mortality and the 
development of heart failure in asymptomatic patients with reduced left 
ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 
327 (10):685-91 
 
[127] Song YH. 2005. Muscle-specific expression of IGF-1 blocks 
angiotensin II-induced skeletal muscle wasting. Journal of Clinical 
Investigation. 115 (2):451-458 
 
[128] Soonpaa MH, Koh GY, Klug MG and Field LJ. 1994. Formation of 
nascent intercalated disks between grafted fetal cardiomyocytes and 
host myocardium. Science. 264 (5155):98-101 
 
[129] Strauer BE and Steinhoff G. 2011. 10 years of intracoronary and 
intramyocardial bone marrow stem cell therapy of the heart: from the 
methodological origin to clinical practice. J Am Coll Cardiol. 58 
(11):1095-104 
 
[130] Taekema DG, Ling CHY, Blauw GJ, Meskers CG, Westendorp RGJ, 
de Craen AJM and Maier AB. 2011. Circulating levels of IGF1 are 
associated with muscle strength in middle-aged- and oldest-old women. 
European Journal of Endocrinology. 164 (2):189-196 
 
[131] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K 
and Yamanaka S. 2007. Induction of pluripotent stem cells from adult 
human fibroblasts by defined factors. Cell. 131 (5):861-72 
 
[132] Takahashi K and Yamanaka S. 2006. Induction of pluripotent stem 
cells from mouse embryonic and adult fibroblast cultures by defined 
factors. Cell. 126 (4):663-76 
 
[133] Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, 
Hutcheson KA, Glower DD and Kraus WE. 1998. Regenerating 
functional myocardium: improved performance after skeletal myoblast 
transplantation. Nat Med. 4 (8):929-33 
 
[134] Thoennissen NH, Allroggen A, Ritter M, Dittrich R, Schmid C, Schmid 
HH, Ringelstein EB and Nabavi DG. 2006. Influence of inflammation 
Bibliography 
	   109 
and pump dynamic on cerebral microembolization in patients with 
Continuous-Flow DeBakey LVAD. ASAIO J. 52 (3):243-7 
 
[135] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, 
Marshall VS and Jones JM. 1998. Embryonic stem cell lines derived 
from human blastocysts. Science. 282 (5391):1145-7 
 
[136] Tian Y and Morrisey EE. 2012. Importance of Myocyte-Nonmyocyte 
Interactions in Cardiac Development and Disease. Circulation 
Research. 110 (7):1023-1034 
 
[137] Tiburcy M, Didie M, Boy O, Christalla P, Doker S, Naito H, Karikkineth 
BC, El-Armouche A, Grimm M, Nose M, Eschenhagen T, Zieseniss A, 
Katschinksi DM, Hamdani N, Linke WA, Yin X, Mayr M and 
Zimmermann WH. 2011. Terminal differentiation, advanced 
organotypic maturation, and modeling of hypertrophic growth in 
engineered heart tissue. Circ Res. 109 (10):1105-14 
 
[138] Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T and Jia ZQ. 
1999. Autologous transplantation of bone marrow cells improves 
damaged heart function. Circulation. 100 (19 Suppl):II247-56 
 
[139] Turovets N, Semechkin A, Kuzmichev L, Janus J, Agapova L and 
Revazova E. 2011. Derivation of human parthenogenetic stem cell 
lines. Methods Mol Biol. 767 37-54 
 
[140] Tzahor E. 2007. Wnt/beta-catenin signaling and cardiogenesis: timing 
does matter. Dev Cell. 13 (1):10-3 
 
[141] Vallier L, Reynolds D and Pedersen RA. 2004. Nodal inhibits 
differentiation of human embryonic stem cells along the 
neuroectodermal default pathway. Dev Biol. 275 (2):403-21 
 
[142] van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, 
Freund C, den Ouden K, Ward-van Oostwaard D, Korving J, Tertoolen 
LG, van Echteld CJ, Doevendans PA and Mummery CL. 2007. Human 
embryonic stem cell-derived cardiomyocytes survive and mature in the 
mouse heart and transiently improve function after myocardial 
infarction. Stem Cell Res. 1 (1):9-24 
 
[143] Van Winkle AP, Gates ID and Kallos MS. 2012. Mass transfer 
limitations in embryoid bodies during human embryonic stem cell 
differentiation. Cells Tissues Organs. 196 (1):34-47 
 
[144] Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer 
DB, Levy D and Wilson PWF. 2003. Serum Insulin-like Growth Factor I 
and Risk for Heart Failure in Elderly Individuals without a Previous 
Myocardial Infarction: The Framingham Heart Study. Annals of Internal 
Medicine. 139 (8):642-648 
 
Bibliography 
	   110 
[145] Vunjak-Novakovic G and Scadden DT. 2011. Biomimetic platforms for 
human stem cell research. Cell Stem Cell. 8 (3):252-61 
 
[146] Walsh RG. 2005. Design and features of the Acorn CorCap Cardiac 
Support Device: the concept of passive mechanical diastolic support. 
Heart Fail Rev. 10 (2):101-7 
 
[147] Welch S, Plank D, Witt S, Glascock B, Schaefer E, Chimenti S, 
Andreoli AM, Limana F, Leri A, Kajstura J, Anversa P and Sussman 
MA. 2002. Cardiac-specific IGF-1 expression attenuates dilated 
cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ 
Res. 90 (6):641-8 
 
[148] Xu C, Police S, Rao N and Carpenter MK. 2002. Characterization and 
enrichment of cardiomyocytes derived from human embryonic stem 
cells. Circ Res. 91 (6):501-8 
 
[149] Xu XQ, Zweigerdt R, Soo SY, Ngoh ZX, Tham SC, Wang ST, Graichen 
R, Davidson B, Colman A and Sun W. 2008. Highly enriched 
cardiomyocytes from human embryonic stem cells. Cytotherapy. 10 
(4):376-89 
 
[150] Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, Tomaselli 
GF and Li RA. 2005. Functional integration of electrically active cardiac 
derivatives from genetically engineered human embryonic stem cells 
with quiescent recipient ventricular cardiomyocytes: insights into the 
development of cell-based pacemakers. Circulation. 111 (1):11-20 
 
[151] Yamashita K, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, 
Anversa P and Webster KA. 2001. Reperfusion-activated Akt kinase 
prevents apoptosis in transgenic mouse hearts overexpressing insulin-
like growth factor-1. Circulation Research. 88 (6):609-614 
 
[152] Yildirim Y, Naito H, Didie M, Karikkineth BC, Biermann D, 
Eschenhagen T and Zimmermann WH. 2007. Development of a 
biological ventricular assist device: preliminary data from a small 
animal model. Circulation. 116 (11 Suppl):I16-23 
 
[153] Zhang M, Methot D, Poppa V, Fujio Y, Walsh K and Murry CE. 2001. 
Cardiomyocyte grafting for cardiac repair: graft cell death and anti-
death strategies. J Mol Cell Cardiol. 33 (5):907-21 
 
[154] Zimmermann WH. 2011. Embryonic and embryonic-like stem cells in 
heart muscle engineering. J Mol Cell Cardiol. 50 (2):320-6 
 
[155] Zimmermann WH and Eschenhagen T. 2003. Cardiac tissue 
engineering for replacement therapy. Heart Fail Rev. 8 (3):259-69 
 
Bibliography 
	   111 
[156] Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J and 
Eschenhagen T. 2000. Three-dimensional engineered heart tissue 
from neonatal rat cardiac myocytes. Biotechnol Bioeng. 68 (1):106-14 
 
[157] Zimmermann WH, Melnychenko I and Eschenhagen T. 2004. 
Engineered heart tissue for regeneration of diseased hearts. 
Biomaterials. 25 (9):1639-47 
 
[158] Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, 
Nixdorff U, Hess A, Budinsky L, Brune K, Michaelis B, Dhein S, 
Schwoerer A, Ehmke H and Eschenhagen T. 2006. Engineered heart 
tissue grafts improve systolic and diastolic function in infarcted rat 
hearts. Nat Med. 12 (4):452-8 
 
[159] Zimmermann WH, Schneiderbanger K, Schubert P, Didie M, Munzel F, 
Heubach JF, Kostin S, Neuhuber WL and Eschenhagen T. 2002. 
Tissue engineering of a differentiated cardiac muscle construct. Circ 
Res. 90 (2):223-30 
 
[160] Zweigerdt R, Olmer R, Singh H, Haverich A and Martin U. 2011. 
Scalable expansion of human pluripotent stem cells in suspension 
culture. Nat Protoc. 6 (5):689-700 
 
 
 
 
 
 
 
Appendix 
112 
7. Appendix 
 
Cell Culture Reagents and Medium 
 
bFGF stock solution 
1. Dissolve bFGF according to manufacturer’s protocol to obtain a stock 
concentration of 10 µg/ml. 
2. Aliquot into sterile microfuge tubes and store at -20 °C. 
 
bFGF working solution 
1. Add 10 µl of bFGF stock solution into 10 ml of hESC maintenance 
medium per 100 mm hES cultured plates (final bFGF concentration: 10 
ng/ml). 
 
Collagenase IV stock solution  
1. Dissolve 10 mg of collagenase IV in 1 ml of DPBS+. 
2. Sterile filter the solution, aliquot (1 ml) in 15 ml centrifuge tubes, and 
store at -20 °C. 
 
Collagenase IV working solution 
1. Thaw 1 aliquot of Collagenase IV stock solution in a 37 °C water bath. 
2. Add 9 ml pre-warmed DPBS+ into the stock solution just prior to usage. 
3. Additional amounts of collagenase IV solution can be stored at 4 °C for 
1 week. 
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hESC medium  
500 ml KO-DMEM (#10829-018, Invitrogen) 
 128.2 ml KOSR (#10828028, Invitrogen) 
 6.4 ml L-glutamine (200 mmol/L; #25030-024, Invitrogen) 
 6.4 ml MEM NEAA (10 mmol/L; #11140-050, Invitrogen) 
bFGF is only added according to the required amount of medium used per 
hESC plate. 
 
HFF medium 
500 ml DMEM (#42430, Invitrogen) 
120 ml Fetal Bovine Serum (FBS; #A15102, PAA) 
6     ml Penicillin and Streptomycin (P/S: 5.000 U/ml and 5 mg/ml; 
#15070-063, Invitrogen) 
 
TSA medium 
500 ml DMEM + GlutaMax™ (#61965, Invitrogen) 
120 ml Fetal Bovine Serum (FBS; #A15102, PAA) 
6     ml Penicillin and Streptomycin (P/S: 5.000 U/ml and 5 mg/ml; 
#15070-063, Invitrogen) 
 
Cryopreservation medium 
18   ml Fetal Bovine serum (FBS; #A15102, PAA) 
2     ml DMSO (#276855, Sigma Aldrich) 
DMSO is added to FBS and mixed just prior to resuspension of cells for 
cryopreservation at -152oC. 
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SF (serum free) monolayer differentiation medium 
500 ml RPMI 1640 with GlutaMAX™ (#61870, Invitrogen) 
5     ml Sodium Pyruvate (100 mmol/L; #11360-039, Invitrogen) 
5     ml Penicillin and Streptomycin (P/S: 5.000 U/ml and 5 mg/ml; 
#15070-063, Invitrogen) 
All reagents are mixed well and stored at 4oC for two weeks. 2% B27 
supplement is added just prior to use. 
 
SF (serum free) adaptation medium containing 
485 ml DMEM (#11960, Invitrogen) 
5     ml L-Glutamine (200 mmol/L; #25030-024, Invitrogen) 
5     ml MEM NEAA (10 mmol/L; #11140-050, Invitrogen) 
5     ml ITS-X supplement (100X; #51500-056 Gibco, Invitrogen) 
 
bSFS (basal serum free differentiation medium) 
500 ml DMEM (# 11960, Invitrogen) 
5     ml L-Glutamine (200 mmol/L; #25030-024, Invitrogen) 
5     ml MEM NEAA (10 mmol/L; #11140-050, Invitrogen) 
900  µl 2-beta mercaptoethanol (50 mmol/L; #31350-010, Invitrogen) 
690  µl Human Transferrin (4 mg/ml; #030124SA, Gibco, Invitrogen) 
182  µl Sodium Pyruvate (100 mmol/L; #11360-039, Invitrogen) 
50    µl Sodium Selenite (100 µg/ml; #S5361-25G, Sigma Aldrich) 
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hEHM medium (human bioengineered heart muscle medium) 
 500 ml Iscove’s MEM (#F0465, Biochrom) 
120 ml Fetal Bovine Serum (FBS; #A15102, PAA) 
6     ml L-Glutamine (200 mmol/L; #25030-024, Invitrogen) 
6     ml NEAA (10 mmol/L; #11140-050, Invitrogen) 
6     ml Penicillin and Streptomycin (P/S: 5.000 U/ml and 5 mg/ml; 
#15070-063, Invitrogen) 
4.34 µl 2-ß-Mercaptoethanol (#31350-010, Sigma) 
 
 
10X DMEM 
1. Dissolve 669 mg DMEM powder (#52100-039,Invitrogen) in 5 ml sterile 
water. 
2. Filter the solution through a 0.22 µm syringe filter  
 
2X DMEM 
1    ml 10X DMEM  
2    ml FBS (#A15102, PAA) 
100 µl L-glutamine (200 mmol/L; #25030-024, Invitrogen) 
100 µl P/S (5.000 U/ml and 5 mg/ml; #15070-063, Invitrogen) 
adjusted to 5 ml ddH2O. 
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Collagenase I solution  
1. Dissolve 100 mg of collagenase I in 40 ml of DPBS+ and 10 ml FBS. 
2. Sterile filter the solution, aliquot (10 ml) in 15 ml centrifuge tubes, and 
store at -20 °C. 
 
DNAse I solution  
1. Suspend DNAse I in ice cold water at 1 mg/ml. Sterile filter the solution, 
aliquot (5 ml) in 15 ml centrifuge tubes, and store at -20 °C. Keep on 
ice after thawing. 
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Reagents and solutions for Isometric force measurements 
 
Tyrode’s solution 
CaCl2 stock (2.25M) 
165.57 g CaCl2 x 2H2O  (Mw = 147.02) 
500 ml ddH2O 
First, dissolve calcium salt thoroughly in ddH2O. This is stored at 4oC until 
required. 
 
MgCl2 stock (1.05M) 
 106.83 g MgCl2 x 6H2O (Mw = 203.01) 
 500ml  ddH2O 
Next, dissolve magnesium salt thoroughly in ddH2O to make a stock solution 
as indicated. 
 
Then, 3 stock solutions are made up as indicated. Stock solutions are stored 
at 4oC until required. Ca2+ concentration in Stock 1 can be adjusted as shown 
below. 
Stock I             
Tyrode  [Ca2+] = 1.8 mM 0.4 mM 0.2 mM 
NaCl (Mw=58.44) 175 g 175 g 175 g 
KCl (Mw=74.56) 10 g 10 g 10 g 
CaCl2 stock (2.25 M) 20 ml 4.44 ml 2.22 ml 
MgCl2 stock (1.05 M) 25 ml 25 ml 25 ml 
adjusted with ddH2O  1000 ml 1000 ml 1000 ml 
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Stock II 
NaHCO3 (Mw=84.01) 50 g 
H2O 1000 ml 
  
Stock III  
NaH2PO4 (Mw=137.99) 5.8 g 
H2O 1000 ml 
  
All stock solutions can be stored after reconstitution at 4oC until required. 
 
Tyrode’s  Working Solution 
 
Stock I 40 ml 80 ml 120 ml 200 ml 
Stock II 38 ml 76 ml 114 ml 140 ml 
Stock III 10 ml 20 ml 30 ml 50 ml 
Glucose 1 g 2 g 3 g 5 g 
Ascorbic acid 50 mg 100 mg 150 mg 250 mg 
H2O 1 L 2 L 3 L 5 L 
 
Prior to isometric force measurements, Tyrode’s working solutions  were 
mixed as indicated above, dissolved thoroughly and poured into thermostatted 
force transducer reservoirs as measurement buffer. 
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Cloning Reagents and Medium 
 
LB-Medium 
 20 g  Bacto-Tryptone 
 20 g Bacto Yeast Extract 
 20 g NaCl 
 
Dissolve the above reagents with 1 L ddH2O and equilibrate the medium with 
0.1 N NaOH to pH 7.4. Top up to 2 L with ddH2O in a glass bottle and 
autoclave. LB medium can be stored in 4oC for 3 weeks. 
 
 
 
Agarose plates for bacterial colony cultures 
 
Weigh 7.5 g molecular biology grade agarose into a glass bottle. Add 500ml 
LB-Medium and agitate to an even suspension. Autoclave the bottle and allow 
it to cool below 50oC. Add required antibiotics and agitate to mix the solution 
well. Pour about 20 ml of the molten agar into sterile 10 cm Petri dishes and 
allow these to cool and solidify. Store at 4oC for a maximum of 2 weeks. 
 
Antibiotics supplementation in 500 ml LB-Medium: 
2.5 ml Kanamycin and/or 
2.0 ml Ampicillin 
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Ampicillin-Stock 
25 mg/ml  
Weigh out 50 mg of Ampicillin and dissolve in 2 ml of ddH2O. Aliquot and 
freeze in -20oC 
 
Kanamycin-Stock 
10 mg/ml 
Weigh out 20 mg of Kanamycin and dissolve in 2 ml of ddH2O. Aliquot and 
freeze in -20oC 
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Protein blot Reagents 
6x Lämmli Loading buffer 
 2.4     g  SDS 
 12   mg Bromophenol blue 
 13.8 ml Glycerol, 87% 
 5.8   ml Tris-HCL, 1.0M, pH 6.8 
 1.85   g DTT 
 
First add SDS, Glycerol and Tris-HCL in a glass beaker and heat to 50oC for 
10 – 20 minutes. When reagents are completely dissolved, add Bromophenol 
blue and 20 ml ddH2O and mix well. Finally, add DTT to the solution, mix well, 
aliquot and freeze in -20oC. 
  
0.5 M Tris-HCl pH 6.8 
400   ml ddH2O 
30.28   g  Tris-HCl  
 
Adjusted to pH 6.8 and topped up to 500 ml H2O  
 
 
1.5 M Tris-HCl pH 8.8 
400     ml  ddH2O 
90.85    g  Tris-HCl  
 
Adjusted to pH 8.8 and topped up to 500 ml H2O.  
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SDS PAGE with 30% Acrylamide 
Separating Gel (for 2 gels) 
% SDS Agarose gel 
 
5% 6% 8% 10% 12% 15% 18% 
For kDa-proteins 220-60 150-50 105-40 90-25 60-20 45-10 40-4 
H2O 5.6 5.3 4.6 4.0 3.3 2.3 1.3 
30 % Acrylamide 1.7 2.0 2.7 3.3 4.0 5.0 6.0 
1.5 M Tris pH 8,8 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
10 % SDS 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
10 % APS 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
TEMED 0.01 0.008 0.006 0.004 0.004 0.004 0.004 
 
 
Stacking Gel (for 4 gels) 
 Vol (ml) 
H2O 5.6 
30 % Acrylamide 1.7 
0.5 M Tris pH 6.8 2.5 
10 % SDS 0.1 
10 % APS 0.1 
TEMED 0.01 
 
 
Nitrocellulose membrane preparation 
 
Membranes were immersed in 100% Methanol for 10 seconds. Next, they 
were washed in ddH2O for 5 minutes and placed in transfer buffer and 
10 % APS: 150 mg APS 
dissolved in 1500 µl ddH2O.	  
volumes in ml 
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allowed to equilibrate for 10 minutes. Thereafter, PVDF membranes are 
activated for SDS gel blot transfers. 
 
10x Transfer-Buffer I  (for Proteins under 80-100 kDa) 
60.5 g Tris-Base 
288 g Glycine 
 
Dissolve thoroughly in 2 L ddH2O 
 
1x Transfer Stock Solution Buffer  
200 ml  10x Puffer 
400 ml  Methanol  
Adjusted to 2 L ddH2O. 
 
Ponceau-S-Solution 
Ponceau-S-solution was purchased from Applichem and used neat for 
staining of western blot membranes. 
 
Membranes were incubated in Ponceau-S solution for 1-5 minutes in room 
temperature and then rinsed with ddH2O until the background turns white and 
stained bands are clearly contrasted. After image documentation, the 
ponceau stains are rinsed away in TBST. 
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10x TBS Solution 
 121.14 g Tris-Base 
175.32 g NaCl 
Add all reagents and 1.5 L of ddH2O in a suitable glass beaker and mix until 
all reagents are dissolved. Equilibrate the solution with fuming HCl till pH 7.5, 
then top up till 2 L with ddH2O. 
 
1x TBST Stock Solution 
100 ml  10x TBS 
900 ml  H2O 
     1    ml  Tween 20 
 
Mix all reagents until they dissolve. Tween 20 is extremely viscous and 
requires about 10 – 15 minutes to dissolve completely. 
 
10x Gel-Electrophoresis Buffer = Running Buffer (pH 8,3-8,7) 
 60.6 g  Tris- Base 
 288 g  Glycine 
   20 g  SDS 
 
Dissolve all reagents in 1 L ddH2O and topped up to 2 L ddH2O and mix 
thoroughly. During gel electrophoresis, 1 : 10 ml dilution with ddH2O is 
prepared fresh to obtain 1X running buffer. 
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DNA Agarose Gel Electrophoresis Reagents 
 
50x TAE 
 242 g Tris-Base 
100 ml EDTA 0.5M pH 8.0 
57.1 ml Glacial Acetic Acid 
 
Dissolve first in 800 ml, pH 8.5 adjusted and topped up to 1 L H2O. Gel 
electrophoresis run is diluted 1 : 50 to obtain 1X TAE gel running buffer prior 
to use. 
 
6x DNA loading buffer (2 coloured) 
 75 mg Bromophenol-Blue 
25 mg Xylene cyanol 
100 ml 30% Glycerol 
All reagents are mixed thoroughly and can be stored in 4oC indefinitely 
 
 
3.0 M NaOAc pH 5.4 
Anhydrous NaOAc: M = 82.03 g/mol 
To make 0.3 M of NaOAc, 24.609 g of anhydrous NaOAc was dissolved 
thoroughly in 70ml H2O and adjusted to pH 5.4 with dropwise addition of 
fuming HCL and topped up till100 ml ddH2O. 
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Reagents for Immunohistochemistry 
Permeabilizing / Blocking buffer 
500 ml Phosphate Buffered Saline (0.05 M, pH 7.4, Invitrogen) 
 25 ml Fetal Calf Serum 
 5 g Bovine Serum Albumin 
 2.5 ml Triton X-100 
All reagents are mixed together thoroughly. Triton X-100 is viscous and 
requires constant stirring to dissolve. Blocking buffer can be aliquot and 
stored at -20oC. 
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Gene 
transcripts 
5’ Forward primer 3’ Reverse primer Taqman probe 
Cardiac 
actin 
CCGGGAGAAGATGACTCAGA GCAAAGCGTAGCCCTCATAG CTGGCCGTACCACAGGCATTGTTCT 
Skeletal 
actin 
TGCCCATTTATGAGGGCTAC GCCATCTCGTTCTCGAAGTC CGTGACCACAGCTGAGCGCGAGAT 
α MHC GAAGTCCTCCCTCAAGCTCA CAAAGTGAGGATGGGTGGTC ACTGCCGATACTGGGGACAGTGGT 
ß MHC GAGGAAATGAGGGACGAGAG ATGGAGGCCATCTCCTTCTC CTGCTGGAACGTAGAGACTCCCTGCT 
RyR 2 TGGAAATGGTGTTGGAGATG AATTCGGAACGAGATGCTTG TTCATCTCTGGTCAGGTTGTATTGCTCGT 
SERCA GAGTTGAACCCTCCCACAAG CCAATCTCGGCTTTCTTCAG AGATTACAGCTATGACTGGCGATGGCGT 
CSQ 2 CTACCATGAGCCGGTGTCTT GCTTCTTTCTTGGCATCCAC ATCGTGCTTGAGCTTGTGGCCCA 
PLB CCCAGCTAAACACCCGTAAG TCCATGATACCAGCAGGACA GATGATCACAGCTGCCAAGGCTACCT 
Table 3. Primers and probes used in quantitative PCR. 
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ABSTRACT
The advent of pluripotent human embryonic stem cells has created the unique opportunity
for the development of a wide variety of humanized cellular tools for basic research,
as well as industrial and clinical applications. It has, however, become apparent that
embryonic stem cell derivatives in classical monolayer or embryoid body culture do
not resemble bona fide tissues, mainly because of their limited organotypic organization
and maturation in these culture formats. This shortcoming may be addressed by tissue
engineering technologies aiming at the provision of a “natural” growth environment to
facilitate organotypic tissue assembly. In this unit, we provide two harmonized basic
protocols for (1) cardiac differentiation of human embryonic stem cells under serum-free
conditions and (2) the assembly of the stem cell–derived cardiomyocytes into engineered
heart muscle. This protocol can be easily adapted to bioengineer heart muscle also from
other stem cell–derived cardiomyocytes, including cardiomyocytes from human-induced
pluripotent stem cells. Curr. Protoc. Cell Biol. 55:23.8.1-23.8.21. C© 2012 by John Wiley
& Sons, Inc.
Keywords: human embryonic stem cells  pluripotent stem cells  cardiac
differentiation  cardiomyocytes  tissue engineering  engineered heart muscle
INTRODUCTION
The introduction of robust protocols to derive and maintain human embryonic stem cells
(hESCs) in a self-renewing state with pluripotent differentiation potential (Thomson
et al., 1998) is likely to have an enormous impact on the utility of cell models in
human developmental biology, as well as drug discovery and development (Braam and
Mummery, 2010). Moreover, hESCs and other pluripotent stem cells appear to be a
promising source for cell-based organ repair (Laflamme et al., 2007).
hESCs can give rise to derivatives of the three germ lines—ectoderm, mesoderm, and
endoderm. Other human pluripotent stem cells, including induced pluripotent stem cells
(Takahashi et al., 2007) and parthenogenetic stem cells (Turovets et al., 2011), have
similar biological properties. hESC are nevertheless considered the “gold standard” for
a pluripotent stem cell, and mechanisms underlying pluripotent stem cell biology must
be scrutinized in hESC to attain general acceptance. Ectodermal differentiation is ap-
parently the default differentiation pathway in most hESC lines (Vallier et al., 2004).
Spontaneous mesoderm and in particular cardiomyocyte differentiation are minimal, but
may be enhanced by stage-specific differentiation protocols, adapted to simulate the
paracrine milieu that governs embryonic heart development (Kattman et al., 2011a). Al-
ternatively, cardiomyocytes may be isolated and enriched by manual dissection of sponta-
neously beating areas within differentiating embryoid bodies (EBs; Kehat et al., 2001; Xu
et al., 2002), Percoll gradient centrifugation (Laflamme et al., 2007), genetic selection in
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transgenic hESC lines (Xu et al., 2008), or immune-assisted cell sorting via unique cell
surface markers (Dubois et al., 2011; Elliott et al., 2011).
Isolated cardiomyocytes from hESCs display morphological and electrophysiological
features of fetal cardiomyocytes (Kehat et al., 2001; Mummery et al., 2003). Advancing
maturation in monolayer and EB cultures is severely compromised. Hence, it appears
necessary to introduce novel culture formats to unlock the intrinsic capacity of ESC-
derived cardiomyocytes to form heart muscle surrogates in vitro. To this end, tissue
engineering has been developed, as it may not only enable the adjustment of paracrine,
but also of biophysical conditions, which may both be essential to facilitate bona fide
heart muscle formation for a wide variety of applications, including (1) basic research
(e.g., in developmental biology), (2) industrial (e.g., in drug development and toxicity
screens), and (3) clinical (e.g., in cell-based heart repair) applications.
The complex architecture of the heart and its associated function, as well as the scarcity
of adequate cell material, impose considerable challenges on the cardiac tissue engineer.
Firstly, cardiomyocytes, even at an early developmental stage, are largely post-mitotic
and thus refractory to commonly used cell amplification protocols. Secondly, the heart
is a multi-cellular organ with a delicate balance of myocytes and nonmyocytes, each
with specific roles in tissue organization, function, and maintenance. Thirdly, the my-
ocytes have to be organized in a highly specialized functional syncytium embedded in
extracellular matrix. Accordingly, it is essential to (1) have access to large quantities
of bona fide cardiomyocytes, (2) supplement the myocyte pool with supporting stromal
cells, and (3) provide an extracellular matrix to hold the cellular components together.
In vitro vascularization is not required for myocardial tissue engineering if size limita-
tions are considered (Tiburcy et al., 2011), but will be a prerequisite for the survival of
tissue-engineered heart muscle if applied as surrogate tissue in vivo. Whether “precapil-
larization” of tissue engineered heart muscle already in vitro will be instrumental under
these circumstances remains to be documented.
Here we provide two harmonized protocols to firstly enable the allocation of a so-
matic cell pool with defined cardiomyocyte and mesodermal nonmyocyte content from
hESCs, and secondly allow the construction of human engineered heart muscle (EHT;
Zimmermann et al., 2000) with the characteristic morphological and functional features
of native myocardium (i.e., anisotropic arrangement, force developing contractions, and
electrical conductivity). The cardiomyocyte derivation protocol we provide here is not
optimized for cardiomyocyte purity, but for process reliability, low costs, and fast car-
diomyocyte allocation. Moreover, it is scalable to enable mass cardiomyocyte derivation
and subsequent assembly of engineered heart muscle.
STRATEGIC PLANNING
This unit contains two protocols: Basic Protocol 1 describes a method to robustly gener-
ate cardiomyocytes from hESCs under serum-free conditions; Basic Protocol 2 describes
a method to engineer human myocardium. Basic Protocol 2 can also be utilized with
minor modification to engineer heart muscle from other cardiomyocyte sources, includ-
ing induced pluripotent and other stem cells; the main prerequisite is that the input cell
population contains more than 10% immature cardiomyocytes and more than 40% meso-
dermal stromal cells. The described protocols should be highly robust in the hands of
researchers familiar with basic mammalian cell culture. However, it must be emphasized
that handling and maintaining of hESC is challenging and may require additional expert
training.
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NOTE: All protocol steps, with the exception of the casting mold and silicone holder
preparations, must be performed under sterile conditions. Casting molds and silicone
holders can be autoclaved and reused.
NOTE: All cultures should be maintained in a humidified incubator at 37◦C supplemented
with 5% CO2.
NOTE: Legal requirements for hESC use in academia and industry can vary substantially
and users of our protocols are recommended to contact the relevant regulatory authorities
to attain approval for the intended studies.
BASIC
PROTOCOL 1
CARDIAC DIFFERENTIATION IN HUMAN EMBRYONIC STEM CELLS
CULTURES
The ability to maintain high-quality hESC cultures is an essential precondition for the
successful execution of the following protocols. Basic hESC cultures are generally main-
tained under serum. We prefer to induce cardiogenesis in serum-free conditions for
optimal control of this highly sensitive process. This protocol describes the adaptation
of standard hESC-cultures to serum-free conditions and the induction of cardiac differ-
entiation by MAPK inhibition in embryoid body cultures.
Materials
hESCs (e.g., HES3 hESCs)
100-mm feeder cell-coated culture plates (see Support Protocol 1)
hESC maintenance medium (see recipe)
Dulbecco’s phosphate-buffered saline with Mg2+ and Ca2+ (DPBS+; Invitrogen,
cat. no. 14040-091)
Collagenase IV working solution (see recipe)
SF adaptation medium (see recipe)
bSFS medium (see recipe)
SB203580 (CalBiochem, cat. no. 559389-5MG)
100-mm tissue culture dishes (Nunc, cat. no. 150679)
Stereomicroscope (Leica, cat. no. MZ8)
Glass Pasteur pipets
Stem Cell EZ passaging Tool (Invitrogen, cat. no. 23181-010)
Cell scraper
Graded disposable serological pipets
50-ml centrifuge tubes (BD Falcon, cat. no. 352070), sterile
Centrifuge
100-mm ultra-low petri dishes (Corning, cat. no. 3262)
40-μm cell strainers (BD Falcon, cat. no. 352340)
Tube rack
Culture of hESC
1. Seed hESC (2 × 106) on a 100-mm feeder cell-coated culture plate containing
10 ml hESC culture medium. Place the plates in the incubator.
Feeder cells can be, e.g., mouse embryonic fibroblasts or human foreskin fibroblasts; both
have to be growth-inhibited either by mitomycin C or γ -irradiation.
2. Grow hEHCs to 60% to 90% confluency. Change the hESC culture medium every
day (use 10 ml culture medium per 100-mm culture dish).
Good-quality hESC colonies show a “pancake-like” appearance composed of densely
packed cells with a high nucleus:cytoplasm ratio, a clear demarcation, and a rather
circular morphology (Fig. 23.8.1A).
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Figure 23.8.1 hESC culture and processing (all displayed data are from HES3). (A) Single
hESC colony on irradiated human foreskin fibroblast. Notice the “pancake” morphology with clearly
defined borders. The absence of raised centers/cystic areas indicates that this is a good quality
hESC colony. Scale bar: 500 μm. (B) hESC colony manually “scored” using the StemPro EZ
Passage tool. Scale bar: 1 cm. (C) EBs with uniform size formed from manually cut hESC colonies
at culture day 1 of serum-free differentiation. Scale bar: 100 μm. (D) 50-ml centrifuge tubes with
cell strainers inverted (left) and correctly fitted (right) in the collection tube. EBs will be retained
by the inverted cell strainer while cell debris will flow through and can be discarded. After turning
over the cell strainer, the EBs can be washed into a fresh collection tube for further processing.
3. Split at a 1:9 ratio for further propagation.
Time to split cultures can vary depending on the adaptation of the hESC to the culture
conditions. Well-established cultures are typically split after 7 days.
4. For splitting, aspirate cell culture medium from hESC plates. If necessary, as-
pirate cystic/differentiated parts of hESC colonies under optical control using a
stereomicroscope.
Place the stereomicroscope underneath a laminar flow hood to ensure sterile handling of
cell cultures.
5. Rinse the tissue culture plate once with 5 ml DPBS+.
6. Aspirate DPBS+ and add 3 ml collagenase IV working solution. Incubate for 4 to
6 min at 37◦C.
Avoid over-digestion to prevent detachment of entire “feeder-mat” with hESC cell
colonies.
7. Remove the hESC plate carefully from the incubator and aspirate the collagenase
IV working solution with a glass Pasteur pipet.
Ensure that the Pasteur pipet does not contact the hESC colonies. hESC colonies are now
loosely located on the culture dish and can be easily aspirated.
Stem Cells
23.8.5
Current Protocols in Cell Biology Supplement 55
8. Quickly, but carefully, use the Stem Cell EZ Passage Tool to score the entire plate
by the rolling method. Rotate the plate 90◦ and repeat scoring (Fig. 23.8.1B). The
resulting squares are referred to as “cell rafts.”
The scoring step can also be performed with alternative tools (e.g., glass needle). We find
the Stem Cell EZ Passage Tool very well suited to produce homogeneously sized cell rafts
(∼1 mm2).
9. Add 10 ml hESC medium to neutralize the enzymatic activity of the collagenase.
10. Detach the cell rafts with a cell scraper.
Use short strokes starting from the edge of the plate inwards.
11. Verify that most of the cell rafts have been mechanically detached from the
plate.
Inspect using a stereomicroscope.
12. Using a 10-ml disposable serological pipet, aspirate the cell rafts and transfer into a
50-ml sterile centrifuge tube.
Prewet the pipet interior to minimize adhesion of cell rafts.
13. Repeat steps 2 to 12 for each individual hESC plate.
Drying of cultures must be prevented. Parallel plates can be handled once a sufficient
level of experience has been reached.
14. Pool the cell rafts into one 50-ml sterile centrifuge tube and pellet by centrifuging
for 4 min at 300 × g, room temperature.
15. Discard the supernatant.
Adapt to serum-free conditions
16. Resuspend the cell pellet in 10 ml SF adaptation medium.
Trituration of the cell pellet 5 times is sufficient to dislodge most cell rafts without breaking
them up too much.
17. Pool cell rafts from two 100-mm hESC plates into one 100-mm ultra-low petri dish
containing 10 ml prewarmed SF adaptation medium.
18. Incubate the ultra-low petri dishes in a 37◦C incubator with 5% CO2.
Homogeneously sized EBs form within 24 hr (Fig. 23.8.1C).
Cardiac differentiation
19. Insert a 40-μm cell strainer in inverted orientation into an open 50-ml centrifuge
tube and place carefully in a tube rack (Fig. 23.8.1D).
20. Carefully remove the ultra-low petri dishes from the incubator.
21. Using a sterile 10-ml serological pipet, gently aspirate the entire culture medium
including EBs and pass through the inverted cell strainer.
During serum-free adaptation and EB formation, cells are constantly shed. This straining
step is important to separate single cells and cell debris from the formed EBs.
22. Rinse the ultra-low petri dishes once with 10 ml bSFS medium and pass again
through the inverted cell strainer.
EBs are collected on top of the cell strainer. Work quickly to prevent drying of EBs.
We introduce bSFS here to reduce the insulin content. Insulin can interfere with cardio-
genesis in hESC culture.
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23. After the flow through is complete, turn the cell strainer so that it sits properly inside
the opening of a new sterile 50-ml centrifuge tube (Fig. 23.8.1D).
The EBs are now at the bottom of the cell strainer and can be washed inside the centrifu-
gation tube.
24. Add 10 ml bSFS containing 5 μM SB203580 in the dark.
SB203580 is a highly light-sensitive MAPK inhibitor.
25. Transfer the entire volume back into the source ultra-low petri dish.
26. Place the culture plates back into the incubator.
This is marked as day 1 of differentiation.
27. Perform medium change every day following steps 19 to 26, until culture day 3
where it is then changed every 2 days.
The daily washing steps during the first 3 culture days minimize the amount of cell debris
that develops during serum-free adaptation.
Spontaneously beating EBs can be observed from culture day 8 onwards (see Video 1 at
http://www.currentprotocols.com/protocol/cb2308).
EB culture can be continued for several weeks for cardiomyocyte harvest. We typically
harvest EBs for further processing (see Basic Protocol 2) on culture day 13.
BASIC
PROTOCOL 2
BIOENGINEERING OF HEART MUSCLE
ESC-derived cardiomyocytes in classical monolayer or EB culture do not resemble post-
natal myocytes or myocardial tissue. Tissue engineering aims at assembling cells typically
in biological extracellular matrix into tissue-like organoids. This protocol describes the
generation of EHT with morphological and functional properties of native myocardium.
This protocol can be used with several human cardiomyocyte sources including embry-
onic and induced pluripotent stem cells. This protocol requires the provision of casting
molds.
Materials
Culture day 13 EBS in ultra-low petri dishes (see Basic Protocol 1)
Collagenase I (see recipe)
DNase I (see recipe)
Iscove MEM F0465 (Biochrom)
0.25%Trypsin-EDTA (Invitrogen, cat. no. 24200-056)
Fetal bovine serum (FBS; PAA, cat. no. A15102)
hEHT medium (see recipe)
Dulbecco’s phosphate-buffered saline without Mg2+ and Ca2+ (DPBS-; Invitrogen,
cat. no. 14190-94)
70% (v/v) ethanol
15- and 50-ml centrifuge tubes
37◦C shaking water bath
10-ml serological pipets
Centrifuge (Eppendorf, cat. no. 5804R)
Glass Pasteur pipet
Hemacytometer
Casting molds (see Support Protocol 2; Figure 23.8.2A)
Silicone holders (Fig. 23.8.2B)
Sterile curved forceps
100-μl pipet tips, sterile
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Figure 23.8.2 Casting mold and silicone holder for extended culture under defined mechanical load.
(A) Glass culture dish filled with transparent silicone and four circular recesses with central spacers: (i)
Teflon disc of 11-mm diameter and 5-mm height with central hole used as spacer during the silicone hardening
process; (ii) recess with thin silicone core; (iii) silicone tubing used as inner spacer during the EHT formation
process placed over a central silicon core. (B) Flexible silicone poles (length: 11 mm, thickness: 1.5 mm,
inner/outer distance: 3/6 mm) with circular base (diameter: 20 mm, thickness: 1.6 mm) as resilient holder
(resilient force can be adapted as desired by for example altering the silicone curing conditions or changing
the pole dimensions). Scale bars: 10 mm.
Perform enzymatic digestion of hESC-EBs to obtain single cells
1. Harvest culture day 13 EBs from the ultra-low petri dishes (from Basic Protocol 1)
and pool into a 50-ml centrifuge tube.
2. Let settle for 15 min at room temperature.
3. Aspirate the supernatant carefully and add 5 ml collagenase I and 100 μl DNase I
(20 μl/ml collagenase solution).
At this stage, the EBs are only loosely pelleted and care should be taken to avoid aspiration
of EBs.
4. Incubate at 37◦C in a shaking water bath for 45 min.
5. Add 20 ml Iscove MEM and triturate at least 5 times with a 10-ml serological pipet
to mechanically aid in dispersion of compact EBs.
Always prewet the pipets to minimize cell adhesion.
6. Centrifuge the tube for 5 min at 200 × g, room temperature.
7. Aspirate the supernatant and add 5 ml of 0.25% Trypsin-EDTA into the tube.
8. Incubate the tube in the 37◦C shaking water bath again for 5 to 10 min.
Keep the time as short as possible to minimize cell damage. Aim at a dissociation of
>80% of the starting amount of EBs.
9. Triturate briefly with a glass Pasteur pipet to disperse any remaining cell clumps.
10. Add 20 ml Iscove MEM supplemented with fetal bovine serum at 1:1 ratio with
400 μl DNase I and triturate with a 10-ml serological pipet until a uniform cell
suspension is obtained.
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11. Centrifuge the tube for 5 min at 200 × g, 4◦C.
12. Aspirate the supernatant and discard.
13. Resuspend the cell pellet evenly in 20 ml cold hEHT medium.
14. Perform a cell count with a hemacytometer.
We anticipate to retrieve ∼8 × 106 cells per ultra-low petri dish. Cell viability should be
>90% based on Trypan blue exclusion assay.
15. Transfer 1 × 106 cells into a separate 15-ml centrifuge tube and centrifuge for 5 min
at 200 × g, 4◦C. Keep the remaining cells on ice.
16. Aspirate the supernatant and rinse with 10 ml cold DPBS-.
17. Centrifuge the 15-ml tube for an additional 5 min at 200 × g, 4◦C, and aspirate the
supernatant leaving an intact cell pellet.
18. Tap the base of the 15-ml centrifuge tube at least 5 times to dislodge the cell pellet
and add 3 ml of ice-cold 70% ethanol in a dropwise manner while gently shaking
(“vortex”).
19. Store the tube of ethanol-fixed cells at 4◦C until required for flow cytometry and
morphological cell smear analyses (Fig. 23.8.3).
The maximum storage time for ethanol-fixed cells should not exceed 1 week.
20. Centrifuge the remaining cells for 5 min at 200 × g, 4◦C.
21. Aspirate the supernatant and resuspend the cell pellet in an appropriate volume of
cold hEHT medium.
Adjust the volume of the cell suspension according to the EHT reconstitution protocol
(see below and Table 23.8.1).
Generate human EHTs
22. Mix the components in the exact order as indicated in Table 23.8.1 into a prechilled
15-ml (for 4 EHTs) or 50-ml (for 20 EHTs) centrifuge tube.
All reagents must be cold and kept on ice throughout the entire procedure. Work quickly
to prevent reagents from warming up.
23. Triturate the EHT master mix on ice with a prechilled serological pipet to ensure
homogeneous distribution of cells.
24. Quickly distribute 500 μl of the cell-collagen mixture into the individual casting
mold recesses (Fig. 23.8.2A).
25. Place the casting molds with minimal agitation in a 37◦C humidified incubator with
5% CO2 for 1 hr.
26. Remove the dishes and move into a sterile laminar hood and overlay carefully with
6 ml prewarmed hEHT medium. Ensure that all hEHTs are completely covered with
medium.
27. Return the dishes into the incubator for 24 hr.
28. Remove the dishes from the incubator and move into the laminar flow and exchange
the hEHT medium.
Microscopic inspection at this time point should demonstrate evenly distributed cells
within the hydrogel. Isolated beating of single cells and cell clusters should be visible.
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Figure 23.8.3 Assessment of hESC-EB cell composition by flow cytometry and fluorescence
microscopy (all data from HES3 EBs). (A) hESC-EBs on culture day 13 should contain >10%
cardiomyocytes (α-sarcomeric actinin-positive; right panel); left panel: isotype control. Analysis
was performed by flow cytometry (input cell number 1 × 106). (B) Microscopic analysis of cell
smears after enzymatic dispersion of hESC-EBs, demonstrating mainly mesodermal components
(vimentin and tropomyosin positive cells) and few cells positive for endodermal (alpha-fetoprotein),
as well as ectodermal (pan-neurofilament) markers. Oct 4 and Nanog (marking residual pluripotent
cells) were not detectable.
The hEHTs will progressively condense and will be ready for transfer onto resilient
silicone holders (Fig. 23.8.2B).
hEHT should be fully condensed around the central silicone tube within the casting mold
recess (Fig. 23.8.2A) on EHT culture day 3. The EHT transfer may be postponed by 2 days
if condensation is not complete by culture day 3.
Transfer hEHTs onto flexible silicone holders for mechanical stretching
29. Place the necessary number of silicone holders into a tissue culture plate, fill with
hEHT medium.
Silicone holders can be adjusted in size to facilitate EHT culture in variable culture plate
formats (single dish to 48-well plate).
30. Remove casting mold dishes from the incubator under the laminar hood.
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Table 23.8.1 Composition of Master Mix for Generation
of EHTs
Volume (μl)
Number of EHTs 4 20
Collagen (3.2 mg/ml)a 440 2,200
2× DMEM (see recipe) 535 2,675
0.1 N NaOHb 95 475
Matrigel (BD, cat. no. 354234) 200 1,000
Cell suspensionc 829 4,145
TOTAL VOLUME 2,100 10,500
aWe prefer to prepare collagen type 1 from rat tail tendons by classical
acid solubilization technique (adapted to 3 to 5 mg/ml). Stability of
collagen at 4◦C is approximately 1 year. Quality of most commercially
available collagens is insufficient.
bAdd dropwise until phenol red color indicator changes from yellow
(acidic) to pink.
cAdjust to 1.5 × 106 cells per EHT.
31. Gently pinch the top of the removable silicone tubing of a casting mold dish with
curved forceps and slowly remove the silicone tube. Ensure that the EHT is attached
around the silicone tube.
32. Place the silicone tube over one of the paired silicone poles of a silicone holder and
release the EHT by gentle shaking or nudging of the EHT carefully with a pipet tip.
EHTs typically slip from the silicon tubing with little extra manipulation.
33. Using another sterile pipet tip, gently bend the other silicone pole to suspend the
EHT between the two poles.
The EHTs are fragile at this stage and it is crucial that they are transferred from the
casting molds in an extremely careful manner. Tissue ruptures at this stage constitute
predetermined breaking points during subsequent EHT culture.
This step also has to be executed quickly to prevent drying of the EHT.
34. Position EHT horizontally suspended on the resilient silicone holder.
35. Transfer the holder with EHT into a tissue culture dish with fresh hEHT medium
and ensure that EHTs are fully covered.
36. Incubate for 24 hr at 37◦C.
37. Exchange medium and always ensure that EHTs are fully submerged. From now on
exchange medium every other day.
The EHTs will further condense around the poles over the next 5 to 7 days and start to
contract visibly. The resilient silicone poles facilitate auxotonic contractions (see video 2
at http://www.currentprotocols.com/protocol/cb2308). Their size can be easily adjusted
as desired.
EHT are ready for end-point analyses on culture day 10 or may be cultured for an extended
period of time (for at least 6 months).
We control the quality of EHT typically at culture day 10 by assessment of contractile
properties under isometric conditions with and without field stimulation in thermostatted
(37oC) organ baths filled with modified Tyrode’s solution (Fig. 23.8.4A) (Zimmermann
et al., 2000). This is typically followed by additional morphological (Fig. 23.8.4B) and
other analyses (see Anticipated Results).
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Figure 23.8.4 Functional and morphological parameters of hEHTs. (A) Force of contraction
measured under isometric conditions at 37◦C and electrical field stimulation at 2 Hz (n = 4). A
positive inotropic response (increase in force of contraction) is anticipated for muscle preparations
under increasing extracellular calcium concentrations. (B) Demonstration of an aligned muscle
bundle with characteristic sarcomeric cross-striation by confocal microscopy (red: α-actinin; green:
f-actin; blue; DAPI stained nuclei). Scale bar: 20 μm. For the color version of this figure go to
http://www.currentprotocols.com/protocol/cb2308.
SUPPORT
PROTOCOL 1
Embryonic stem cells are typically maintained in a pluripotent state on fibroblast feeders.
Feeder cultures can be prepared from fetal mice or human foreskin. Basic Protocol 1
utilizes human foreskin fibroblast (HFF) feeder cell–coated culture plates prepared as
outlined in this protocol.
Materials
Human foreskin fibroblasts (HFF; ATCC# SCRC-1041)
HFF maintenance medium (see recipe)
Human basic fibroblast growth factor (bFGF; Stemgent, cat. no. 03-0002 or
Miltenyi Biotech, cat. no. 130-093-841)
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37◦C water bath
15-ml conical tubes
Hemacytometer
Standard inverted microscope
Irradiation source
100-mm tissue culture plates
37◦C, 5% CO2 incubator
1. Thaw a vial of frozen HFF cells in a 37◦C water bath.
2. Transfer HFFs into a 15-ml conical tube containing 9 ml prewarmed HFF mainte-
nance medium.
3. Centrifuge the cells for 4 min at 300 × g, room temperature.
4. Aspirate the supernatant and resuspend the cells in 10 ml HFF maintenance medium.
Perform steps 1 to 4 quickly and without interruption to minimize cell damage.
5. Count the number of cells using a hemacytometer under a standard inverted micro-
scope.
Viability should be >90% based on Trypan blue exclusion.
6. Transfer the desired number of HFFs for feeder layer plating into a separate 15-ml
or 50-ml conical tube.
Calculate 2 × 106 irradiated HFFs per 100-mm tissue culture plate. Mark the conical
tube for irradiation.
Plate the remaining HFFs into 75-cm2 tissue culture flasks (2.2 × 106 HFFs/75-cm2 flask)
and supplement the medium with 10 ng/ml bFGF for continual passaging.
Alternatively, cryopreserve in 90% fetal bovine serum (FBS; PAA, cat. no. A15-102) and
10% DMSO; freeze down for storage in liquid nitrogen or −152◦C freezer.
7. Expose the tube marked for irradiation to 30-Gray γ -irradiation for 20 min at room
temperature.
Irradiation causes the HFFs to be mitotically arrested.
8. Centrifuge the irradiated HFFs for 4 min at 300 × g, room temperature.
9. Aspirate the supernatant and resuspend the cells in 10 ml HFF maintenance medium
for each 100-mm tissue culture plate.
10. Place the 100-mm tissue culture plates containing irradiated HFFs in a 37◦C incubator
with 5% CO2.
These plates can be used as feeder layer for hESC cultures after 24 hr.
SUPPORT
PROTOCOL 2
PREPARATION OF CASTING MOLDS FOR EHT CULTURE
EHTs are typically created in a defined circular geometry in casting molds (Fig. 23.8.2).
The circular geometry is advantageous in terms of tissue formation and cellular orienta-
tion compared to, e.g., lattice formats (Zimmermann et al., 2000). Casting molds can be
adapted in size depending on the respective application (Naito et al., 2006, Yildirim et al.,
2007). For large-scale applications in cardiac repair, fusion of individual units to complex
tissue-engineered myocardium can be performed (Naito et al., 2006; Zimmermann et al.,
2006).
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Materials
Sylgard silicone elastomer and curing agent 184 (Dow Corning, cat. no. 1673921)
Distilled water
Teflon spacer (Fig. 23.8.2A,i, custom made: 11-mm diameter, 5-mm height)
60 × 20–mm glass petri dishes (Schott Duran, cat. no. 217554101)
50-ml centrifuge tubes
Forceps
Silicone core (Figure 23.8.2A,ii, 1-mm diameter)
55◦C incubator
5-liter glass beakers
Silicone tubing (Figure 23.8.2A,iii, 4-mm diameter; VWR, cat. no. 224-0563)
Aluminum foil
Autoclave
1. Place four Teflon spacers evenly spaced in a glass petri dish (Fig. 23.8.2A).
2. Into a 50-ml centrifuge tube, pipet 9 ml Sylgard silicone and 1 ml of curing agent
and mix well.
3. Centrifuge the tube for 3 min at 300 × g, room temperature, to get rid of air bubbles.
4. Pour the silicone mixture into the glass dish around the Teflon spacers.
Avoid air bubbles.
5. Let set for 24 hr at room temperature or place in a 55◦C drying incubator for at least
1 hr for the silicone to cure.
6. Carefully remove the Teflon spacers with forceps (Fig. 23.8.2A, i).
7. Apply a droplet of premixed silicone to each of the centers of the four recesses,
attach a short silicone core upright (Fig. 23.8.2A,ii), and allow this to cure overnight
at 55◦C.
8. Place the newly fabricated molds in a 5-liter glass beaker filled with distilled water,
boil, drain, and dry. Discard water and repeat boiling steps at least 4 times.
This step removes cell toxic residuals from the casting molds.
9. Place silicone tubings (Fig. 23.8.2A,iii) over the silicone cores, wrap in aluminum
foil, and autoclave.
Casting molds can be reused indefinitely.
REAGENTS AND SOLUTIONS
Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see
APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
bFGF stock solution
Dissolve human basic fibroblast growth factor (bFGF; Stemgent, cat. no. 03-0002
or Miltenyi Biotech, cat. no. 130-093.841) according to the manufacturer’s protocol
to obtain a stock concentration of 10 μg/ml. Divide into 50-μl aliquots into sterile
microcentrifuge tubes. Store up to 2 months at −20◦C.
bFGF working solution
Add 10 μl bFGF stock solution (see recipe) into 10 ml hESC maintenance medium
(see recipe) per 100-mm hES cultured plates (final bFGF concentration: 10 ng/ml).
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bSFS (basal serum-free differentiation medium)
500 ml DMEM (Invitrogen, cat. no. 11960)
5 ml L-glutamine (200 mmol/liter; Invitrogen, cat. no. 25030-024)
5 ml MEM NEAA (10 mmol/liter; Invitrogen, cat. no. 11140-050)
900 μl 2-mercaptoethanol (50 mmol/liter; Invitrogen, cat. no. 31350-010)
690 μl human transferrin (4 mg/ml; Invitrogen, cat. no. 0030124SA)
182 μl sodium pyruvate (100 mmol/liter; Invitrogen, cat. no. 11360-039)
50 μl sodium selenite (100 μg/ml; Sigma Aldrich, cat. no. S5361-25G)
Store up to 2 weeks at 4◦C
Collagenase I solution
Dissolve 100 mg collagenase I (Sigma Aldrich, cat. no. C0130) in 40 ml Dul-
becco’s phosphate-buffered saline with Mg2+ and Ca2+ (DPBS+; Invitrogen, cat.
no. 14040-091) and 10 ml fetal bovine serum (FBS). Sterile filter the solution.
Divide into 10-ml aliquots in 15-ml centrifuge tubes and store up to 2 months at
−20◦C.
Collagenase IV stock solution
Dissolve 10 mg collagenase IV (Worthington, cat. no. CLS4) in 1 ml DPBS+.
Sterile filter the solution. Divide into 1-ml aliquots in 15-ml centrifuge tubes and
store up to 2 months at −20◦C.
Collagenase IV working solution
Thaw one aliquot of collagenase IV stock solution (see recipe) in a 37◦C water bath
Add 9 ml prewarmed DPBS+ into the stock solution just prior to usage
Additional amounts of collagenase IV solution can be stored up to 1 week at 4◦C
DMEM, 2×
1 ml 10× DMEM (see recipe)
2 ml fetal bovine serum (FBS; PAA, cat. no. A15102)
100 μl L-glutamine (200 mmol/liter; Invitrogen, cat. no. 25030-024)
100 μl penicillin/streptomycin (5000 U/ml and 5 mg/ml; Invitrogen, cat. no. 15070-
063)
1.8 ml H2O
Store up to 2 weeks at 4◦C
DMEM, 10×
Dissolve 669 mg DMEM powder (Invitrogen, cat. no. 52100-039) in 5 ml sterile
water
Filter the solution through a 0.22-μm syringe filter
Store up to 2 weeks at 4◦C
DNase I solution
Suspend DNase I (Calbiochem, cat. no. 260913) in ice-cold water at 1 mg/ml.
Sterile filter the solution. Divide into 5-ml aliquots in 15-ml centrifuge tubes and
store up to 2 months at −20◦C. Keep on ice after thawing.
hEHT medium (human bioengineered heart muscle medium)
500 ml Iscove’s MEM (Biochrom, cat. no. F0465)
120 ml fetal bovine serum (FBS; PAA, cat. no. A15102)
6 ml L-glutamine (200 mmol/liter; Invitrogen, cat. no. 25030-024)
6 ml NEAA (10 mmol/liter; Invitrogen, cat. no. 11140-050)
continued
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6 ml penicillin/streptomycin (5000 U/ml and 5 mg/ml; Invitrogen, cat. no. 15070-
063)
4.34 μl 2-mercaptoethanol (Sigma, cat. no. 31350-010)
Store up to 2 weeks at 4◦C
hESC maintenance medium
500 ml KO-DMEM (Invitrogen, cat. no. 10829-018)
128.2 ml Xeno-Free KnockOut-Serum Replacement (KOSR; Invitrogen, cat.
no. 10828-028)
6.4 ml L-glutamine (200 mmol/liter; Invitrogen, cat. no. 25030-024)
6.4 ml MEM NEAA (10 mmol/liter; Invitrogen, cat. no. 11140-050)
Human basic fibroblast growth factor (bFGF; Stemgent, cat. no. 03-0002 or
Miltenyi Biotech, cat. no. 130-093.841) is only added according to the required
amount of medium used per hESC plate
Store up to 2 weeks at 4◦C
HFF maintenance medium
500 ml DMEM (Invitrogen, cat. no. 42430)
100 ml fetal bovine serum (FBS; PAA, cat. no. A15-102)
6.4 ml penicillin/streptomycin (5000 U/ml and 5 mg/ml; Invitrogen, cat. no. 15070-
063)
Store up to 2 weeks at 4◦C
SF (serum-free) adaptation medium
485 ml DMEM (Invitrogen, cat. no. 11960)
5 ml L-glutamine (200 mmol/liter; Invitrogen, cat. no. 25030-024)
5 ml MEM NEAA (10 mmol/liter; Invitrogen, cat. no. 11140-050)
5 ml ITS-X supplement (100×; Invitrogen, cat. no. 51500-056)
Store up to 2 weeks at 4◦C
COMMENTARY
Background Information
The advent of stable mouse ESC lines
has without question revolutionized biologi-
cal/biomedical sciences (Evans and Kaufman,
1981; Martin, 1981). Given the fast introduc-
tion of this seminal technology into a vari-
ety of animal species (Schnieke et al., 1997;
Wilmut et al., 1997, 2002), it appeared only a
matter of time until stable hESC lines would
be established. The first successful isolation
and culture of hESCs was reported in 1994 by
Ariff Bongso and colleagues (Bongso et al.,
1994). This was followed by the establishment
of stable hESC lines by James Thomson and
colleagues in 1998 (Thomson et al., 1998). In
this study, pluripotency of the unique hESC
lines was unambiguously established and cul-
ture conditions for long-term maintenance of
hESCs were defined. Several groups have sub-
sequently characterized specific derivatives of
hESCs, including neurons (Schuldiner et al.,
2001) and cardiomyocytes (Kehat et al., 2001).
Despite its anticipated versatility for research
and even clinical applications, difficulties in
controlling the differentiation process and sub-
sequently the tissue-like maturation of ESC
derivatives have delayed its widespread use.
The properties of virtually unlimited self-
renewal and tri-lineage differentiation poten-
tial has generated the desire to scale-up hESC
amplification and processing to, e.g., obtain
large numbers of high-quality cardiomyocytes
(Xu et al., 2011). The excitement in the cardiac
research community is based on the expec-
tation that human bona fide cardiomyocytes
can finally be made widely available at quasi-
unlimited quantities, a scenario that was un-
realistic so far because of the limited prolif-
eration capacity in postnatal cardiomyocytes
(Soonpaa et al., 1996; Bergmann et al., 2009).
Unlimited availability of human cardiomy-
ocytes would be a prerequisite not only for
the introduction of novel cell-based therapies,
but also for applications in drug discovery and
safety pharmacology (Braam and Mummery,
2010).
When hESCs are allowed to spontaneously
differentiate, they form EBs containing the
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three embryonic germ layers (Thomson et al.,
1998). Their fate can be influenced by vari-
ous growth factors (Schuldiner et al., 2000).
When cultured for extended periods of time,
spontaneously differentiating embryoid bod-
ies develop cells that contract and possess
structural, functional, and electrophysiologi-
cal properties similar to those of fetal car-
diomyocytes (Kehat et al., 2001). However, the
amount of cardiomyocytes in standard EB cul-
tures is typically below the 1% range. Adapta-
tion of culture conditions by integration of the
rapidly increasing knowledge from cardiac de-
velopmental biology has dramatically helped
to optimize the differentiation processes to-
wards the cardiac lineage (Kattman et al.,
2006, 2011b). Moreover, further process opti-
mization has enabled industrial-scale produc-
tion of hESC-derived cardiomyocytes (Lecina
et al., 2010; Melkoumian et al., 2010; Xu et al.,
2011).
While the issue of limited scale appears to
be in principle overcome, albeit at still un-
acceptable costs for widespread applications,
it has to be acknowledged that hESC-derived
cardiomyocytes resemble embryonic rather
than postnatal stage cardiomyocytes. Impor-
tantly, even growth factor–enhanced mono-
layer or EB cultures appear to offer only
limited support for organotypic maturation
of hESC-derived cardiomyocytes. Conversely,
three-dimensional culture does not only en-
able growth factor support, but also biophys-
ical conditioning, a property that may be of
pivotal importance especially for organs with
predominantly biophysical functions.
The first macroscopic three-dimensional
heart-like tissues were engineered from em-
bryonic chick cardiomyocytes as in vitro mod-
els for pharmacological studies and as a test-
bed for target validation (Eschenhagen et al.,
1997). This was followed by the advent of
mammalian engineered heart tissues (EHTs;
Zimmermann et al., 2000). In contrast to other
original tissue-engineered heart muscle mod-
els (Bursac et al., 1999; Carrier et al., 1999; Li
et al., 1999; Leor et al., 2000), EHTs displayed
coordinated beating with directed force devel-
opment and heart muscle-like physiological
(e.g., Frank-Starling mechanism) and pharma-
cological responses (e.g., beta-adrenergic and
muscarinic modulation of contractile prop-
erties). Subsequently, alternative tissue engi-
neering modalities with comparable function-
ality have been introduced (Shimizu et al.,
2002; Radisic et al., 2004; Tulloch et al., 2011).
Importantly, EHT cultures support anisotropic
tissue organization and maturation of im-
mature cardiomyocytes (Zimmermann et al.,
2002; Tiburcy et al., 2011). Based on this, it
appeared straightforward to postulate that the
EHT culture format would also support the as-
sembly of immature hESC-derived cardiomy-
ocytes into functional myocardium.
Critical Parameters
We find the following parameters to be cru-
cial for the successful implementation of the
described protocol:
1. The described culture media are supple-
mented with a variety of growth factors and
serum components. It has to be anticipated that
the activity of culture media supplements can
vary substantially, despite having a nominally
similar concentration. Hence, it is critical that
batch testing of growth factors and sera be per-
formed and considerable batches secured for
the anticipated experiments. We expect that
fully defined serum-free medium conditions
will soon become available; this will clearly
be another important milestone for further de-
velopment of tissue-engineered myocardium.
2. It is essential to work with highest-
quality hESC cultures. These can be identified
morphologically and should display round,
flat, and cell-dense (“pancake”) colonies (Fig.
23.8.1A). Any deviation from such morphol-
ogy, such as “bubbly” or cystic centers, non-
defined border zones, or wispy fragile cen-
ters suggests that the hESC colonies are “un-
healthy.” This can be due to several factors,
including unwanted pH fluctuations in the cul-
ture medium, suboptimal oxygen levels, and
depletion of critical nutrients and growth fac-
tors in the medium. Overcrowding of hESC
colonies can also trigger cystic colony forma-
tion. Such cultures are unsuitable for down-
stream experiments and should be discarded.
In addition, the quality of the hESC should be
regularly scrutinized by flow cytometry or an-
tibody staining for pluripotency markers (such
as Oct4, SSEA4, Tra1-60; see Fig. 23.8.5) and
karyotyping using advanced technologies such
as chromosome painting and array-CGH anal-
yses are necessary if one wants to claim a nor-
mal karyotype (Rudolph and Schlegelberger,
2009). Simple Giemsa-banding is in our view
not sufficient to control for chromosomal in-
tegrity.
3. In this protocol, we use SB203580 for
MAPK inhibition and improvement of car-
diac differentiation in hESC cultures as orig-
inally described by Graichen and co-workers
(Graichen et al., 2008). To achieve robust re-
sults, SB203580 must be handled with care in
the dark to prevent loss of its activity.
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Figure 23.8.5 Assessment of pluripotency in hESC cultures by flow cytometry (all data from HES3). (A) IgG isotype
control, (B) SSEA 4, (C) Tra 1-60, and (D) Oct 4. High-quality hESC cultures must exhibit uniform expression of the
tested stemness surrogate markers.
4. We describe cardiac differentiation in
serum-free medium. This helps enhance the
robustness of this protocol as it avoids the
supplementation with difficult to define an-
imal sera. Our protocol is not optimized to
achieve optimal cardiomyocyte purity, but for
procedural simplicity, low costs, and fast car-
diomyocyte generation. During the first day
of serum-free adaptation, there will be plenty
of shedding of dead cells, which must be re-
moved from the medium to prevent damage of
the remaining healthy cells. This is achieved
by changing the medium daily for the first
3 days of differentiation.
5. The cardiomyocyte content in EB cul-
tures should be regularly monitored by flow
cytometry and fluorescence microscopy (e.g.,
see data in Fig. 23.8.3). Flow cytometry condi-
tions (in particular gating parameters and anti-
body labeling) have to be carefully established
to avoid false-positive or false-negative counts.
6. Our tissue engineering technology re-
lies on the use of high-quality collagen type 1.
Most commercially available collagens can-
not be used as they lack cardio-instructive
properties. We typically prepare collagen type
1 from rat tails using a classical acetic acid
solubilization protocol (Eschenhagen et al.,
2002). The collagen concentration in the col-
lagen stock solution should be adjusted to
>3 mg/ml for optimal results. Collagen type 1
degrades spontaneously even if stored at 4◦C
in acetic acid. We recommend preparing fresh
collagen stock solutions at least once a year.
Human
Embryonic Stem
Cells and
Assembly into
Engineered Heart
Muscle
23.8.18
Supplement 55 Current Protocols in Cell Biology
Table 23.8.2 Possible Problems and Their Solutions
Problem Possible solution
No or too little cardiac
differentiation in hESC cultures
Check the quality of undifferentiated hESCs
Prepare fresh bSFS
EHTs do not form/condense Prepare new batch of collagen with better
gelation capacity
Adjust the number of cells
Confirm the quality of the cells
Confirm proper cell myocyte/stroma cell
composition
EHTs do not beat Perform cell viability counts to determine
quality of the cells
Adjust cardiomyocyte content
Confirm the quality of cardiomyocytes and
nonmyocytes with flow cytometry analysis
Alternatively, collagen formulations from
commercial suppliers must be screened for
suitable collagen batches.
7. The described EHT reconstitution mix-
ture and in particular Matrigel are highly
sensitive to temperature. Premature gelation
during its preparation must be avoided under
any circumstances. We perform all EHT prepa-
ration steps on ice. Gelation will subsequently
be facilitated at 37◦C in a standard cell culture
incubator.
8. Casting mold and silicone holder dimen-
sions have been optimized for EHT culture
in a standard 12-well culture format. EHT
size can be adapted and functional properties
modified by alteration of the molds and hold-
ers. Single ring-shaped EHTs can be fused eas-
ily into larger functional syncytia by culturing
EHTs in direct contact with each other (Naito
et al., 2006). Ring-shaped EHTs allow easy as-
sessment of contractile parameters as a quality
control measure for tissue formation and tissue
maturation (Zimmermann et al., 2002).
Troubleshooting
For troubleshooting information, see
Table 23.8.2 for a list of possible problems
and their solutions.
Anticipated Results
The following results are expected:
1. Small round EBs should be observed on
culture day 1 of serum-free culture differenti-
ation.
2. First spontaneously beating of EBs
should be visible from culture day 8.
3. The number and beating activity of EBs
increases until culture day 13.
4. Flow cytometry of dissociated day 13
EBs should yield: >10% alpha-sarcomeric
actinin (Fig. 23.8.2A) or tropomyosin-
positive (Fig. 23.8.2B) cardiomyocytes,
>40% vimentin-positive mesodermal nonmy-
ocytes (Fig. 23.8.2B), few endodermal (based
on alpha-fetoprotein) or ectodermal (based
on neurofilament) cells (Fig. 23.8.2B), and
no pluripotent cells (based on Oct3/4 and/or
Nanog).
5. Localized beating should be observed
24 hr after EHT casting.
6. Synchronous contractions of EHT should
be observed after 3 days in culture; beating will
become more rigorous after transferring to sil-
icone poles leading to macroscopically visible
deflections of the silicone poles (see Video 2
at http://www.currentprotocols.com/protocol/
cb2308).
High-quality hEHTs should meet the
following quality control parameters:
i. Spontaneous macroscopically visible
contractions at >60 beats a minute at 37◦C (see
Video 2 at http://www.currentprotocols.com/
protocol/cb2308).
ii. Isometric force development of >0.2
mN at 2 mmol/liter calcium concentration
(Fig. 23.8.4A).
iii. Positive inotropic response to beta-
adrenergic receptor stimulation with isopre-
naline (1 μmol/liter), which can be antago-
nized by muscarinic receptor stimulation with
carbamylcholine (10 μmol/liter).
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iv. A tissue stiffness of >20 kPa measured
by uniaxial tension testing.
v. Conduction velocity of >0.1 m/sec mea-
sured by high-speed optical imaging or for ex-
ample multi-electrode arrays.
vi. Morphological identification of
anisotropically organized muscle bundles
with aligned sarcomeres (Fig. 23.8.4B).
vii. Absence of contaminating pluripotent
cells (Oct4, Rex2, Nanog transcripts not de-
tectable by quantitative PCR).
Time Considerations
Standard hESC cultures takes 7 days from
thawing cells until passaging/initiation of
differentiation. Daily medium change from
culture day 2 post thawing is required.
Differentiation of hESC colonies into beat-
ing EBs requires at least 8 days.
We harvest beating EBs typically on culture
day 13 or later for the generation of EHTs.
Condensation of EHTs requires 3 days.
EHT culture under defined mechanical load
to enhance tissue formation requires 7 days.
Taken together, hESC-derived EHTs can be
generated in 30 days (20 days hESC culture
and differentiation followed by 10 days EHT
generation).
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